{"PMC7112084": [], "ac35eeb6eaaf382fe0e123719f7dc409046e5d87": [["The latent infection ratio was estimated from the number of people traveling from Wuhan to other destinations of mainland China. before the lockdown, and the confirmed 2019-nCoV case reporting data in these destinations.", [["infection", "DISEASE", 11, 20], ["people", "ORGANISM", 60, 66], ["people", "SPECIES", 60, 66], ["The latent infection ratio", "PROBLEM", 0, 26], ["latent", "OBSERVATION_MODIFIER", 4, 10], ["infection", "OBSERVATION", 11, 20]]], ["The estimation of the latent infection ratio enabled additional epidemiological modeling work such as calculating the 2019-nCoV's basic reproduction number and inferring the actual size of the epidemic in Wuhan.", [["infection", "DISEASE", 29, 38], ["the latent infection ratio", "PROBLEM", 18, 44], ["latent", "OBSERVATION_MODIFIER", 22, 28], ["infection", "OBSERVATION", 29, 38], ["size", "OBSERVATION_MODIFIER", 181, 185]]]], "5f9db5381c15cb1cd77d11eef019e14829da5b92": [["IntroductionThe family Coronaviridae is comprised of large, enveloped, single-stranded, and positive-sense RNA viruses that can infect a wide range of animals and human [1] .", [["human", "ORGANISM", 163, 168], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 163, 168], ["large, enveloped, single-stranded, and positive-sense RNA viruses", "PROBLEM", 53, 118], ["large", "OBSERVATION_MODIFIER", 53, 58]]], ["Two coronavirus pandemics in human have emerged in the past two decades.", [["coronavirus pandemics", "DISEASE", 4, 25], ["human", "ORGANISM", 29, 34], ["human", "SPECIES", 29, 34], ["human", "SPECIES", 29, 34], ["Two coronavirus pandemics", "PROBLEM", 0, 25], ["coronavirus", "OBSERVATION_MODIFIER", 4, 15], ["pandemics", "OBSERVATION", 16, 25]]], ["Severe acute respiratory syndrome coronavirus (SARS-CoV) was first recognized in 2003, causing a global outbreak [2] .", [["acute respiratory syndrome coronavirus", "DISEASE", 7, 45], ["SARS-CoV)", "DISEASE", 47, 56], ["Severe acute respiratory syndrome coronavirus", "ORGANISM", 0, 45], ["SARS-CoV", "ORGANISM", 47, 55], ["Severe acute respiratory syndrome coronavirus", "SPECIES", 0, 45], ["SARS-CoV", "SPECIES", 47, 55], ["Severe acute respiratory syndrome coronavirus", "PROBLEM", 0, 45], ["acute", "OBSERVATION_MODIFIER", 7, 12], ["respiratory syndrome coronavirus", "OBSERVATION", 13, 45]]], ["It was followed by another pandemic event in 2012 designated as Middle East respiratory syndrome coronavirus (MERS-CoV) [3] .", [["Middle East respiratory syndrome coronavirus", "DISEASE", 64, 108], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 64, 108], ["MERS-CoV", "ORGANISM", 110, 118], ["Middle East respiratory syndrome coronavirus", "SPECIES", 64, 108], ["MERS-CoV", "SPECIES", 110, 118], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 64, 108], ["Middle", "ANATOMY_MODIFIER", 64, 70], ["respiratory syndrome", "OBSERVATION", 76, 96]]], ["In December 2019, emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) originating in Wuhan, China, has rapidly spread worldwide, and the World white blood cell count were obtained.Immunogenicity AssessmentThe indicators for immunogenicity assessment included seropositivity rate and determination of the geometric mean titer (GMT).", [["white blood cell", "ANATOMY", 165, 181], ["acute respiratory syndrome coronavirus", "DISEASE", 38, 76], ["SARS-CoV-2", "ORGANISM", 80, 90], ["blood cell", "CELL", 171, 181], ["severe acute respiratory syndrome coronavirus", "SPECIES", 31, 76], ["SARS-CoV-2", "SPECIES", 80, 90], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 31, 76], ["SARS", "TEST", 80, 84], ["CoV", "TEST", 85, 88], ["the World white blood cell count", "TEST", 155, 187], ["Immunogenicity Assessment", "TEST", 202, 227], ["immunogenicity assessment", "TEST", 246, 271], ["seropositivity rate", "TEST", 281, 300], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["acute", "OBSERVATION_MODIFIER", 38, 43], ["respiratory syndrome", "OBSERVATION", 44, 64], ["China", "ANATOMY", 114, 119]]], ["The neutralizing antibody titer was calculated by Reed-Muench method on day 5.", [["The neutralizing antibody titer", "TEST", 0, 31], ["neutralizing", "OBSERVATION_MODIFIER", 4, 16], ["antibody titer", "OBSERVATION", 17, 31]]], ["A titer of 1:4 or higher indicated seropositivity.", [["A titer", "TEST", 0, 7], ["seropositivity", "PROBLEM", 35, 49], ["seropositivity", "OBSERVATION", 35, 49]]], ["For calculation of GMT, antibody titers of <1:8, >1:512, and >1:1024 were assigned values of 1:4, 1:(512+512/2), and 1:(1024+1024/2), respectively.Immunogenicity AssessmentThe presence of neutralizing antibody was determined with a modified cytopathogenic assay.Immunogenicity AssessmentSerum samples were inactivated at 56\u00b0C for 30 minutes and serially diluted with cell culture medium in two-fold steps.", [["samples", "ANATOMY", 293, 300], ["cell", "ANATOMY", 367, 371], ["cell", "CELL", 367, 371], ["GMT", "PROTEIN", 19, 22], ["neutralizing antibody", "PROTEIN", 188, 209], ["calculation of GMT, antibody titers", "TEST", 4, 39], ["Immunogenicity Assessment", "TEST", 147, 172], ["neutralizing antibody", "PROBLEM", 188, 209], ["a modified cytopathogenic assay", "PROBLEM", 230, 261], ["Immunogenicity AssessmentSerum samples", "TEST", 262, 300], ["cell culture medium", "TEST", 367, 386], ["neutralizing antibody", "OBSERVATION", 188, 209]]], ["The diluted serums were mixed with a virus suspension of 100 CCID50 in 96-well plates at a ratio of 1:1, followed by 2 hours incubation at 36.5\u00b0C in a 5% CO 2 incubator.Immunogenicity Assessment1-2 X104 Vero cells were then added to the serum-virus mixture, and the plates were incubated for 5 days at 36.5\u00b0C in a 5% CO 2 incubator.", [["serums", "ANATOMY", 12, 18], ["Vero cells", "ANATOMY", 203, 213], ["serum", "ANATOMY", 237, 242], ["CCID50", "CHEMICAL", 61, 67], ["CO 2", "CHEMICAL", 154, 158], ["CO 2", "CHEMICAL", 317, 321], ["serums", "ORGANISM_SUBSTANCE", 12, 18], ["Assessment1-2 X104 Vero cells", "CELL", 184, 213], ["serum", "ORGANISM_SUBSTANCE", 237, 242], ["X104 Vero cells", "CELL_LINE", 198, 213], ["The diluted serums", "TEST", 0, 18], ["a virus suspension", "TREATMENT", 35, 53], ["a 5% CO 2 incubator", "TREATMENT", 149, 168], ["Immunogenicity", "TEST", 169, 183], ["Assessment1", "TEST", 184, 195], ["Vero cells", "PROBLEM", 203, 213], ["the serum-virus mixture", "TEST", 233, 256], ["the plates", "TEST", 262, 272], ["a 5% CO 2 incubator", "TREATMENT", 312, 331]]], ["Cytopathic effect (CPE) of each well was recorded under microscopes, and the neutralizing titer was calculated by the dilution number of 50% protective condition.Role of the Funding SourceThe funders had no role in study design, data collection, data analysis, data interpretation, or writing of the report.Characteristics of the PatientsOf the 70 patients enrolled into this study, 58 were recovered and discharged from hospital ( Table 1 ).", [["patients", "ORGANISM", 348, 356], ["patients", "SPECIES", 348, 356], ["Cytopathic effect", "PROBLEM", 0, 17], ["the neutralizing titer", "TEST", 73, 95], ["data collection", "TEST", 229, 244], ["data analysis", "TEST", 246, 259], ["data interpretation", "TEST", 261, 280], ["this study", "TEST", 371, 381]]], ["The mean age of the patients was 45.1 years (range 16.0-84.0).", [["patients", "ORGANISM", 20, 28], ["patients", "SPECIES", 20, 28]]], ["A total of 58.6% were female.Characteristics of the PatientsAmong them, 38 (54.2%) patients were residents or travelled in Wuhan, Hubei.", [["Patients", "ORGANISM", 52, 60], ["patients", "ORGANISM", 83, 91], ["Patients", "SPECIES", 52, 60], ["patients", "SPECIES", 83, 91], ["total", "OBSERVATION_MODIFIER", 2, 7]]], ["The number of patients having history of cardiovascular disease, diabetes, and hypertension was 2 (2.8%), 5 (7.1%) and 9 (12.9%), respectively.", [["cardiovascular", "ANATOMY", 41, 55], ["cardiovascular disease", "DISEASE", 41, 63], ["diabetes", "DISEASE", 65, 73], ["hypertension", "DISEASE", 79, 91], ["patients", "ORGANISM", 14, 22], ["cardiovascular", "ANATOMICAL_SYSTEM", 41, 55], ["patients", "SPECIES", 14, 22], ["cardiovascular disease", "PROBLEM", 41, 63], ["diabetes", "PROBLEM", 65, 73], ["hypertension", "PROBLEM", 79, 91], ["cardiovascular", "ANATOMY", 41, 55], ["disease", "OBSERVATION", 56, 63], ["diabetes", "OBSERVATION", 65, 73], ["hypertension", "OBSERVATION", 79, 91]]], ["One (1.4%) patient was asymptomatic infected, 22 (31.4%) had mild clinical manifestations, 43 (61.5%) were moderate, and the remaining 4 (5.7%) were in severe condition (1 was inpatients and 3 were convalescent patients).", [["patient", "ORGANISM", 11, 18], ["patients", "ORGANISM", 211, 219], ["patient", "SPECIES", 11, 18], ["patients", "SPECIES", 211, 219], ["asymptomatic infected", "PROBLEM", 23, 44], ["mild clinical manifestations", "PROBLEM", 61, 89], ["severe condition", "PROBLEM", 152, 168], ["asymptomatic", "OBSERVATION_MODIFIER", 23, 35], ["infected", "OBSERVATION", 36, 44], ["mild", "OBSERVATION_MODIFIER", 61, 65], ["moderate", "OBSERVATION_MODIFIER", 107, 115], ["severe", "OBSERVATION_MODIFIER", 152, 158]]], ["Platelets for inpatients andChanges on Antibody Levels with Days since OnsetThe seropositivity rate reached up to 100.0% for 117 blood samples at different stages of illness.Changes on Antibody Levels with Days since OnsetThe total GMT was 1:163.7 (95% CI, 128.5 to 208.6), of which 52.1% (61/117) had a titer between 1:64 and 1:512 (Table 2) .Changes on Antibody Levels with Days since OnsetWe analyzed the changes on antibody levels according to the time course since onset ( Table 2 ).", [["Platelets", "ANATOMY", 0, 9], ["blood samples", "ANATOMY", 129, 142], ["illness", "DISEASE", 166, 173], ["Platelets", "CELL", 0, 9], ["blood", "ORGANISM_SUBSTANCE", 129, 134], ["Platelets", "TEST", 0, 9], ["Antibody Levels", "TEST", 39, 54], ["OnsetThe seropositivity rate", "TEST", 71, 99], ["blood samples", "TEST", 129, 142], ["illness", "PROBLEM", 166, 173], ["Antibody Levels", "TEST", 185, 200], ["OnsetThe total GMT", "TEST", 217, 235], ["CI", "TEST", 253, 255], ["a titer", "TEST", 302, 309], ["Antibody Levels", "TEST", 355, 370], ["the changes", "PROBLEM", 404, 415], ["antibody levels", "TEST", 419, 434], ["illness", "OBSERVATION", 166, 173]]], ["The antibody levels according to different time course since onset were significantly different (P=0.0012).", [["The antibody levels", "TEST", 0, 19], ["P", "TEST", 97, 98]]], ["The GMT of day 31-40 since onset (1: 271.2, 95% CI, 175.8 to 418.5) reached the highest, and decreased slightly after that time period.", [["The GMT", "TEST", 0, 7], ["CI", "TEST", 48, 50], ["decreased", "OBSERVATION_MODIFIER", 93, 102]]], ["Univariate GEE analysis showed that the antibody level during day 31-40 was significantly higher than other phases (Table 4 ).", [["Univariate GEE analysis", "TEST", 0, 23], ["the antibody level", "TEST", 36, 54]]], ["However, multivariate GEE analysis showed that the antibody level during day 31-40 was only higher than day 10-20 (\u03b2= -0.6276, P=0.0201).Changes on Antibody Levels with Days since OnsetAll rights reserved.", [["multivariate GEE analysis", "TEST", 9, 34], ["the antibody level", "TEST", 47, 65], ["P", "TEST", 127, 128], ["Antibody Levels", "TEST", 148, 163], ["OnsetAll rights", "TREATMENT", 180, 195]]], ["No reuse allowed without permission.Changes on Antibody Levels with Days since Onset(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["Antibody Levels", "TEST", 47, 62], ["med", "ANATOMY", 163, 166]]], ["Table 3 and 4.DiscussionDue to the COVID-19 widely spreading around the world, the specific therapeutic agents or vaccines for COVID-19 are urgently needed.", [["COVID-19", "DNA", 35, 43], ["the COVID", "TEST", 31, 40], ["vaccines", "TREATMENT", 114, 122], ["COVID", "TREATMENT", 127, 132]]], ["We analyzed the neutralizing antibody levels among different classification patient with increased days since onset of symptoms, the results indicated that a significant neutralizing antibody response was observed in convalescent patients, moreover, there were individual differences in changes of antibody levels.DiscussionIn the study, typical antibody responses to live viral infection were seen induced in all COVID-19 patients regardless the stage of the disease.", [["viral infection", "DISEASE", 373, 388], ["patient", "ORGANISM", 76, 83], ["patients", "ORGANISM", 230, 238], ["patients", "ORGANISM", 423, 431], ["patient", "SPECIES", 76, 83], ["patients", "SPECIES", 230, 238], ["patients", "SPECIES", 423, 431], ["the neutralizing antibody levels", "TEST", 12, 44], ["symptoms", "PROBLEM", 119, 127], ["a significant neutralizing antibody response", "PROBLEM", 156, 200], ["individual differences in changes of antibody levels", "PROBLEM", 261, 313], ["the study", "TEST", 327, 336], ["typical antibody responses", "PROBLEM", 338, 364], ["live viral infection", "PROBLEM", 368, 388], ["the disease", "PROBLEM", 456, 467], ["significant", "OBSERVATION_MODIFIER", 158, 169], ["neutralizing", "OBSERVATION_MODIFIER", 170, 182], ["antibody response", "OBSERVATION", 183, 200], ["antibody levels", "OBSERVATION", 298, 313], ["disease", "OBSERVATION", 460, 467]]], ["Moreover, the immunity levels were already strong enough even at the early stage of illness, with seropositivity rate reaching up to 100.0% at day 10.DiscussionThe GMT reached the peak at day 31-40 after onset of symptoms.", [["GMT", "PROTEIN", 164, 167], ["the immunity levels", "TEST", 10, 29], ["illness", "PROBLEM", 84, 91], ["seropositivity rate", "TEST", 98, 117], ["The GMT", "TEST", 160, 167], ["symptoms", "PROBLEM", 213, 221]]], ["Even though the GMT had a slightly decreased at day 41-53, the seropositivity rate remained 100.0%.", [["GMT", "PROTEIN", 16, 19], ["the GMT", "TEST", 12, 19], ["the seropositivity rate", "TEST", 59, 82], ["slightly", "OBSERVATION_MODIFIER", 26, 34], ["decreased", "OBSERVATION_MODIFIER", 35, 44]]], ["However, the results were different from other study which indicated the titers of antibodies reached their peak at 10 to 15 days after disease onset [12] .", [["antibodies", "PROTEIN", 83, 93], ["other study", "TEST", 41, 52], ["the titers of antibodies", "PROBLEM", 69, 93]]], ["After adjusting cofounding factors, multivariate GEE analysis demonstrated that the antibody levels were comparable between day 31-40 and day 41-53 since disease onset.", [["cofounding factors", "PROTEIN", 16, 34], ["multivariate GEE analysis", "TEST", 36, 61], ["the antibody levels", "TEST", 80, 99], ["disease onset", "PROBLEM", 154, 167]]], ["However, the proportion with a titer of 1:512 or above decreased from 52.8% during day 31-40 to 27.6% during day 41-53.", [["a titer", "TEST", 29, 36]]], ["Due to the lack of blood samples collected from patients in the later stages of illness, whether and when seropositivity rate declined below 100.0% remained unknown.", [["blood samples", "ANATOMY", 19, 32], ["blood samples", "ORGANISM_SUBSTANCE", 19, 32], ["patients", "ORGANISM", 48, 56], ["patients", "SPECIES", 48, 56], ["blood samples", "TEST", 19, 32], ["illness", "PROBLEM", 80, 87], ["seropositivity rate", "TEST", 106, 125]]], ["How long any immunity in patients will last is a key and big unknown problem for safe and effect antiviral treatments and vaccines in the future [13] .", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["antiviral treatments", "TREATMENT", 97, 117], ["vaccines", "TREATMENT", 122, 130]]], ["For other coronaviruses, immunity after an infection was strong for several months, but then began to wane [14] .", [["infection", "DISEASE", 43, 52], ["coronaviruses", "ORGANISM", 10, 23], ["other coronaviruses", "PROBLEM", 4, 23], ["an infection", "PROBLEM", 40, 52], ["infection", "OBSERVATION", 43, 52]]], ["Chang [15] indicated that peak IgG titers in all SARS-CoV patients appeared at 1 month or 1 to 3 months after the disease onset, and a drop (4.4-fold on average) in IgG titers was evident between 1 month and 6 months after onset.", [["SARS", "DISEASE", 49, 53], ["IgG", "GENE_OR_GENE_PRODUCT", 31, 34], ["SARS-CoV", "ORGANISM", 49, 57], ["patients", "ORGANISM", 58, 66], ["IgG", "GENE_OR_GENE_PRODUCT", 165, 168], ["IgG", "PROTEIN", 165, 168], ["patients", "SPECIES", 58, 66], ["SARS-CoV", "SPECIES", 49, 57], ["peak IgG titers", "TEST", 26, 41], ["the disease onset", "PROBLEM", 110, 127], ["a drop (4.4-fold", "PROBLEM", 133, 149], ["IgG titers", "TEST", 165, 175], ["disease", "OBSERVATION", 114, 121]]], ["These studies suggested that it's worthy of further study to analyze antibodies after COVID-19 patients recovered for a longer time.DiscussionAll rights reserved.", [["patients", "ORGANISM", 95, 103], ["antibodies", "PROTEIN", 69, 79], ["patients", "SPECIES", 95, 103], ["These studies", "TEST", 0, 13], ["further study", "TEST", 44, 57], ["COVID", "TEST", 86, 91]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 18, 2020.", [["med", "ANATOMY", 125, 128]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 125, 128]]], ["Data are expressed as mean\u00b1SD if not specified.DiscussionAll rights reserved.", [["SD", "DISEASE", 27, 29]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 125, 128]]], ["27.6 (12.7-47.2) 0.0227 b a P value for GMT was calculated using Kruskal-Wallis rank-sum nonparametric method. b P value for proportions with titer less than 1:64 and 1:512 or above was calculated using trend Chi-square test. c P value for proportions with titer between 1:64 and 1:512 was calculated using Chi-square test.DiscussionAll rights reserved.", [["a P value", "TEST", 26, 35], ["GMT", "TEST", 40, 43], ["Kruskal-Wallis rank", "TEST", 65, 84], ["P value", "TEST", 113, 120], ["titer", "TEST", 142, 147], ["trend Chi-square test", "TEST", 203, 224], ["P value", "TEST", 228, 235], ["Chi-square test", "TEST", 307, 322]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. # P value for GMT was calculated using Kruskal-Wallis rank-sum nonparametric method.DiscussionAll rights reserved.", [["P", "DNA", 184, 185], ["P value", "TEST", 184, 191], ["GMT", "TEST", 196, 199], ["Kruskal-Wallis rank", "TEST", 221, 240], ["med", "ANATOMY", 125, 128]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 18, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 18, 2020.", [["med", "ANATOMY", 125, 128], ["med", "ANATOMY", 345, 348]]], ["In the figure, a, b , c, d, e, f, g and h represented the 8 representative convalescent patients.", [["patients", "ORGANISM", 88, 96], ["patients", "SPECIES", 88, 96]]], ["In Figure 2 -A, four patients whose antibody titers showed the obvious increasing trend were included.", [["patients", "ORGANISM", 21, 29], ["patients", "SPECIES", 21, 29], ["antibody titers", "TEST", 36, 51]]], ["Figure 2 -B included the other four patients whose antibody titers showed the decreasing trend.DiscussionAll rights reserved.", [["patients", "ORGANISM", 36, 44], ["patients", "SPECIES", 36, 44], ["Figure", "TEST", 0, 6], ["antibody titers", "TEST", 51, 66], ["decreasing", "OBSERVATION_MODIFIER", 78, 88], ["trend", "OBSERVATION_MODIFIER", 89, 94]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.", [["med", "ANATOMY", 125, 128]]], ["No reuse allowed without permission.Discussion(which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 18, 2020. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.DiscussionThe copyright holder for this preprint this version posted April 18, 2020. . https://doi.org/10.1101/2020.04.", [["med", "ANATOMY", 125, 128], ["med", "ANATOMY", 345, 348]]]], "PMC7282403": [["CLEFT LIP/PALATE AND ASSOCIATED ANCILLARY PROCEDURESPrimary cleft lip and palate repair is a low acuity surgery performed in a healthy patient, making this a Tier 1a procedure; CMS recommends these surgeries be postponed.", [["lip", "ANATOMY", 66, 69], ["palate", "ANATOMY", 74, 80], ["cleft lip and palate", "DISEASE", 60, 80], ["lip", "ORGAN", 66, 69], ["palate", "ORGAN", 74, 80], ["patient", "ORGANISM", 135, 142], ["patient", "SPECIES", 135, 142], ["CLEFT LIP/PALATE", "PROBLEM", 0, 16], ["ASSOCIATED ANCILLARY PROCEDURESPrimary cleft lip", "TREATMENT", 21, 69], ["palate repair", "TREATMENT", 74, 87], ["a low acuity surgery", "TREATMENT", 91, 111], ["a Tier 1a procedure", "TREATMENT", 156, 175], ["these surgeries", "TREATMENT", 192, 207], ["LIP", "ANATOMY", 6, 9], ["PALATE", "ANATOMY", 10, 16], ["cleft", "OBSERVATION", 60, 65], ["lip", "ANATOMY", 66, 69], ["palate", "ANATOMY", 74, 80], ["repair", "OBSERVATION", 81, 87]]], ["However, cleft palate repair performed after the age of 12 months is associated with worse speech outcomes; for this reason, cleft palate repair is usually favored to be performed prior to 12 months of age.1213 Cleft lip and palate revisions, including lip revision, tip rhinoplasty, and speech surgery, are likewise Tier 1a procedures and should be postponed.", [["cleft palate", "ANATOMY", 9, 21], ["cleft palate", "ANATOMY", 125, 137], ["lip", "ANATOMY", 217, 220], ["palate", "ANATOMY", 225, 231], ["lip", "ANATOMY", 253, 256], ["cleft palate", "DISEASE", 9, 21], ["cleft palate", "DISEASE", 125, 137], ["palate", "ORGAN", 15, 21], ["palate", "ORGAN", 131, 137], ["lip", "ORGAN", 217, 220], ["palate", "ORGAN", 225, 231], ["lip", "ORGAN", 253, 256], ["cleft palate repair", "TREATMENT", 9, 28], ["worse speech outcomes", "PROBLEM", 85, 106], ["cleft palate repair", "TREATMENT", 125, 144], ["Cleft lip and palate revisions", "TREATMENT", 211, 241], ["lip revision", "TREATMENT", 253, 265], ["tip rhinoplasty", "TREATMENT", 267, 282], ["speech surgery", "TREATMENT", 288, 302], ["cleft palate", "ANATOMY", 9, 21], ["repair", "OBSERVATION", 22, 28], ["palate", "ANATOMY", 131, 137], ["repair", "OBSERVATION", 138, 144], ["lip", "ANATOMY", 217, 220], ["palate", "ANATOMY", 225, 231], ["revisions", "OBSERVATION", 232, 241], ["lip", "ANATOMY", 253, 256], ["revision", "OBSERVATION", 257, 265], ["tip", "OBSERVATION_MODIFIER", 267, 270], ["rhinoplasty", "OBSERVATION", 271, 282]]], ["Alveolar bone grafting is a time-sensitive procedure as this must be timed with eruption of the permanent canines; this timing should be taken into account when scheduling the intervention.CLEFT LIP/PALATE AND ASSOCIATED ANCILLARY PROCEDURESNo state guidelines specifically mention cleft lip or palate repair or associated procedures.ORTHOGNATHIC SURGERYOrthognathic surgery is a low acuity surgery generally performed in a healthy patient, making this a Tier 1a procedure.", [["Alveolar bone", "ANATOMY", 0, 13], ["cleft lip", "ANATOMY", 282, 291], ["palate", "ANATOMY", 295, 301], ["cleft lip or palate", "DISEASE", 282, 301], ["Alveolar bone", "MULTI-TISSUE_STRUCTURE", 0, 13], ["canines", "ORGAN", 106, 113], ["lip", "ORGAN", 288, 291], ["palate", "ORGAN", 295, 301], ["patient", "ORGANISM", 432, 439], ["patient", "SPECIES", 432, 439], ["Alveolar bone grafting", "TREATMENT", 0, 22], ["a time-sensitive procedure", "TREATMENT", 26, 52], ["the permanent canines", "TREATMENT", 92, 113], ["the intervention", "TREATMENT", 172, 188], ["ANCILLARY PROCEDURESNo state guidelines", "TREATMENT", 221, 260], ["cleft lip", "PROBLEM", 282, 291], ["palate repair", "TREATMENT", 295, 308], ["associated procedures", "TREATMENT", 312, 333], ["ORTHOGNATHIC SURGERYOrthognathic surgery", "TREATMENT", 334, 374], ["a low acuity surgery", "TREATMENT", 378, 398], ["a Tier 1a procedure", "TREATMENT", 453, 472], ["bone", "ANATOMY", 9, 13], ["grafting", "OBSERVATION", 14, 22], ["LIP", "ANATOMY", 195, 198], ["PALATE", "ANATOMY", 199, 205], ["lip", "ANATOMY", 288, 291], ["palate", "ANATOMY", 295, 301], ["repair", "OBSERVATION", 302, 308]]], ["Though timing of orthognathic surgery is dependent on orthodontic treatment and skeletal maturity, postponement of orthognathic surgery does not interfere with orthodontic treatment.ORTHOGNATHIC SURGERYNo state guidelines specifically mention orthognathic surgery; however, 12 states and the District of Columbus specifically mention that elective dental procedures be postponed.21415161718192021222324", [["skeletal", "ANATOMY", 80, 88], ["21415161718192021222324", "CHEMICAL", 379, 402], ["skeletal", "ORGAN", 80, 88], ["orthognathic surgery", "TREATMENT", 17, 37], ["orthodontic treatment", "TREATMENT", 54, 75], ["skeletal maturity", "PROBLEM", 80, 97], ["orthognathic surgery", "TREATMENT", 115, 135], ["orthodontic treatment", "TREATMENT", 160, 181], ["orthognathic surgery", "TREATMENT", 243, 263], ["elective dental procedures", "TREATMENT", 339, 365], ["skeletal", "ANATOMY", 80, 88]]]], "e9c35d59c0b3959e727af742253dff99b60384a1": [["IntroductionThe rejection of immunization by the population was born with the creation of the first vaccine in 1796 when Jenner presented protection against smallpox to the Royal Society of London.", [["smallpox", "DISEASE", 157, 165], ["immunization", "TREATMENT", 29, 41], ["the first vaccine", "TREATMENT", 90, 107], ["rejection", "OBSERVATION", 16, 25]]], ["From this point, a rise in England's first compulsory vaccination through a strong campaign began to appear unhappy [1] , which led to the constitution of the League against Mandatory Vaccination of London in 1867, and it began to spread this movement to the rest of Europe [2] .IntroductionThis movement won strength in 1998 when Wakefield published an article in \"The Lancet\", in which he related the possibility of suffering autism with the administration of the vaccine against rubella, mumps and measles.", [["autism", "DISEASE", 428, 434], ["rubella, mumps", "DISEASE", 482, 496], ["measles", "DISEASE", 501, 508], ["rubella", "ORGANISM", 482, 489], ["mumps", "ORGANISM", 491, 496], ["England's first compulsory vaccination", "TREATMENT", 27, 65], ["suffering autism", "PROBLEM", 418, 434], ["the vaccine", "TREATMENT", 462, 473], ["rubella", "PROBLEM", 482, 489], ["mumps", "PROBLEM", 491, 496], ["measles", "PROBLEM", 501, 508]]], ["This sonorous article caused a 9% drop in the vaccination rate in the United Kingdom in just one year.", [["a 9% drop", "PROBLEM", 29, 38], ["the vaccination rate", "TREATMENT", 42, 62]]], ["In the end, it was proved that Wakefield and the co-authors of the article had conflicts of interest and the journal was forced to publish a retraction but, despite that, this belief is still maintained today [3] .IntroductionCurrently, a study by the American Academy of Pediatrics reveals that 74% of pediatricians find parents who oppose or have delayed the administration of vaccines to their children.", [["pediatricians", "ORGANISM", 303, 316], ["children", "ORGANISM", 397, 405], ["children", "SPECIES", 397, 405], ["a study", "TEST", 237, 244], ["vaccines", "TREATMENT", 379, 387], ["retraction", "OBSERVATION", 141, 151]]], ["Another survey of parents with children aged 6 months to 6 years shows that 13% opted for an alternative immunization program, 53% rejected one vaccine and 17% rejected all [4] .IntroductionThe anti-vaccination groups base their arguments on their lack of confidence in the information provided by health professionals and official sources about vaccines.", [["children", "ORGANISM", 31, 39], ["children", "SPECIES", 31, 39], ["an alternative immunization program", "TREATMENT", 90, 125], ["The anti-vaccination groups base", "TREATMENT", 190, 222], ["vaccines", "TREATMENT", 346, 354]]], ["Generally, they have doubts about the administration of multiple vaccines at such early ages and the lack of individualization of these drugs.", [["multiple vaccines", "TREATMENT", 56, 73], ["these drugs", "TREATMENT", 130, 141]]], ["Their fear lies in the possible adverse effects and the constant change in the vaccination schedule, as well as in the differences between autonomous communities.", [["adverse effects", "PROBLEM", 32, 47], ["the vaccination schedule", "TREATMENT", 75, 99]]], ["This is linked to the belief that because the disease has very low incidence it is not necessary to vaccinate their children (which is, in fact, due to the vaccine) or because they believe in natural remedies or alternative medicine, so people in the anti-vaccine group end up looking for information that confirms their beliefs [5, 6] .", [["children", "ORGANISM", 116, 124], ["people", "ORGANISM", 237, 243], ["children", "SPECIES", 116, 124], ["people", "SPECIES", 237, 243], ["the disease", "PROBLEM", 42, 53]]], ["In addition, it shows that people who refuse vaccines are more likely to obtain information from social networks, not from health professionals or verified healthcare websites [6] .", [["people", "ORGANISM", 27, 33], ["social networks", "MULTI-TISSUE_STRUCTURE", 97, 112], ["people", "SPECIES", 27, 33], ["vaccines", "TREATMENT", 45, 53]]], ["Another study informs that 52% of people who use the Internet consider this medium reliable in terms of health issues [7] .IntroductionDespite the fact that healthcare professionals remain the main source of health information, including vaccines, the Internet has grown as a resource for finding information due to its high accessibility [8] .", [["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["Another study", "TEST", 0, 13], ["vaccines", "TREATMENT", 238, 246]]], ["In fact, vaccine-related searches on the Internet have increased, most of them coinciding with the start of influenza vaccination campaigns [9] .", [["vaccine", "TREATMENT", 9, 16], ["influenza vaccination campaigns", "TREATMENT", 108, 139], ["increased", "OBSERVATION_MODIFIER", 55, 64]]], ["The increase of web information search causes an opportunity for the appearance of websites with unreliable content generating false beliefs [10] .IntroductionConsidering the importance that the anti-vaccine movement has gradually acquired, the aim of this study was to analyze social networks' information about the anti-vaccine movement.", [["the anti-vaccine movement", "PROBLEM", 191, 216], ["this study", "TEST", 252, 262], ["increase", "OBSERVATION_MODIFIER", 4, 12]]], ["Thus, the PICO question that guided the review was: Which information (O) does the anti-vaccine movement (P) use in social networks (I) to influence the global population (C)?Materials and MethodsA systematic literature review was conducted following the PRISMA guideline.", [["the PRISMA guideline", "TREATMENT", 251, 271]]], ["No protocol was registered.Eligibility CriteriaWe included primary studies related to the use of social networks and the anti-vaccine movement that collect samples on the main social networks (Twitter, Facebook, Instagram and YouTube), published in English and Spanish and conducted over the last 10 years.Eligibility CriteriaAll articles were exclusively related to the measles outbreak and the HPV vaccine; articles using samples not obtained on Twitter, Facebook, Instagram or YouTube and articles without statistical information and duplicate articles were excluded.Information Sources and SearchThe databases used were CINHAL, CUIDEN, PubMed (Medline) and Scopus.", [["social networks", "MULTI-TISSUE_STRUCTURE", 176, 191], ["HPV", "ORGANISM", 396, 399], ["HPV", "SPECIES", 396, 399], ["protocol", "TREATMENT", 3, 11], ["primary studies", "TEST", 59, 74], ["social networks", "TREATMENT", 97, 112], ["the anti-vaccine movement", "TREATMENT", 117, 142], ["the measles outbreak", "PROBLEM", 367, 387], ["the HPV vaccine", "TREATMENT", 392, 407]]], ["The first search equation based on MeSH terms was \"Vaccine and social networking\".Study Selection and Risk of BiasThe selection of the studies was done independently by two researchers and had 4 phases.", [["Study Selection", "TEST", 82, 97], ["the studies", "TEST", 131, 142]]], ["Then, a reverse search was done with the included studies to locate as many documents as possible; and finally, a critical reading of the studies was carried out to evaluate possible biases in the methodology.", [["the included studies", "TEST", 37, 57], ["the studies", "TEST", 134, 145], ["biases in the methodology", "PROBLEM", 183, 208]]], ["The SIGN classification (2011) was used to provide the level of evidence.Data Collection, Variables and Data AnalysisA data collection notebook was used to extract the data from each study.", [["Data Collection", "TEST", 73, 88], ["each study", "TEST", 178, 188]]], ["The following data were collected from each study:Data Collection, Variables and Data Analysis1.Data Collection, Variables and Data AnalysisVariables about the characteristics of the sample: year of publication, country of study, study design, number of tweets, Facebook or Instagram comments or YouTube videos.2.Variables about the study: aim and main results of each article.2.The analysis of the data was descriptive.Study SelectionA total of 503 articles were obtained from the database search as of December 2019.", [["Data Collection", "TEST", 50, 65], ["Data Analysis1", "TEST", 81, 95], ["Data Collection", "TEST", 96, 111], ["the study", "TEST", 329, 338], ["the data", "TEST", 395, 403]]], ["After reading the title and abstract, 486 studies were excluded for not meeting the inclusion criteria or being duplicates.", [["486 studies", "TEST", 38, 49]]], ["Finally, four studies were included after the reverse search, leaving a sample of n = 12 articles.", [["four studies", "TEST", 9, 21], ["a sample", "TEST", 70, 78]]], ["The flow chart with the study selection process is shown in Figure 1 .Data Collection, Variables and Data AnalysisA data collection notebook was used to extract the data from each study.", [["the study selection process", "TEST", 20, 47], ["Data Collection", "TEST", 70, 85], ["each study", "TEST", 175, 185]]], ["The following data were collected from each study:Data Collection, Variables and Data Analysis1.", [["Data Collection", "TEST", 50, 65], ["Data Analysis1", "TEST", 81, 95]]], ["Variables about the study: aim and main results of each article.Data Collection, Variables and Data AnalysisThe analysis of the data was descriptive.Study SelectionA total of 503 articles were obtained from the database search as of December 2019.", [["the study", "TEST", 16, 25], ["Data Collection", "TEST", 64, 79], ["Data Analysis", "TEST", 95, 108], ["the data", "TEST", 124, 132]]], ["After reading the title and abstract, 486 studies were excluded for not meeting the inclusion criteria or being duplicates.", [["486 studies", "TEST", 38, 49]]], ["Finally, four studies were included after the reverse search, leaving a sample of n = 12 articles.", [["four studies", "TEST", 9, 21], ["a sample", "TEST", 70, 78]]], ["The flow chart with the study selection process is shown in Figure 1 .Study CharacteristicsAll selected articles were descriptive cross-sectional studies.", [["The flow chart", "TEST", 0, 14], ["the study selection process", "TEST", 20, 47], ["descriptive cross-sectional studies", "TEST", 118, 153]]], ["The 41.66% of the articles were published in 2019, 50% show data obtained on Twitter and 50% have been made in the United States.", [["the articles", "TEST", 14, 26]]], ["The 12 articles included showedStudy CharacteristicsAll selected articles were descriptive cross-sectional studies.", [["descriptive cross-sectional studies", "TEST", 79, 114]]], ["The 41.66% of the articles were published in 2019, 50% show data obtained on Twitter and 50% have been made in the United States.", [["the articles", "TEST", 14, 26]]], ["Half of the studies (50%) were based on Twitter.", [["the studies", "TEST", 8, 19]]], ["After the analysis, two categories of results were established.Twitter and Vaccine InformationThe study by Gunaratne et al [12] shows an increase in Twitter content in favor of vaccines; despite this, it highlights an increase in users defending the anti-vaccine movement.", [["the analysis", "TEST", 6, 18], ["The study", "TEST", 94, 103], ["vaccines", "TREATMENT", 177, 185], ["increase", "OBSERVATION_MODIFIER", 137, 145], ["increase", "OBSERVATION_MODIFIER", 218, 226]]], ["This information is reinforced in the study led by Blankenship et al [13] , which highlights that everything related to the anti-vaccine group has a greater number of interactions, retweets or likes.Twitter and Vaccine InformationAnother study indicates that approximately 12% of websites with vaccine content shared on Twitter have low credibility [14] and use a different language between those webs that are in favor and those that are against vaccines.", [["the study", "TEST", 34, 43], ["greater", "OBSERVATION_MODIFIER", 149, 156]]], ["For example, those that favor vaccines refer to all stages of life, while the anti-vaccine refer only to childhood.", [["vaccines", "TREATMENT", 30, 38]]], ["In addition, the type of words most often used by websites against vaccine are names of diseases that may have been related to the administration of vaccines, such as autism, relating it to vaccine components [15] .", [["autism", "DISEASE", 167, 173], ["vaccine", "TREATMENT", 67, 74], ["diseases", "PROBLEM", 88, 96], ["vaccines", "TREATMENT", 149, 157]]], ["This is supported by the study of Love et al. [16] , which determines that tweets against vaccines focus on the supposed harm that they cause.", [["the study", "TEST", 21, 30], ["vaccines", "TREATMENT", 90, 98]]], ["All studies agree that the mechanisms to spread the anti-vaccine message in Twitter are the use of personal stories, talking about the risks of vaccines and their components, the business of the pharmaceutical industry and conspiracy theories, sometimes supported with links to websites based on no evidence [12] [13] [14] [15] [16] [17] .", [["[12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 308, 337], ["All studies", "TEST", 0, 11], ["vaccines", "TREATMENT", 144, 152]]], ["Nevertheless, pro-vaccine tweets and users have more presence on Twitter than anti-vaccine tweets and users [12] [13] [14] [15] [16] [17] .Facebook and YouTube and Vaccine InfringementFacebook users who showed negative feelings about vaccines are introduced as a \"pro-science\" group that tries to give information about vaccines that is supposedly being hidden [18] .", [["[12] [13] [14] [15] [16] [17]", "SIMPLE_CHEMICAL", 108, 137], ["vaccines", "TREATMENT", 234, 242], ["vaccines", "TREATMENT", 320, 328]]], ["Tustin et al. [19] revealed that the comments of this social network mostly speak about distrust towards pharmacists or healthcare providers and include negative experiences with vaccines.", [["vaccines", "TREATMENT", 179, 187]]], ["These studies are based on the new advertising tool from Facebook, in which anti-vaccination ads have been included talking about alleged institutional fraud and promoting vaccination [20] .", [["These studies", "TEST", 0, 13]]], ["In terms of interaction, comments in favor of immunization receive more \"likes\" than those against [21] , although the latter group consumes more content [22] .", [["immunization", "TREATMENT", 46, 58]]], ["As on Twitter, antivaccine users based their posts and comments on personal stories, vaccines risks, vaccine components, distrust in pharmaceutical industry and conspiratory theories [18] [19] [20] [21] [22] .", [["[18] [19] [20] [21] [22]", "SIMPLE_CHEMICAL", 183, 207], ["vaccine components", "TREATMENT", 101, 119]]], ["Even though pro-vaccine users and posts have more presence, anti-vaccine users seems to grow more cohesively on Facebook than pro-vaccine groups [22] .Facebook and YouTube and Vaccine InfringementOn YouTube the most watched videos about vaccines are about personal stories that had more views than videos by health agencies.", [["vaccines", "TREATMENT", 237, 245]]], ["Table 1 summarizes the information from the included studies.", [["the included studies", "TEST", 40, 60]]], ["They analyzed two hashtags: #vaccine and #vaccineworks selecting a random sample.", [["vaccine", "TREATMENT", 29, 36], ["vaccineworks", "TREATMENT", 42, 54]]], ["From 1344 analyzed tweets with the hashtag #vaccine, 24 .2% were about the anti-vaccine sentiment and 59.1% of them had links to websites.", [["the hashtag #vaccine", "TREATMENT", 31, 51]]], ["Anti-vaccine tweets were focused on risk and dangers and distrust of pharmaceutical industry, science or government.", [["Anti-vaccine tweets", "TREATMENT", 0, 19]]], ["Tweets against vaccines were more likely to interact (retweets) than those expressing feelings for them.", [["vaccines", "TREATMENT", 15, 23]]], ["[14]Descriptive cross-sectional study.6,591,566 tweetsTo characterize the potential scope of shared vaccine websites on Twitter in relation to credibility.6,591,566 tweetsAmong shared websites, 11.86% maintained low credibility and generated 112,225 retweets (14.68%).", [["Descriptive cross-sectional study", "TEST", 4, 37]]], ["The low-credibility web pages linked in twitter were related to individual stories and autonomy.", [["low", "OBSERVATION_MODIFIER", 4, 7]]], ["To know the opinion about vaccines of Twitter users through the semantics of the web pages they share.6,591,566 tweetsOf the web pages shared, 23 pages showed positive feelings towards vaccines, 21 were negative and 6 were neutral.", [["vaccines", "TREATMENT", 26, 34], ["positive feelings", "PROBLEM", 159, 176], ["vaccines", "TEST", 185, 193]]], ["The most commonly used concepts in the negative pages were: children, mercury, autism, industrialization of vaccines, ingredients of vaccines.Love et al, 2013, United States.", [["mercury", "CHEMICAL", 70, 77], ["autism", "DISEASE", 79, 85], ["mercury", "CHEMICAL", 70, 77], ["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["vaccines", "TREATMENT", 108, 116], ["vaccines", "TREATMENT", 133, 141]]], ["[16]Descriptive cross-sectional study.Love et al, 2013, United States.", [["Descriptive cross-sectional study", "TEST", 4, 37]]], ["[16]To analyze the content provided by Twitter on vaccination, taking into account the medical reliability to know the type of information about which users are interested and thus lead educational campaigns.Love et al, 2013, United States.", [["vaccination", "TREATMENT", 50, 61]]], ["[16]Of the tweets analyzed, 33% were positive for immunization, 54% maintained a neutral position and 13% were against.", [["immunization", "TEST", 50, 62]]], ["Those in favour made contributions promoting their administration, the neutrals reported experiences on the subject and the negatives consisted of claims about vaccine damage.Broniatowski et al, 2018, United States.", [["vaccine damage", "PROBLEM", 160, 174]]], ["[17]Descriptive cross-sectional study.Broniatowski et al, 2018, United States.", [["Descriptive cross-sectional study", "TEST", 4, 37]]], ["[17]Accounts identified as trolls or bots were more likely to tweet about vaccine content than normal users and were less likely to create preventable disease content.", [["preventable disease content", "PROBLEM", 139, 166], ["preventable", "OBSERVATION_MODIFIER", 139, 150], ["disease", "OBSERVATION", 151, 158]]], ["Bot accounts tended to post more anti-vaccine content than normal users but their message was less polarized.", [["more anti-vaccine content", "TREATMENT", 28, 53]]], ["From the analysis of 253 tweets with the hashtag #vaccinateUS, 38% were anti-vaccine.", [["the analysis", "TEST", 5, 17], ["the hashtag #vaccinateUS", "TEST", 37, 61]]], ["Their anti-vaccination posts were about their risks and damages, indicating that vaccines caused diseases and death, personal stories and conspiracy theories.Tustin et al, 2018, Canada.", [["death", "DISEASE", 110, 115], ["damages", "PROBLEM", 56, 63], ["diseases", "PROBLEM", 97, 105], ["death", "PROBLEM", 110, 115]]], ["[19]Descriptive cross-sectional study.comments from FacebookTo analyze the content of Facebook users' comments to find out the main feelings towards vaccinations.comments from FacebookOf the 85 commentators 77% were female.", [["Descriptive cross-sectional study", "TEST", 4, 37]]], ["Of all comments about vaccinations, 43.6% were positive, 35% negative and the rest were ambiguous.", [["vaccinations", "TEST", 22, 34]]], ["Negative comments included misperceptions of risk, inaccurate knowledge, distrust of pharmacists or health care providers, negative experiences with vaccines or beliefs.", [["vaccines", "TREATMENT", 149, 157]]], ["Almost 40% of positive reviews spoke of the risks of non-vaccination and judged the level of knowledge of anti-vaccination.Jamison et al, 2019, USA.", [["non-vaccination", "TREATMENT", 53, 68], ["anti-vaccination", "TREATMENT", 106, 122]]], ["[20]Descriptive cross-sectional study.vaccine-related ads on FacebookTo analyze the new Facebook tool to publish ads and the reliability of these related vaccines.vaccine-related ads on FacebookOf all ads, 53% were pro-vaccines and 47% anti-vaccine.", [["Descriptive cross-sectional study", "TEST", 4, 37], ["vaccine", "TREATMENT", 38, 45], ["FacebookTo", "TREATMENT", 61, 71], ["these related vaccines", "TREATMENT", 140, 162], ["vaccine", "TREATMENT", 163, 170], ["pro-vaccines", "TREATMENT", 215, 227]]], ["However, only 27 people were anti-vaccine ad buyers, while 83 were pro-vaccine.", [["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23]]], ["The pro-vaccine announcements were divided into five themes: vaccine promotion, philanthropic work, advocacy of vaccination policies, news and anti-vaccine views.", [["vaccine promotion", "TREATMENT", 61, 78]]], ["Anti-vaccines were more unified, described the damage done, promoted the choice of vaccine and revealed an alleged institutional fraud.", [["Anti-vaccines", "TREATMENT", 0, 13], ["the damage", "PROBLEM", 43, 53], ["vaccine", "TREATMENT", 83, 90]]], ["Descriptive cross-sectional study.vaccine-related ads on Facebook1489 comments from Facebook.vaccine-related ads on FacebookTo investigate the language used by people for and against immunization in the same conversation in order to provide an optimal education.vaccine-related ads on FacebookComments in favor of vaccines received more \"likes\" than those against and neutrals, the latter being the least receiving of the three.", [["people", "ORGANISM", 160, 166], ["people", "SPECIES", 160, 166], ["Descriptive cross-sectional study", "TEST", 0, 33], ["vaccine", "TREATMENT", 34, 41], ["vaccine", "TREATMENT", 93, 100], ["immunization", "TREATMENT", 183, 195], ["vaccine", "TREATMENT", 262, 269], ["FacebookComments", "TREATMENT", 285, 301], ["vaccines", "TREATMENT", 314, 322]]], ["[22]Descriptive cross-sectional study.Schmidt et al, 2018, Italy.", [["Descriptive cross-sectional study", "TEST", 4, 37]]], ["[22]To assess whether the conduct of users about immunization is polarized and how it evolves over time.Schmidt et al, 2018, Italy.", [["immunization", "TREATMENT", 49, 61]]], ["[22]Most users were active in one group, for or against vaccines, but not in both.", [["vaccines", "TREATMENT", 56, 64]]], ["Anti-vaccine were more committed to their post consumption.", [["Anti-vaccine", "TREATMENT", 0, 12]]], ["The ant-vaccine community grew in a more cohesive manner on the social network, with less fragmentation.Yiannakoulias et al, 2019, Canada.", [["social network", "MULTI-TISSUE_STRUCTURE", 64, 78], ["The ant-vaccine", "TREATMENT", 0, 15], ["more cohesive", "OBSERVATION_MODIFIER", 36, 49], ["less fragmentation", "OBSERVATION", 85, 103]]], ["[23]Descriptive cross-sectional study.YouTube videosTo report strategies that increase useful information on YouTube regarding pro and anti-vaccine content.YouTube videosThe most frequent searches were about personal stories rather than about the benefits or how vaccines worked, so videos from public health agencies had fewer views.", [["Descriptive cross-sectional study", "TEST", 4, 37], ["pro and anti-vaccine content", "TREATMENT", 127, 155]]], ["In addition, the search terms are very similar for both pro-vaccine and anti-vaccine content.", [["anti-vaccine", "SIMPLE_CHEMICAL", 72, 84]]], ["Anti-vaccine videos contained more target words and had higher likeability.", [["Anti-vaccine videos", "TREATMENT", 0, 19]]], ["The words mercury, syringe, cheical and toxic were more used in anti-vaccine videos.DiscussionAfter the literature review, it was observed that Twitter seemed to be the most used social network by the anti-vaccine movement.", [["mercury", "CHEMICAL", 10, 17], ["mercury", "CHEMICAL", 10, 17], ["mercury", "SIMPLE_CHEMICAL", 10, 17], ["social network", "MULTI-TISSUE_STRUCTURE", 179, 193]]], ["The anti-vaccine users are fewer than pro-vaccine, but they are more active.", [["anti-vaccine", "ANATOMY", 4, 16], ["The anti-vaccine users", "TREATMENT", 0, 22], ["pro-vaccine", "TREATMENT", 38, 49]]], ["The anti-vaccine groups usually use the same reasons in their tweets or posts (vaccine risks, autism, vaccine component and conspiracy theories) and base their speech on personal stories.", [["autism", "DISEASE", 94, 100], ["The anti-vaccine groups", "TREATMENT", 0, 23], ["posts (vaccine risks", "TREATMENT", 72, 92], ["autism, vaccine component", "TREATMENT", 94, 119]]], ["This is linked to the distrust of pharmaceuticals by the anti-vaccine group [17] , which is based on the belief that they have great economic gains from vaccines, having no evidence for the information that they disseminate [5, 24] .", [["vaccines", "TREATMENT", 153, 161], ["no evidence for", "UNCERTAINTY", 170, 185]]], ["They also argue that because there is no incidence of some diseases, there is no need for vaccination; but the low incidence of some diseases is due to vaccines [6, 8] .DiscussionIt is also interesting to see how people who are against immunization use words in their language related to vaccine components such as \"mercury\", inciting users' distrust [22] .", [["mercury", "CHEMICAL", 316, 323], ["mercury", "CHEMICAL", 316, 323], ["people", "ORGANISM", 213, 219], ["mercury", "SIMPLE_CHEMICAL", 316, 323], ["people", "SPECIES", 213, 219], ["some diseases", "PROBLEM", 54, 67], ["vaccination", "TREATMENT", 90, 101], ["some diseases", "PROBLEM", 128, 141], ["vaccines", "TREATMENT", 152, 160], ["no incidence", "UNCERTAINTY", 38, 50], ["diseases", "OBSERVATION", 59, 67], ["no need for", "UNCERTAINTY", 78, 89], ["diseases", "OBSERVATION", 133, 141]]], ["This is due to the rejection of chemical products for fear of suffering health problems [25] and the preference for alternatives with natural products by the anti-vaccine group [5] .", [["anti-vaccine", "SIMPLE_CHEMICAL", 158, 170], ["chemical products", "TREATMENT", 32, 49], ["suffering health problems", "PROBLEM", 62, 87], ["natural products", "TREATMENT", 134, 150], ["rejection", "OBSERVATION", 19, 28]]], ["This movement is mainly growing in western countries partly due to unlimited access to health-related information on the Internet [26] .DiscussionAnother example of the spread of false information on social networks can be seen with the recent SARS-Covid-19 pandemic that we are suffering.", [["social networks", "MULTI-TISSUE_STRUCTURE", 200, 215], ["mainly", "OBSERVATION_MODIFIER", 17, 23], ["growing", "OBSERVATION_MODIFIER", 24, 31]]], ["The novelty of the disease causes false news of both its origin and its treatment to spread rapidly.", [["the disease", "PROBLEM", 15, 26], ["disease", "OBSERVATION", 19, 26], ["false news", "OBSERVATION", 34, 44], ["origin", "OBSERVATION_MODIFIER", 57, 63]]], ["One of the most popular formulas has been to mix sodium chlorite with citric acid as a treatment against the virus, a remedy that has no evidence [27, 28] .", [["sodium chlorite", "CHEMICAL", 49, 64], ["citric acid", "CHEMICAL", 70, 81], ["sodium chlorite", "CHEMICAL", 49, 64], ["citric acid", "CHEMICAL", 70, 81], ["sodium chlorite", "SIMPLE_CHEMICAL", 49, 64], ["citric acid", "SIMPLE_CHEMICAL", 70, 81], ["mix sodium chlorite", "TREATMENT", 45, 64], ["citric acid", "TREATMENT", 70, 81], ["a treatment", "TREATMENT", 85, 96], ["the virus", "PROBLEM", 105, 114], ["no evidence", "UNCERTAINTY", 134, 145]]], ["This type of news can confuse the population, as well as be dangerous to their health, as is the case with vaccines.", [["vaccines", "TREATMENT", 107, 115]]], ["Moreover, as it happens with other vaccines, some false information is growing on the Internet and social networks with the COVID-19 pandemic, with some groups saying that the virus does not exist or that future vaccine will have a microchip to control us [29, 30] .", [["other vaccines", "TREATMENT", 29, 43], ["the virus", "PROBLEM", 172, 181], ["future vaccine", "TREATMENT", 205, 219], ["a microchip", "TREATMENT", 230, 241]]], ["The trend and future of this movement depend on the efforts of healthcare professionals, health organizations and social networks to prevent fake information dissemination which is the main technique that they use to hook people [31, 32] .", [["people", "SPECIES", 222, 228]]], ["Without any intervention, surely this movement will grow.DiscussionThe influence of the anti-vaccine movement on social networks can be prevented with strategies that are already working, like creating social networks accounts for official health organizations or modifying the search logarithm of social networks, showing the official information from verified sources first when a user looks for information about vaccines or the COVID-19 pandemic (as it is being done on the main social networks) [33, 34] .", [["social networks", "MULTI-TISSUE_STRUCTURE", 298, 313], ["social networks", "MULTI-TISSUE_STRUCTURE", 483, 498], ["any intervention", "TREATMENT", 8, 24], ["the anti-vaccine movement", "TREATMENT", 84, 109], ["vaccines", "TREATMENT", 416, 424]]], ["Furthermore, a strong emphasis on parents' education about how to find and trust checked information in health institutions should be taken into account [26] .DiscussionThis study shows the need for greater training for the population to learn how to detect fake information and, on the part of health agencies, to be attentive to possible misinformation that may arise and refute it with true and accessible data in a simple language accessible to the population.", [["This study", "TEST", 169, 179], ["greater training", "TREATMENT", 199, 215]]], ["They should also promote strategies to try to reach more people on the net to combat misinformation and fake news.LimitationsThis study has some limitations.", [["people", "ORGANISM", 57, 63], ["people", "SPECIES", 57, 63], ["This study", "TEST", 125, 135]]], ["First, the number of articles is low, mainly because the use of social networks to find health-related information is a recent phenomenon.", [["a recent phenomenon", "PROBLEM", 118, 137], ["low", "OBSERVATION_MODIFIER", 33, 36]]], ["Differences between countries should also be taken into account in the interpretation of the results, as some have less access to the Internet or its influence on the population is lower.", [["lower", "OBSERVATION_MODIFIER", 181, 186]]], ["Future research could analyze this movement against concrete vaccines, like the HPV, or to analyze how training courses on fake information detection can influence the beliefs of the population.ConclusionsAnti-vaccine groups are using social networks to spread health information, creating their own content without any evidence to confuse users who access their pages.", [["HPV", "ORGANISM", 80, 83], ["HPV", "SPECIES", 80, 83], ["concrete vaccines", "TREATMENT", 52, 69], ["the HPV", "PROBLEM", 76, 83]]], ["To do this, most of the time they use alleged stories about children who have suffered side effects that end up moving the readers-a fact that impacts more than the scientific data provided by health agencies.ConclusionsAnother method used by the anti-vaccine groups to attract different users is the debate generated by bots and trolls about vaccination.", [["children", "ORGANISM", 60, 68], ["children", "SPECIES", 60, 68], ["side effects", "PROBLEM", 87, 99], ["Another method", "TREATMENT", 220, 234], ["the anti-vaccine groups", "TREATMENT", 243, 266], ["vaccination", "TREATMENT", 343, 354]]], ["The methods used by groups against vaccination on social networks are diverse and in many cases are useful for their task.", [["social networks", "MULTI-TISSUE_STRUCTURE", 50, 65], ["The methods", "TREATMENT", 0, 11]]]], "PMC4967842": [["IntroductionAvian infectious bronchitis virus (IBV) is the microorganism that causes a significant economic loss in the poultry industry worldwide.", [["infectious bronchitis virus", "DISEASE", 18, 45], ["IntroductionAvian infectious bronchitis virus", "ORGANISM", 0, 45], ["IBV", "ORGANISM", 47, 50], ["infectious bronchitis virus", "SPECIES", 18, 45], ["IntroductionAvian infectious bronchitis virus", "SPECIES", 0, 45], ["IBV", "SPECIES", 47, 50], ["IntroductionAvian infectious bronchitis virus", "PROBLEM", 0, 45], ["the microorganism", "PROBLEM", 55, 72], ["a significant economic loss", "PROBLEM", 85, 112], ["infectious", "OBSERVATION_MODIFIER", 18, 28], ["significant", "OBSERVATION_MODIFIER", 87, 98], ["economic", "OBSERVATION_MODIFIER", 99, 107], ["loss", "OBSERVATION", 108, 112]]], ["IBV is a positive-sense, single-stranded RNA virus that belongs to the coronaviruses.", [["IBV", "ORGANISM", 0, 3], ["coronaviruses", "ORGANISM", 71, 84], ["IBV", "SPECIES", 0, 3], ["IBV", "PROBLEM", 0, 3], ["single-stranded RNA virus", "PROBLEM", 25, 50], ["positive", "OBSERVATION", 9, 17], ["coronaviruses", "OBSERVATION", 71, 84]]], ["All viruses in the family of coronavirus replicate in the cytoplasm of infected cells (Maclachlanand Dubovi, 2010 \u25b6; Cavanagh, 2007 \u25b6).", [["cytoplasm", "ANATOMY", 58, 67], ["cells", "ANATOMY", 80, 85], ["coronavirus", "ORGANISM", 29, 40], ["cytoplasm", "ORGANISM_SUBSTANCE", 58, 67], ["cells", "CELL", 80, 85], ["infected cells", "CELL_TYPE", 71, 85], ["All viruses", "PROBLEM", 0, 11], ["coronavirus", "PROBLEM", 29, 40], ["infected cells", "PROBLEM", 71, 85], ["viruses", "OBSERVATION", 4, 11], ["infected cells", "OBSERVATION", 71, 85]]], ["Virion of IBV has four kinds of proteins in its structure including the spike (S), the membrane (M), the envelope (E) and the nucleocapsid (N).", [["membrane", "ANATOMY", 87, 95], ["IBV", "ORGANISM", 10, 13], ["membrane", "CELLULAR_COMPONENT", 87, 95], ["envelope", "CELLULAR_COMPONENT", 105, 113], ["nucleocapsid", "CELLULAR_COMPONENT", 126, 138], ["spike (S)", "PROTEIN", 72, 81], ["envelope (E)", "PROTEIN", 105, 117], ["nucleocapsid (N)", "PROTEIN", 126, 142], ["IBV", "SPECIES", 10, 13], ["Virion of IBV", "PROBLEM", 0, 13], ["proteins in its structure", "PROBLEM", 32, 57], ["IBV", "OBSERVATION", 10, 13], ["four kinds", "OBSERVATION_MODIFIER", 18, 28], ["proteins", "OBSERVATION", 32, 40], ["spike", "OBSERVATION_MODIFIER", 72, 77]]], ["The major target of IBV is the respiratory system and can also affect the reproductive system and kidneys (Raj and Jones, 1997 \u25b6).", [["respiratory system", "ANATOMY", 31, 49], ["reproductive system", "ANATOMY", 74, 93], ["kidneys", "ANATOMY", 98, 105], ["IBV", "ORGANISM", 20, 23], ["reproductive system", "ANATOMICAL_SYSTEM", 74, 93], ["kidneys", "ORGAN", 98, 105], ["IBV", "SPECIES", 20, 23], ["major", "OBSERVATION_MODIFIER", 4, 9], ["target", "OBSERVATION_MODIFIER", 10, 16], ["IBV", "OBSERVATION", 20, 23], ["respiratory system", "ANATOMY", 31, 49], ["kidneys", "ANATOMY", 98, 105]]], ["There is no exact cure for infectious bronchitis (IB) due to IBV so, the vaccination is the best way to prevent.", [["infectious bronchitis", "DISEASE", 27, 48], ["IBV", "ORGANISM", 61, 64], ["IBV", "SPECIES", 61, 64], ["infectious bronchitis", "PROBLEM", 27, 48], ["IBV", "PROBLEM", 61, 64], ["the vaccination", "TREATMENT", 69, 84], ["no exact", "UNCERTAINTY", 9, 17], ["infectious", "OBSERVATION_MODIFIER", 27, 37], ["bronchitis", "OBSERVATION", 38, 48]]], ["However, the variations of IBV that is made during replication may reduce the efficacy of some IBV vaccines (Jackwoodet al, 2007 \u25b6).", [["IBV", "ORGANISM", 27, 30], ["IBV", "ORGANISM", 95, 98], ["IBV", "SPECIES", 27, 30], ["IBV", "SPECIES", 95, 98], ["IBV", "TREATMENT", 27, 30], ["some IBV vaccines", "TREATMENT", 90, 107], ["IBV", "OBSERVATION", 27, 30]]], ["Although the vaccination strategy has been adopted, medicinal plants that have antiviral effects can be regarded as an alternative to vaccination or at least can be added to the vaccination programs (de Wit and Cook, 2014 \u25b6).", [["the vaccination strategy", "TREATMENT", 9, 33], ["medicinal plants", "TREATMENT", 52, 68], ["antiviral effects", "TREATMENT", 79, 96]]], ["Allium sativum, garlic in English, belongs to the Alliaceae family (Delahaand Garagusi, 1985 \u25b6).", [["Allium sativum, garlic", "CHEMICAL", 0, 22], ["Allium sativum", "ORGANISM", 0, 14], ["garlic", "ORGANISM", 16, 22], ["Allium sativum", "SPECIES", 0, 14], ["garlic", "SPECIES", 16, 22], ["Allium sativum", "SPECIES", 0, 14], ["sativum", "OBSERVATION_MODIFIER", 7, 14]]], ["It has different minerals such as Ca, Fe, K, Cu and Mg and also contains variety of vitamins (This plant is full of water-soluble organosulfur compounds like S-allyl cysteine (SAC), S-ethyl cysteine (SEC), and S-propyl cysteine (SPC) (Suleria et al., 2015 \u25b6).IntroductionTraditionally, garlic has been used for curing disease (Bayanet al., 2014 \u25b6) and some of its medicinal effects like hypoglycemic (Johnson et al., 2006 \u25b6) anticancer (Dion and Milner, 1997 \u25b6) and antimicrobial activities (Rose et al., 2005 \u25b6) have been proven.", [["anticancer", "ANATOMY", 425, 435], ["Ca", "CHEMICAL", 34, 36], ["Fe", "CHEMICAL", 38, 40], ["K", "CHEMICAL", 42, 43], ["Cu", "CHEMICAL", 45, 47], ["Mg", "CHEMICAL", 52, 54], ["vitamins", "CHEMICAL", 84, 92], ["S-allyl cysteine", "CHEMICAL", 158, 174], ["SAC", "CHEMICAL", 176, 179], ["S-ethyl cysteine", "CHEMICAL", 182, 198], ["S-propyl cysteine", "CHEMICAL", 210, 227], ["garlic", "CHEMICAL", 286, 292], ["hypoglycemic", "DISEASE", 387, 399], ["Ca", "CHEMICAL", 34, 36], ["Fe", "CHEMICAL", 38, 40], ["K", "CHEMICAL", 42, 43], ["Cu", "CHEMICAL", 45, 47], ["Mg", "CHEMICAL", 52, 54], ["vitamins", "CHEMICAL", 84, 92], ["organosulfur", "CHEMICAL", 130, 142], ["S-allyl cysteine", "CHEMICAL", 158, 174], ["SAC", "CHEMICAL", 176, 179], ["S-ethyl cysteine", "CHEMICAL", 182, 198], ["SEC", "CHEMICAL", 200, 203], ["S-propyl cysteine", "CHEMICAL", 210, 227], ["SPC", "CHEMICAL", 229, 232], ["Ca", "SIMPLE_CHEMICAL", 34, 36], ["Fe", "SIMPLE_CHEMICAL", 38, 40], ["K", "SIMPLE_CHEMICAL", 42, 43], ["Cu", "SIMPLE_CHEMICAL", 45, 47], ["Mg", "SIMPLE_CHEMICAL", 52, 54], ["vitamins", "SIMPLE_CHEMICAL", 84, 92], ["organosulfur compounds", "SIMPLE_CHEMICAL", 130, 152], ["S-allyl cysteine", "SIMPLE_CHEMICAL", 158, 174], ["SAC", "SIMPLE_CHEMICAL", 176, 179], ["S-ethyl cysteine", "SIMPLE_CHEMICAL", 182, 198], ["SEC", "SIMPLE_CHEMICAL", 200, 203], ["S-propyl cysteine", "SIMPLE_CHEMICAL", 210, 227], ["SPC", "SIMPLE_CHEMICAL", 229, 232], ["garlic", "ORGANISM", 286, 292], ["anticancer", "CANCER", 425, 435], ["garlic", "SPECIES", 286, 292], ["Fe", "TEST", 38, 40], ["Mg", "TREATMENT", 52, 54], ["vitamins", "TREATMENT", 84, 92], ["water-soluble organosulfur compounds", "TREATMENT", 116, 152], ["S-allyl cysteine (SAC", "TREATMENT", 158, 179], ["S-ethyl cysteine (SEC)", "TREATMENT", 182, 204], ["S-propyl cysteine", "TREATMENT", 210, 227], ["SAC", "ANATOMY", 176, 179]]], ["Experimental trial of garlic gave it a place in veterinary medicine industry and it is used for health improvement and disease prevention in animal sciences.", [["garlic", "CHEMICAL", 22, 28], ["garlic", "SIMPLE_CHEMICAL", 22, 28], ["garlic", "SPECIES", 22, 28], ["garlic", "TREATMENT", 22, 28], ["disease prevention", "TREATMENT", 119, 137]]], ["Due to industrialization, in the 21st century, a part of our diet is synthetic.", [["industrialization", "OBSERVATION", 7, 24]]], ["Not only our daily food but also most of the medicines are synthetic.", [["the medicines", "TREATMENT", 41, 54]]], ["Although the most of the chemical medicines are effective, their wide side effects are known.", [["the chemical medicines", "TREATMENT", 21, 43]]], ["Although it is thought that the medicinal plants will go aside in human life little by little, people gradually figure out the complications of using the chemical medicines and attentions come back to the medicinal plants (Bayan et al., 2014 \u25b6).", [["human", "ORGANISM", 66, 71], ["people", "ORGANISM", 95, 101], ["human", "SPECIES", 66, 71], ["people", "SPECIES", 95, 101], ["human", "SPECIES", 66, 71], ["the chemical medicines", "TREATMENT", 150, 172]]], ["For infectious bronchitis due to IBV, no certain treatment exists.", [["infectious bronchitis", "DISEASE", 4, 25], ["IBV", "DISEASE", 33, 36], ["IBV", "ORGANISM", 33, 36], ["IBV", "SPECIES", 33, 36], ["infectious bronchitis", "PROBLEM", 4, 25], ["IBV", "PROBLEM", 33, 36], ["certain treatment", "TREATMENT", 41, 58], ["infectious", "OBSERVATION_MODIFIER", 4, 14], ["bronchitis", "OBSERVATION", 15, 25], ["IBV", "OBSERVATION", 33, 36]]], ["Removal of cold stress, high-quality air and management factors can help to control this disease.", [["Removal", "TREATMENT", 0, 7], ["cold stress", "PROBLEM", 11, 22], ["management factors", "TREATMENT", 45, 63], ["this disease", "PROBLEM", 84, 96], ["cold stress", "OBSERVATION", 11, 22]]], ["Antibacterial agents reduce death due to airsaculitis (Maclachlanand Dubovi, 2010 \u25b6).", [["death", "DISEASE", 28, 33], ["airsaculitis", "DISEASE", 41, 53], ["Antibacterial agents", "TREATMENT", 0, 20], ["death", "PROBLEM", 28, 33], ["airsaculitis", "PROBLEM", 41, 53]]], ["Therefore, it is logical to use medicinal plants for treatment of the disease for which the only way to control is vaccination and the vaccination in some region is not impressively effective.", [["medicinal plants", "TREATMENT", 32, 48], ["treatment", "TREATMENT", 53, 62], ["the disease", "PROBLEM", 66, 77], ["vaccination", "TREATMENT", 115, 126], ["the vaccination", "TREATMENT", 131, 146], ["disease", "OBSERVATION", 70, 77]]], ["The aim of this study is evaluation of the effect of Allium sativum (garlic) extract on infectious bronchitis virus in SPF embryonic egg as a pilot study.Materials and Methods", [["embryonic egg", "ANATOMY", 123, 136], ["Allium sativum (garlic) extract", "CHEMICAL", 53, 84], ["infectious bronchitis virus", "DISEASE", 88, 115], ["Allium sativum", "ORGANISM", 53, 67], ["garlic", "SIMPLE_CHEMICAL", 69, 75], ["infectious bronchitis virus", "ORGANISM", 88, 115], ["Allium sativum", "SPECIES", 53, 67], ["garlic", "SPECIES", 69, 75], ["infectious bronchitis virus", "SPECIES", 88, 115], ["Allium sativum", "SPECIES", 53, 67], ["infectious bronchitis virus", "SPECIES", 88, 115], ["SPF", "SPECIES", 119, 122], ["this study", "TEST", 11, 21], ["evaluation", "TEST", 25, 35], ["Allium sativum (garlic) extract", "PROBLEM", 53, 84], ["infectious bronchitis virus", "PROBLEM", 88, 115], ["SPF embryonic egg", "PROBLEM", 119, 136], ["a pilot study", "TEST", 140, 153], ["Methods", "TREATMENT", 168, 175], ["infectious", "OBSERVATION_MODIFIER", 88, 98], ["bronchitis", "OBSERVATION", 99, 109], ["SPF embryonic egg", "OBSERVATION", 119, 136]]]], "66f332afb3cfd68bcacc440946484860f418bf46": [["IntroductionBreast milk delivers not only immunologic components that protect the infant against pathogen invasion, but also nutritional factors that promote normal organ development (Wang and Brand-Miller, 2003) .", [["Breast milk", "ANATOMY", 12, 23], ["organ", "ANATOMY", 165, 170], ["Breast milk", "ORGANISM_SUBSTANCE", 12, 23], ["infant", "ORGANISM", 82, 88], ["organ", "ORGAN", 165, 170], ["infant", "SPECIES", 82, 88], ["IntroductionBreast milk", "TREATMENT", 0, 23], ["immunologic components", "TREATMENT", 42, 64], ["pathogen invasion", "PROBLEM", 97, 114], ["invasion", "OBSERVATION", 106, 114]]], ["Colostrum is the natural food produced by female mammals during the first 24-72 h after giving birth (Robison et al., 1988) .", [["Colostrum", "CHEMICAL", 0, 9]]], ["It contains concentrated nutrients, antibodies, cytokines, and growth factors (Playford et al., 2000; Jouan et al., 2006) , providing immediate immune protection to the newborns (Asakuma et al., 2007; Benson et al., 2012) .IntroductionInfluenza is a single-stranded RNA orthomyxovirus, subdivided into influenza A, B and C (Gatherer, 2009) .", [["Influenza", "DISEASE", 235, 244], ["newborns", "ORGANISM", 169, 177], ["Influenza", "ORGANISM", 235, 244], ["antibodies", "PROTEIN", 36, 46], ["cytokines", "PROTEIN", 48, 57], ["growth factors", "PROTEIN", 63, 77], ["immediate immune protection", "TREATMENT", 134, 161], ["Influenza", "PROBLEM", 235, 244], ["concentrated nutrients", "OBSERVATION", 12, 34]]], ["The H1N1 and H3N2 subtypes of influenza A and influenza B are widely recognized as causes of seasonal flu (Goldstein et al., 2011) .", [["influenza A", "DISEASE", 30, 41], ["influenza B", "DISEASE", 46, 57], ["H3N2 subtypes", "ORGANISM", 13, 26], ["influenza A", "ORGANISM", 30, 41], ["influenza B", "ORGANISM", 46, 57], ["H3N2", "SPECIES", 13, 17], ["influenza A and influenza", "SPECIES", 30, 55], ["The H1N1", "PROBLEM", 0, 8], ["H3N2", "PROBLEM", 13, 17], ["influenza A", "PROBLEM", 30, 41], ["influenza B", "PROBLEM", 46, 57], ["seasonal flu", "PROBLEM", 93, 105], ["H1N1", "OBSERVATION", 4, 8], ["H3N2", "OBSERVATION", 13, 17], ["influenza", "OBSERVATION", 30, 39]]], ["The virus can evade humoral immunity by antigenic drift, i.e. changes in the amino acid sequence of the surface hemag-glutinin and/or neuraminidase (Webster et al., 1982; Sandbulte et al., 2011) , which is why influenza can cause epidemics annually.", [["surface", "ANATOMY", 104, 111], ["amino acid", "CHEMICAL", 77, 87], ["influenza", "DISEASE", 210, 219], ["amino acid", "CHEMICAL", 77, 87], ["amino acid", "AMINO_ACID", 77, 87], ["hemag-glutinin", "GENE_OR_GENE_PRODUCT", 112, 126], ["amino acid sequence", "PROTEIN", 77, 96], ["glutinin", "PROTEIN", 118, 126], ["neuraminidase", "PROTEIN", 134, 147], ["The virus", "PROBLEM", 0, 9], ["antigenic drift", "PROBLEM", 40, 55], ["the amino acid sequence", "TEST", 73, 96], ["the surface hemag", "TEST", 100, 117], ["influenza", "PROBLEM", 210, 219], ["virus", "OBSERVATION", 4, 9], ["antigenic drift", "OBSERVATION", 40, 55]]], ["Although in most cases symptoms resolve within a week without the need for treatment, in high-risk groups influenza can lead to severe illness or death (World Health Organization, 2009 ).", [["influenza", "DISEASE", 106, 115], ["illness", "DISEASE", 135, 142], ["death", "DISEASE", 146, 151], ["symptoms", "PROBLEM", 23, 31], ["treatment", "TREATMENT", 75, 84], ["influenza", "PROBLEM", 106, 115], ["severe illness", "PROBLEM", 128, 142], ["death", "PROBLEM", 146, 151]]], ["In the United States, the influenza-attributable mortality rate is estimated at 1.4-16.7 deaths per 100,000 cases, which translates to between 3,339 and 48,614 deaths annually (Centers for Disease Control and Prevention, 2010) .", [["deaths", "DISEASE", 89, 95], ["deaths", "DISEASE", 160, 166], ["the influenza-attributable mortality rate", "TEST", 22, 63], ["Disease Control", "TREATMENT", 189, 204]]], ["Influenza is a serious public health and economic issue.", [["Influenza", "DISEASE", 0, 9], ["Influenza", "PROBLEM", 0, 9]]], ["In developed countries especially, epidemics can result in high levels of worker absenteeism and productivity losses (World Health Organization, 2009 ).", [["epidemics", "PROBLEM", 35, 44], ["productivity losses", "PROBLEM", 97, 116]]], ["Therefore, much effort has been put into preventing infections.IntroductionIt is known that the oligosaccharide contents of bovine colostrum are different from those of human colostrum.", [["colostrum", "ANATOMY", 131, 140], ["colostrum", "ANATOMY", 175, 184], ["infections", "DISEASE", 52, 62], ["bovine", "ORGANISM", 124, 130], ["colostrum", "ORGANISM_SUBSTANCE", 131, 140], ["human", "ORGANISM", 169, 174], ["colostrum", "ORGANISM_SUBDIVISION", 175, 184], ["bovine", "SPECIES", 124, 130], ["human", "SPECIES", 169, 174], ["bovine", "SPECIES", 124, 130], ["human", "SPECIES", 169, 174], ["infections", "PROBLEM", 52, 62], ["the oligosaccharide contents of bovine colostrum", "PROBLEM", 92, 140], ["infections", "OBSERVATION", 52, 62], ["bovine colostrum", "OBSERVATION", 124, 140]]], ["6sialyllactosamine and 3-sialyllactose are the most abundant in bovine colostrum while 3-sialyl-3-fucosyllactose and sialyllacto-N-tetraoses are in human colostrum (Martin-Sosa et al., 2003) .", [["colostrum", "ANATOMY", 71, 80], ["6sialyllactosamine", "CHEMICAL", 0, 18], ["3-sialyllactose", "CHEMICAL", 23, 38], ["3-sialyl-3-fucosyllactose", "CHEMICAL", 87, 112], ["sialyllacto-N-tetraoses", "CHEMICAL", 117, 140], ["6sialyllactosamine", "CHEMICAL", 0, 18], ["3-sialyllactose", "CHEMICAL", 23, 38], ["3-sialyl-3-fucosyllactose", "CHEMICAL", 87, 112], ["sialyllacto-N-tetraoses", "CHEMICAL", 117, 140], ["6sialyllactosamine", "SIMPLE_CHEMICAL", 0, 18], ["3-sialyllactose", "SIMPLE_CHEMICAL", 23, 38], ["bovine", "ORGANISM", 64, 70], ["colostrum", "ORGANISM_SUBSTANCE", 71, 80], ["3-sialyl-3-fucosyllactose", "SIMPLE_CHEMICAL", 87, 112], ["sialyllacto-N-tetraoses", "SIMPLE_CHEMICAL", 117, 140], ["human", "ORGANISM", 148, 153], ["colostrum", "ORGANISM_SUBSTANCE", 154, 163], ["bovine", "SPECIES", 64, 70], ["human", "SPECIES", 148, 153], ["bovine", "SPECIES", 64, 70], ["human", "SPECIES", 148, 153], ["6sialyllactosamine", "TREATMENT", 0, 18], ["sialyllactose", "TREATMENT", 25, 38], ["sialyl", "TEST", 89, 95], ["fucosyllactose", "TREATMENT", 98, 112], ["sialyllacto", "TREATMENT", 117, 128], ["tetraoses", "TREATMENT", 131, 140], ["bovine colostrum", "OBSERVATION", 64, 80]]], ["Although there are differences in the oligosaccharide contents, both colostrums have been regarded to have biological functions to modulate diseases.", [["modulate diseases", "PROBLEM", 131, 148], ["differences", "OBSERVATION_MODIFIER", 19, 30], ["oligosaccharide contents", "OBSERVATION", 38, 62]]], ["Previous reports have shown that human colostrum can modulate the immune system and enhance protection against pathogens (Claud et al., 2003; Wang and Brand-Miller, 2003) .", [["colostrum", "ANATOMY", 39, 48], ["immune system", "ANATOMY", 66, 79], ["human", "ORGANISM", 33, 38], ["colostrum", "ORGANISM_SUBSTANCE", 39, 48], ["human", "SPECIES", 33, 38], ["human", "SPECIES", 33, 38], ["human colostrum", "PROBLEM", 33, 48], ["pathogens", "PROBLEM", 111, 120]]], ["Dietary intake of bovine colostrum has also been suggested to prevent upper respiratory tract (URT) infections (Brinkworth and Buckley, 2003) .", [["colostrum", "ANATOMY", 25, 34], ["upper respiratory tract", "ANATOMY", 70, 93], ["upper respiratory tract (URT) infections", "DISEASE", 70, 110], ["bovine", "ORGANISM", 18, 24], ["colostrum", "ORGANISM_SUBSTANCE", 25, 34], ["upper respiratory", "ORGANISM_SUBDIVISION", 70, 87], ["tract", "ORGANISM_SUBDIVISION", 88, 93], ["bovine", "SPECIES", 18, 24], ["bovine", "SPECIES", 18, 24], ["bovine colostrum", "TREATMENT", 18, 34], ["upper respiratory tract (URT) infections", "PROBLEM", 70, 110], ["upper", "ANATOMY_MODIFIER", 70, 75], ["respiratory tract", "ANATOMY", 76, 93], ["URT", "ANATOMY", 95, 98], ["infections", "OBSERVATION", 100, 110]]], ["However, there has been no direct evidence that dietary bovine colostrum enhances protection against influenza infection.", [["colostrum", "ANATOMY", 63, 72], ["influenza infection", "DISEASE", 101, 120], ["bovine", "ORGANISM", 56, 62], ["colostrum", "ORGANISM_SUBSTANCE", 63, 72], ["bovine", "SPECIES", 56, 62], ["bovine", "SPECIES", 56, 62], ["dietary bovine colostrum", "TREATMENT", 48, 72], ["influenza infection", "PROBLEM", 101, 120], ["no direct evidence", "UNCERTAINTY", 24, 42], ["bovine colostrum", "OBSERVATION", 56, 72]]], ["The amount of acidic proteins and sialic acid in milk is known to decrease significantly as lactation progresses (Bezkorovainy, 1965; Wang and Brand-Miller, 2003) , therefore, the acidic protein fraction is thought to have an important function in colostrum.", [["milk", "ANATOMY", 49, 53], ["colostrum", "ANATOMY", 248, 257], ["sialic acid", "CHEMICAL", 34, 45], ["sialic acid", "CHEMICAL", 34, 45], ["sialic acid", "SIMPLE_CHEMICAL", 34, 45], ["milk", "ORGANISM_SUBSTANCE", 49, 53], ["colostrum", "ORGANISM_SUBSTANCE", 248, 257], ["acidic proteins", "PROTEIN", 14, 29], ["acidic proteins", "PROBLEM", 14, 29], ["sialic acid in milk", "PROBLEM", 34, 53], ["the acidic protein fraction", "TEST", 176, 203], ["amount", "OBSERVATION_MODIFIER", 4, 10], ["acidic proteins", "OBSERVATION", 14, 29], ["sialic acid", "OBSERVATION", 34, 45], ["decrease", "OBSERVATION_MODIFIER", 66, 74]]], ["In this study we isolated the acidic protein fraction of bovine colostrum (AFC) and investigated how dietary intake of AFC modulates the symptoms of influenza infection.Materials and apparatusBovine colostrum powder was provided by Ildong Foodis (Korea).", [["colostrum", "ANATOMY", 64, 73], ["AFC", "ANATOMY", 75, 78], ["AFC", "CHEMICAL", 119, 122], ["influenza infection", "DISEASE", 149, 168], ["bovine", "ORGANISM", 57, 63], ["colostrum", "ORGANISM_SUBSTANCE", 64, 73], ["AFC", "CELL", 75, 78], ["AFC", "SIMPLE_CHEMICAL", 119, 122], ["Bovine", "ORGANISM", 192, 198], ["colostrum", "ORGANISM", 199, 208], ["bovine", "SPECIES", 57, 63], ["Bovine", "SPECIES", 192, 198], ["bovine", "SPECIES", 57, 63], ["Bovine", "SPECIES", 192, 198], ["this study", "TEST", 3, 13], ["the acidic protein fraction", "PROBLEM", 26, 53], ["bovine colostrum", "TREATMENT", 57, 73], ["AFC modulates", "PROBLEM", 119, 132], ["the symptoms", "PROBLEM", 133, 145], ["influenza infection", "PROBLEM", 149, 168], ["Materials", "TREATMENT", 169, 178], ["apparatusBovine colostrum powder", "TREATMENT", 183, 215], ["bovine colostrum", "OBSERVATION", 57, 73], ["influenza", "OBSERVATION_MODIFIER", 149, 158], ["infection", "OBSERVATION", 159, 168]]], ["DEAE-sepharose CL-6B was purchased from GE Healthcare (USA).", [["CL-6B", "CHEMICAL", 15, 20], ["DEAE", "TEST", 0, 4], ["sepharose CL", "TEST", 5, 17]]], ["A Power Pac 3000 power supply and electrophoresis kit (both from Bio-Rad, USA) were used for SDS-polyacrylamide gel electrophoresis (SDS-PAGE, Mini Protean \u00ae II, Bio-Rad).", [["polyacrylamide", "CHEMICAL", 97, 111], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 162, 169], ["A Power Pac 3000 power supply", "TREATMENT", 0, 29], ["electrophoresis kit", "TREATMENT", 34, 53], ["Bio-Rad, USA", "TREATMENT", 65, 77], ["SDS", "TEST", 93, 96], ["polyacrylamide gel electrophoresis", "TREATMENT", 97, 131], ["SDS", "TEST", 133, 136]]], ["The protein fraction separated by SDS-PAGE was visualized by silver staining (GE Healthcare).", [["silver", "CHEMICAL", 61, 67], ["silver", "CHEMICAL", 61, 67], ["silver", "SIMPLE_CHEMICAL", 61, 67], ["The protein fraction", "TEST", 0, 20]]], ["The three mouse groups were given oseltamivir, PBS and AFC orally for 14 days prior to infection with influenza A virus.", [["oseltamivir", "CHEMICAL", 34, 45], ["AFC", "CHEMICAL", 55, 58], ["infection", "DISEASE", 87, 96], ["influenza A virus", "DISEASE", 102, 119], ["oseltamivir", "CHEMICAL", 34, 45], ["mouse", "ORGANISM", 10, 15], ["oseltamivir", "SIMPLE_CHEMICAL", 34, 45], ["PBS", "SIMPLE_CHEMICAL", 47, 50], ["AFC", "SIMPLE_CHEMICAL", 55, 58], ["influenza A virus", "ORGANISM", 102, 119], ["mouse", "SPECIES", 10, 15], ["influenza A virus", "SPECIES", 102, 119], ["mouse", "SPECIES", 10, 15], ["influenza A virus", "SPECIES", 102, 119], ["oseltamivir", "TREATMENT", 34, 45], ["PBS", "TREATMENT", 47, 50], ["AFC orally", "TREATMENT", 55, 65], ["infection", "PROBLEM", 87, 96], ["influenza A virus", "PROBLEM", 102, 119], ["infection", "OBSERVATION", 87, 96]]], ["After the virus challenge, the mice continued to receive oseltamivir, PBS and AFC for 7, 3 and 3 days, respectively.", [["oseltamivir", "CHEMICAL", 57, 68], ["oseltamivir", "CHEMICAL", 57, 68], ["mice", "ORGANISM", 31, 35], ["oseltamivir", "SIMPLE_CHEMICAL", 57, 68], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 31, 35], ["the virus challenge", "TREATMENT", 6, 25], ["oseltamivir", "TREATMENT", 57, 68], ["PBS", "TREATMENT", 70, 73], ["AFC", "TEST", 78, 81]]], ["They were then infected with 1 LD50 or 0.2 LD50 of the virus.", [["the virus", "TREATMENT", 51, 60]]], ["Survival rates and body weight changes were monitored for 14 days after infection.", [["body", "ANATOMY", 19, 23], ["infection", "DISEASE", 72, 81], ["body", "ORGANISM_SUBDIVISION", 19, 23], ["Survival rates", "TEST", 0, 14], ["body weight changes", "PROBLEM", 19, 38], ["infection", "PROBLEM", 72, 81], ["infection", "OBSERVATION", 72, 81]]], ["Influenza A/PR/8/34 virus (H1N1) was kindly donated by Prof. Man-Seong Park (Hallym University, Korea).", [["Influenza A/PR/8/34 virus", "ORGANISM", 0, 25], ["H1N1", "ORGANISM", 27, 31], ["Influenza A/PR/8/34 virus", "SPECIES", 0, 25], ["Influenza A/PR", "TEST", 0, 14], ["virus", "PROBLEM", 20, 25], ["H1N1", "PROBLEM", 27, 31]]], ["Zoletil 50 (Virbac, France) and Rompun (Bayer Animal Health, Germany) were used to anesthetize the mice.", [["Zoletil", "CHEMICAL", 0, 7], ["Zoletil", "CHEMICAL", 0, 7], ["Zoletil", "SIMPLE_CHEMICAL", 0, 7], ["mice", "ORGANISM", 99, 103], ["mice", "SPECIES", 99, 103], ["mice", "SPECIES", 99, 103], ["Zoletil", "TREATMENT", 0, 7]]], ["Phosphate buffered saline (PBS) and oseltamivir (Roche, Switzerland) were used as negative and positive controls in mouse experiments, respectively.AFC purification by anion-exchange chromatographyA 40 g sample of bovine colostrum powder was dissolved in binding buffer (2,000 ml of PBS containing 0.025% Tween 80, pH 7.0, final NaCl concentration was adjusted to 0.13 M).", [["Phosphate", "CHEMICAL", 0, 9], ["oseltamivir", "CHEMICAL", 36, 47], ["anion", "CHEMICAL", 168, 173], ["NaCl", "CHEMICAL", 329, 333], ["Phosphate", "CHEMICAL", 0, 9], ["oseltamivir", "CHEMICAL", 36, 47], ["Tween 80", "CHEMICAL", 305, 313], ["NaCl", "CHEMICAL", 329, 333], ["Phosphate buffered saline", "SIMPLE_CHEMICAL", 0, 25], ["PBS", "SIMPLE_CHEMICAL", 27, 30], ["oseltamivir", "SIMPLE_CHEMICAL", 36, 47], ["mouse", "ORGANISM", 116, 121], ["AFC", "SIMPLE_CHEMICAL", 148, 151], ["anion", "SIMPLE_CHEMICAL", 168, 173], ["bovine", "ORGANISM", 214, 220], ["colostrum", "ORGANISM", 221, 230], ["mouse", "SPECIES", 116, 121], ["bovine", "SPECIES", 214, 220], ["mouse", "SPECIES", 116, 121], ["bovine", "SPECIES", 214, 220], ["Phosphate buffered saline (PBS", "TREATMENT", 0, 30], ["oseltamivir", "TREATMENT", 36, 47], ["AFC purification", "TREATMENT", 148, 164], ["anion-exchange chromatographyA", "TREATMENT", 168, 198], ["bovine colostrum powder", "TREATMENT", 214, 237], ["PBS", "TREATMENT", 283, 286], ["pH", "TEST", 315, 317], ["final NaCl concentration", "TREATMENT", 323, 347]]], ["This starting sample was dialyzed against 10 L of binding buffer at 4\u00b0C for 4 h.", [["sample", "ANATOMY", 14, 20], ["binding buffer", "TREATMENT", 50, 64]]], ["The dialysate was centrifuged for 10 min at 14,000\u00d7g, to obtain the supernatant (i.e. the loading sample).", [["supernatant", "ANATOMY", 68, 79], ["dialysate", "ORGANISM_SUBSTANCE", 4, 13], ["The dialysate", "TREATMENT", 0, 13], ["the loading sample", "TEST", 86, 104]]], ["Anion exchange chromatography was performed in batch mode.", [["Anion", "SIMPLE_CHEMICAL", 0, 5], ["Anion exchange chromatography", "TEST", 0, 29]]], ["The loading sample was mixed with 40 ml DEAE-sepharose CL-6B resin equilibrated with binding buffer in a 2 L bottle, and the mixture was left at 4\u00b0C for 72 h.", [["sample", "ANATOMY", 12, 18], ["CL-6B resin", "CHEMICAL", 55, 66], ["CL-6B resin", "SIMPLE_CHEMICAL", 55, 66], ["The loading sample", "TREATMENT", 0, 18], ["sepharose CL", "TREATMENT", 45, 57], ["6B resin", "TREATMENT", 58, 66], ["binding buffer", "TREATMENT", 85, 99], ["a 2 L bottle", "TREATMENT", 103, 115], ["the mixture", "TREATMENT", 121, 132]]], ["The unbound fraction was removed by centrifugation at 84\u00d7g for 5 min.", [["The unbound fraction", "TREATMENT", 0, 20], ["unbound fraction", "OBSERVATION", 4, 20]]], ["The DEAE resin was centrifuged at 84\u00d7g for 5 min with 200 ml of the binding buffer.", [["The DEAE resin", "TREATMENT", 0, 14], ["the binding buffer", "TREATMENT", 64, 82]]], ["The AFC fraction was isolated with elution buffer (to make elution buffer NaCl was added to the binding buffer, final NaCl concentration of elution buffer was adjusted to 0.652 M).", [["NaCl", "CHEMICAL", 74, 78], ["NaCl", "CHEMICAL", 118, 122], ["NaCl", "CHEMICAL", 74, 78], ["NaCl", "CHEMICAL", 118, 122], ["AFC", "SIMPLE_CHEMICAL", 4, 7], ["The AFC fraction", "TEST", 0, 16], ["elution buffer", "TREATMENT", 35, 49], ["elution buffer NaCl", "TREATMENT", 59, 78], ["the binding buffer", "TREATMENT", 92, 110], ["final NaCl concentration of elution buffer", "TREATMENT", 112, 154], ["AFC fraction", "OBSERVATION", 4, 16]]], ["The protein content of the starting sample, the loading sample and AFC were analyzed as described below.Proteomic analysisThe proteins in each sample were separated on 12% SDS-PAGE gels as described by Laemmli (1970) and visualized by silver staining.", [["sample", "ANATOMY", 36, 42], ["sample", "ANATOMY", 143, 149], ["silver", "CHEMICAL", 235, 241], ["silver", "CHEMICAL", 235, 241], ["silver", "SIMPLE_CHEMICAL", 235, 241], ["the loading sample", "TEST", 44, 62], ["AFC", "TEST", 67, 70], ["Proteomic analysis", "TEST", 104, 122], ["silver staining", "OBSERVATION", 235, 250]]], ["Protein concentration was determined by the Bradford protein concentration assay (Bio-Rad).", [["Protein concentration", "TEST", 0, 21], ["the Bradford protein concentration assay", "TEST", 40, 80]]], ["Twodimensional electrophoresis (2DE) of 800 \u03bcg protein samples was performed by Genomine Inc. (Korea), and the separated proteins were visualized by Coomassie blue staining.Virus preparationInfluenza A virus was propagated in 11-day old fertilized chicken eggs for 48 h at 37\u00b0C. Egg allantoic fluid was clarified by centrifugation at 682\u00d7g for 10 min and filtered using a 0.22 \u03bcm syringe filter.", [["eggs", "ANATOMY", 256, 260], ["allantoic fluid", "ANATOMY", 283, 298], ["Influenza", "DISEASE", 190, 199], ["Coomassie blue", "CHEMICAL", 149, 163], ["Coomassie", "SIMPLE_CHEMICAL", 149, 158], ["Virus", "ORGANISM", 173, 178], ["Influenza", "ORGANISM", 190, 199], ["chicken", "ORGANISM", 248, 255], ["eggs", "DEVELOPING_ANATOMICAL_STRUCTURE", 256, 260], ["Egg allantoic fluid", "ORGANISM_SUBSTANCE", 279, 298], ["Influenza", "SPECIES", 190, 199], ["chicken", "SPECIES", 248, 255], ["Influenza", "SPECIES", 190, 199], ["A virus", "SPECIES", 200, 207], ["chicken", "SPECIES", 248, 255], ["Twodimensional electrophoresis", "TEST", 0, 30], ["protein samples", "TEST", 47, 62], ["the separated proteins", "PROBLEM", 107, 129], ["Virus preparation", "TREATMENT", 173, 190], ["Influenza", "PROBLEM", 190, 199], ["A virus", "PROBLEM", 200, 207], ["Egg allantoic fluid", "TEST", 279, 298], ["a 0.22 \u03bcm syringe filter", "TREATMENT", 370, 394], ["virus", "OBSERVATION", 202, 207], ["fluid", "OBSERVATION", 293, 298]]], ["The 50% lethal dose (LD50) of the virus was determined as described (Reed and Muench, 1938) .Oral administrations of AFC and infection with influenza A (H1N1) virusFive-week-old female Balb/c mice purchased from Orient Bio (Korea) were divided into three groups (PBS, oseltamivir and AFC) of five to six mice each.", [["Oral", "ANATOMY", 93, 97], ["AFC", "CHEMICAL", 117, 120], ["infection", "DISEASE", 125, 134], ["oseltamivir", "CHEMICAL", 268, 279], ["oseltamivir", "CHEMICAL", 268, 279], ["Oral", "ORGANISM_SUBDIVISION", 93, 97], ["AFC", "SIMPLE_CHEMICAL", 117, 120], ["influenza A (H1N1) virusFive", "ORGANISM", 140, 168], ["Balb/c mice", "ORGANISM", 185, 196], ["Orient Bio (Korea", "ORGANISM", 212, 229], ["oseltamivir", "SIMPLE_CHEMICAL", 268, 279], ["mice", "ORGANISM", 304, 308], ["influenza A (H1N1", "SPECIES", 140, 157], ["mice", "SPECIES", 192, 196], ["mice", "SPECIES", 304, 308], ["mice", "SPECIES", 192, 196], ["mice", "SPECIES", 304, 308], ["the virus", "PROBLEM", 30, 39], ["AFC", "PROBLEM", 117, 120], ["infection", "PROBLEM", 125, 134], ["influenza", "PROBLEM", 140, 149], ["Balb/c mice purchased", "TREATMENT", 185, 206], ["oseltamivir", "TREATMENT", 268, 279], ["AFC", "TREATMENT", 284, 287], ["infection", "OBSERVATION", 125, 134]]], ["The dosing schedule for each group is shown in Fig. 1 .", [["The dosing schedule", "TREATMENT", 0, 19]]], ["The mice received PBS (200 \u03bcl/day) or AFC (0.5 mg/kg/day, 0.5 mg indicates protein amount) orally for 14 days before infection.", [["AFC", "CHEMICAL", 38, 41], ["infection", "DISEASE", 117, 126], ["mice", "ORGANISM", 4, 8], ["AFC", "SIMPLE_CHEMICAL", 38, 41], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["PBS", "TREATMENT", 18, 21], ["AFC", "TREATMENT", 38, 41], ["infection", "PROBLEM", 117, 126], ["infection", "OBSERVATION", 117, 126]]], ["The protein concentration of AFC was determined by Bradford protein assay using commercial protein assay kit (Bio-Rad).", [["AFC", "SIMPLE_CHEMICAL", 29, 32], ["Bio-Rad", "GENE_OR_GENE_PRODUCT", 110, 117], ["AFC", "PROTEIN", 29, 32], ["The protein concentration", "TEST", 0, 25], ["AFC", "TEST", 29, 32], ["commercial protein assay kit", "TEST", 80, 108]]], ["They were anesthetized intraperitoneally with a 4:1 mixture of Zoletil 50 and Rompun and infected intranasally with 1 LD50 or 0.2 LD 50 of the influenza A (H1N1) virus.", [["intraperitoneally", "ANATOMY", 23, 40], ["intranasally", "ANATOMY", 98, 110], ["Zoletil", "CHEMICAL", 63, 70], ["Zoletil", "SIMPLE_CHEMICAL", 63, 70], ["influenza A (H1N1) virus", "ORGANISM", 143, 167], ["influenza A (H1N1", "SPECIES", 143, 160], ["influenza A (H1N1) virus", "SPECIES", 143, 167], ["Zoletil", "TREATMENT", 63, 70], ["Rompun", "TREATMENT", 78, 84], ["the influenza A (H1N1) virus", "PROBLEM", 139, 167], ["influenza", "OBSERVATION", 143, 152]]], ["Following infection, the PBS and AFC groups continued to receive PBS (200 \u03bcl/day) and AFC (0.5 mg/kg/day), respectively, for 3 days, and the oseltamivir group continued to receive oseltamivir (10 mg/kg/day) for 7 days.", [["infection", "DISEASE", 10, 19], ["AFC", "CHEMICAL", 86, 89], ["oseltamivir", "CHEMICAL", 141, 152], ["oseltamivir", "CHEMICAL", 180, 191], ["oseltamivir", "CHEMICAL", 141, 152], ["oseltamivir", "CHEMICAL", 180, 191], ["AFC", "SIMPLE_CHEMICAL", 86, 89], ["oseltamivir", "SIMPLE_CHEMICAL", 180, 191], ["infection", "PROBLEM", 10, 19], ["the PBS and AFC groups", "TEST", 21, 43], ["PBS", "TREATMENT", 65, 68], ["AFC", "TREATMENT", 86, 89], ["the oseltamivir group", "TREATMENT", 137, 158], ["oseltamivir", "TREATMENT", 180, 191], ["infection", "OBSERVATION", 10, 19]]], ["Survival rates and changes in body weight were monitored for 14 days after infection.Statistical analysisStudent's t-test was used to evaluate differences between the groups.", [["body", "ANATOMY", 30, 34], ["infection", "DISEASE", 75, 84], ["body", "ORGANISM_SUBDIVISION", 30, 34], ["Survival rates", "TEST", 0, 14], ["changes in body weight", "TEST", 19, 41], ["infection", "PROBLEM", 75, 84], ["Statistical analysisStudent's t-test", "TEST", 85, 121], ["infection", "OBSERVATION", 75, 84]]], ["P-values <0.05, or <0.01 in two-tailed tests, were considered statistically significant.Separation and characterization of AFCAs shown in Fig. 2 , the starting sample and the loading sample were both found to contain three major protein bands with molecular masses of 52-76, 24-31, and 5-17 kDa.", [["sample", "ANATOMY", 160, 166], ["AFCAs", "PROTEIN", 123, 128], ["protein bands", "PROTEIN", 229, 242], ["P-values", "TEST", 0, 8], ["two-tailed tests", "TEST", 28, 44], ["AFCAs", "PROBLEM", 123, 128], ["the loading sample", "TEST", 171, 189], ["molecular masses", "TEST", 248, 264], ["masses", "OBSERVATION", 258, 264]]], ["There was no significant difference between the two samples in terms of protein composition.", [["samples", "ANATOMY", 52, 59], ["significant difference", "PROBLEM", 13, 35], ["no", "UNCERTAINTY", 10, 12], ["significant", "OBSERVATION_MODIFIER", 13, 24], ["difference", "OBSERVATION_MODIFIER", 25, 35], ["protein composition", "OBSERVATION", 72, 91]]], ["It has been suggested that bovine colostrum is composed of 50-75, 25-35, and 5-20 kDa proteins (Senda et al., 2011) , and our results were consistent with this finding.", [["colostrum", "ANATOMY", 34, 43], ["bovine", "ORGANISM", 27, 33], ["colostrum", "ORGANISM_SUBDIVISION", 34, 43], ["bovine", "SPECIES", 27, 33], ["bovine", "SPECIES", 27, 33], ["bovine colostrum", "TEST", 27, 43], ["bovine colostrum", "OBSERVATION", 27, 43], ["consistent with", "UNCERTAINTY", 139, 154]]], ["The 24-31 kDa protein band was the most prominent in AFC, the largest proportion of which was the 28 kDa fraction (Fig. 2) .", [["AFC", "ANATOMY", 53, 56], ["AFC", "CANCER", 53, 56], ["24-31 kDa protein band", "PROTEIN", 4, 26], ["kDa protein band", "TEST", 10, 26], ["most prominent", "OBSERVATION_MODIFIER", 35, 49], ["largest", "OBSERVATION_MODIFIER", 62, 69]]], ["We also compared the isoelectric points (pIs) of the proteins in the starting sample and in AFC (Fig. 3) .", [["sample", "ANATOMY", 78, 84], ["AFC", "CELL_TYPE", 92, 95], ["the proteins", "PROBLEM", 49, 61]]], ["Most of the proteins in AFC had pIs <5 (Fig. 3B) , while the pIs of the proteins in the starting sample ranged from 4 to 10 (Fig. 3A) , suggesting that AFC contains mainly acidic proteins.The effect of dietary intake of AFC on influenza A virus infection in miceWhereas the survival rates in both the oseltamivir and AFC groups were 100%, in the PBS group, only 33% of the animals challenged with 1 LD50 of the virus survived (Fig. 4A ).", [["sample", "ANATOMY", 97, 103], ["AFC", "CHEMICAL", 220, 223], ["influenza A virus infection", "DISEASE", 227, 254], ["oseltamivir", "CHEMICAL", 301, 312], ["oseltamivir", "CHEMICAL", 301, 312], ["AFC", "GENE_OR_GENE_PRODUCT", 24, 27], ["pIs", "GENE_OR_GENE_PRODUCT", 61, 64], ["AFC", "GENE_OR_GENE_PRODUCT", 152, 155], ["AFC", "SIMPLE_CHEMICAL", 220, 223], ["influenza A virus", "ORGANISM", 227, 244], ["AFC", "SIMPLE_CHEMICAL", 317, 320], ["animals", "ORGANISM", 373, 380], ["AFC", "PROTEIN", 24, 27], ["pIs", "PROTEIN", 61, 64], ["AFC", "PROTEIN", 152, 155], ["acidic proteins", "PROTEIN", 172, 187], ["influenza A virus", "SPECIES", 227, 244], ["influenza A virus", "SPECIES", 227, 244], ["AFC", "TEST", 24, 27], ["pIs", "TEST", 32, 35], ["the proteins", "TEST", 68, 80], ["AFC", "TEST", 152, 155], ["mainly acidic proteins", "PROBLEM", 165, 187], ["AFC", "PROBLEM", 220, 223], ["influenza A virus infection", "PROBLEM", 227, 254], ["the survival rates", "TREATMENT", 270, 288], ["the oseltamivir and AFC groups", "TREATMENT", 297, 327], ["the virus", "TREATMENT", 407, 416], ["AFC", "OBSERVATION", 152, 155], ["mainly", "OBSERVATION_MODIFIER", 165, 171], ["acidic proteins", "OBSERVATION", 172, 187]]], ["At the same time, oral administration of AFC significantly reduced body weight loss in the animals receiving 1 LD50 of the virus (Fig. 4B) .", [["oral", "ANATOMY", 18, 22], ["body", "ANATOMY", 67, 71], ["AFC", "CHEMICAL", 41, 44], ["weight loss", "DISEASE", 72, 83], ["oral", "ORGANISM_SUBDIVISION", 18, 22], ["AFC", "SIMPLE_CHEMICAL", 41, 44], ["body", "ORGANISM_SUBDIVISION", 67, 71], ["oral administration", "TREATMENT", 18, 37], ["AFC significantly reduced body weight loss", "PROBLEM", 41, 83], ["the virus", "TREATMENT", 119, 128]]], ["We also compared the changes in body weight in the three groups infected with 0.2 LD 50 .", [["body", "ANATOMY", 32, 36], ["body", "ORGANISM_SUBDIVISION", 32, 36], ["body weight", "TEST", 32, 43]]], ["As shown in Fig. 5 , the mice in the oseltamivir and AFC groups experienced no change in body weight, while significant weight loss was observed in the PBS group in days 4 to 7 after infection.", [["body", "ANATOMY", 89, 93], ["oseltamivir", "CHEMICAL", 37, 48], ["weight loss", "DISEASE", 120, 131], ["infection", "DISEASE", 183, 192], ["oseltamivir", "CHEMICAL", 37, 48], ["mice", "ORGANISM", 25, 29], ["oseltamivir", "SIMPLE_CHEMICAL", 37, 48], ["AFC", "SIMPLE_CHEMICAL", 53, 56], ["body", "ORGANISM_SUBDIVISION", 89, 93], ["mice", "SPECIES", 25, 29], ["mice", "SPECIES", 25, 29], ["the oseltamivir and AFC groups", "TREATMENT", 33, 63], ["change in body weight", "PROBLEM", 79, 100], ["significant weight loss", "PROBLEM", 108, 131], ["infection", "PROBLEM", 183, 192], ["no", "UNCERTAINTY", 76, 78], ["change", "OBSERVATION_MODIFIER", 79, 85], ["significant", "OBSERVATION_MODIFIER", 108, 119], ["weight loss", "OBSERVATION", 120, 131], ["infection", "OBSERVATION", 183, 192]]], ["These results demonstrate that dietary intake of AFC can ameliorate the symptoms associated with influenza.DiscussionPicornaviruses, coronaviruses, adenoviruses, parainfluenza viruses and influenza viruses are the causal pathogens in the vast majority of URT infections (Fendrick et al., 2003) .", [["AFC", "CHEMICAL", 49, 52], ["influenza", "DISEASE", 97, 106], ["parainfluenza viruses", "DISEASE", 162, 183], ["influenza viruses", "DISEASE", 188, 205], ["infections", "DISEASE", 259, 269], ["AFC", "SIMPLE_CHEMICAL", 49, 52], ["coronaviruses", "ORGANISM", 133, 146], ["adenoviruses", "ORGANISM", 148, 160], ["parainfluenza viruses", "ORGANISM", 162, 183], ["influenza viruses", "ORGANISM", 188, 205], ["parainfluenza", "SPECIES", 162, 175], ["parainfluenza viruses", "SPECIES", 162, 183], ["AFC", "PROBLEM", 49, 52], ["the symptoms", "PROBLEM", 68, 80], ["influenza", "PROBLEM", 97, 106], ["DiscussionPicornaviruses", "PROBLEM", 107, 131], ["coronaviruses", "PROBLEM", 133, 146], ["adenoviruses", "PROBLEM", 148, 160], ["parainfluenza viruses", "PROBLEM", 162, 183], ["influenza viruses", "PROBLEM", 188, 205], ["the causal pathogens", "PROBLEM", 210, 230], ["URT infections", "PROBLEM", 255, 269], ["parainfluenza viruses", "OBSERVATION", 162, 183], ["URT", "ANATOMY", 255, 258], ["infections", "OBSERVATION", 259, 269]]], ["Dietary supplementation with concentrated bovine colostrum proteins has been shown to reduce the incidence of symptoms of URT infection in adult men (Brinkworth and Buckley, 2003) .", [["URT infection", "DISEASE", 122, 135], ["bovine", "ORGANISM", 42, 48], ["colostrum", "ORGANISM_SUBSTANCE", 49, 58], ["URT", "CANCER", 122, 125], ["men", "ORGANISM", 145, 148], ["bovine", "SPECIES", 42, 48], ["men", "SPECIES", 145, 148], ["bovine", "SPECIES", 42, 48], ["Dietary supplementation", "TREATMENT", 0, 23], ["concentrated bovine colostrum proteins", "TREATMENT", 29, 67], ["symptoms", "PROBLEM", 110, 118], ["URT infection", "PROBLEM", 122, 135], ["URT", "ANATOMY", 122, 125], ["infection", "OBSERVATION", 126, 135]]], ["Recently, Patiroglu and Kondolot also reported that oral administration of bovine colostrum lessened the severity of viral URT infections in IgA-deficient children (Patiroglu and Kondolot, 2011) .", [["oral", "ANATOMY", 52, 56], ["colostrum", "ANATOMY", 82, 91], ["URT", "CHEMICAL", 123, 126], ["infections", "DISEASE", 127, 137], ["oral", "ORGANISM_SUBDIVISION", 52, 56], ["bovine", "ORGANISM", 75, 81], ["colostrum", "ORGANISM_SUBSTANCE", 82, 91], ["IgA", "GENE_OR_GENE_PRODUCT", 141, 144], ["children", "ORGANISM", 155, 163], ["IgA", "PROTEIN", 141, 144], ["bovine", "SPECIES", 75, 81], ["children", "SPECIES", 155, 163], ["bovine", "SPECIES", 75, 81], ["oral administration of bovine colostrum", "TREATMENT", 52, 91], ["viral URT infections", "PROBLEM", 117, 137], ["viral URT infections", "OBSERVATION", 117, 137]]], ["Based on these findings, we hypothesized that bovine colostrum would improve the symptoms associated with influenza virus.", [["colostrum", "ANATOMY", 53, 62], ["influenza virus", "DISEASE", 106, 121], ["bovine", "ORGANISM", 46, 52], ["colostrum", "ORGANISM", 53, 62], ["influenza virus", "ORGANISM", 106, 121], ["bovine", "SPECIES", 46, 52], ["bovine", "SPECIES", 46, 52], ["influenza virus", "SPECIES", 106, 121], ["bovine colostrum", "TREATMENT", 46, 62], ["the symptoms", "PROBLEM", 77, 89], ["influenza virus", "PROBLEM", 106, 121]]], ["We performed a large number of animal experiments investigating the effect of total bovine colostrum, and found that while some experiments yielded significant reductions in influenza-related morbidity and mortality, the symptom-ameliorating effects of the same bovine colostrum products varied significantly (Supplementary data Fig. S1 ).", [["colostrum", "ANATOMY", 91, 100], ["influenza", "DISEASE", 174, 183], ["bovine", "ORGANISM", 84, 90], ["colostrum", "ORGANISM_SUBSTANCE", 91, 100], ["bovine", "ORGANISM", 262, 268], ["colostrum", "ORGANISM", 269, 278], ["S1", "GENE_OR_GENE_PRODUCT", 334, 336], ["S1", "PROTEIN", 334, 336], ["bovine", "SPECIES", 84, 90], ["bovine", "SPECIES", 262, 268], ["bovine", "SPECIES", 84, 90], ["bovine", "SPECIES", 262, 268], ["animal experiments", "TREATMENT", 31, 49], ["total bovine colostrum", "TREATMENT", 78, 100], ["significant reductions", "PROBLEM", 148, 170], ["influenza", "PROBLEM", 174, 183], ["the symptom", "PROBLEM", 217, 228], ["the same bovine colostrum products", "TREATMENT", 253, 287], ["large", "OBSERVATION_MODIFIER", 15, 20], ["significant", "OBSERVATION_MODIFIER", 148, 159], ["reductions", "OBSERVATION_MODIFIER", 160, 170], ["influenza", "OBSERVATION", 174, 183]]], ["Therefore, the effect of total bovine colostrums on influenza virus infection in mice was significantly different from our expectation.", [["colostrums", "CHEMICAL", 38, 48], ["influenza virus infection", "DISEASE", 52, 77], ["bovine", "ORGANISM", 31, 37], ["colostrums", "GENE_OR_GENE_PRODUCT", 38, 48], ["influenza virus", "ORGANISM", 52, 67], ["mice", "ORGANISM", 81, 85], ["bovine", "SPECIES", 31, 37], ["influenza virus", "SPECIES", 52, 67], ["mice", "SPECIES", 81, 85], ["bovine", "SPECIES", 31, 37], ["mice", "SPECIES", 81, 85], ["total bovine colostrums", "TREATMENT", 25, 48], ["influenza virus infection", "PROBLEM", 52, 77]]], ["On the other hand, AFC showed promising effect for ameliorating symptoms caused by influenza infections (Figs.", [["influenza infections", "DISEASE", 83, 103], ["AFC", "SIMPLE_CHEMICAL", 19, 22], ["AFC", "TEST", 19, 22], ["ameliorating symptoms", "PROBLEM", 51, 72], ["influenza infections", "PROBLEM", 83, 103], ["influenza", "OBSERVATION", 83, 92]]], ["Previous studies implied that the intestinal conditions, i.e. bacterial flora and digestive enzymes involved in the absorption of colostrum components differed between human and animal subjects (Petschow and Talbott, 1994; Johnson et al., 2007; Kobayashi et al., 2012) .", [["intestinal", "ANATOMY", 34, 44], ["digestive", "ANATOMY", 82, 91], ["intestinal", "ORGAN", 34, 44], ["digestive enzymes", "GENE_OR_GENE_PRODUCT", 82, 99], ["colostrum", "ORGANISM", 130, 139], ["human", "ORGANISM", 168, 173], ["digestive enzymes", "PROTEIN", 82, 99], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["Previous studies", "TEST", 0, 16], ["the intestinal conditions", "PROBLEM", 30, 55], ["bacterial flora", "PROBLEM", 62, 77], ["digestive enzymes", "TEST", 82, 99], ["the absorption of colostrum components", "TREATMENT", 112, 150], ["intestinal", "ANATOMY", 34, 44], ["bacterial flora", "OBSERVATION", 62, 77]]], ["In other words, some components contained in bovine colostrum decrease the ameliorating effect or hinder the functions of novel compenents.", [["colostrum", "ANATOMY", 52, 61], ["bovine", "ORGANISM", 45, 51], ["colostrum", "ORGANISM_SUBSTANCE", 52, 61], ["bovine", "SPECIES", 45, 51], ["bovine", "SPECIES", 45, 51], ["bovine colostrum", "TREATMENT", 45, 61], ["bovine colostrum", "OBSERVATION", 45, 61]]], ["We suggest that separations of novel components such as AFC from the hindering components are thought to be critical in mouse experiment.", [["AFC", "GENE_OR_GENE_PRODUCT", 56, 59], ["mouse", "ORGANISM", 120, 125], ["AFC", "PROTEIN", 56, 59], ["mouse", "SPECIES", 120, 125], ["mouse", "SPECIES", 120, 125], ["novel components", "TREATMENT", 31, 47], ["AFC", "TREATMENT", 56, 59]]], ["We found that AFC contains significantly higher level of proteins harboring \u03b12,3-linked sialic acids than total bovine colostrums and acid protein fraction of mature bovine milk does (Supplementary data Fig. S2) , indicating that the anionexchange chromatography separates sialic acid rich fraction from the bovine colostrum.", [["colostrums", "ANATOMY", 119, 129], ["milk", "ANATOMY", 173, 177], ["colostrum", "ANATOMY", 315, 324], ["sialic acids", "CHEMICAL", 88, 100], ["sialic acid", "CHEMICAL", 273, 284], ["sialic acids", "CHEMICAL", 88, 100], ["sialic acid", "CHEMICAL", 273, 284], ["\u03b12,3-linked sialic acids", "SIMPLE_CHEMICAL", 76, 100], ["bovine", "ORGANISM", 112, 118], ["colostrums", "SIMPLE_CHEMICAL", 119, 129], ["bovine", "ORGANISM", 166, 172], ["milk", "ORGANISM_SUBSTANCE", 173, 177], ["sialic acid", "SIMPLE_CHEMICAL", 273, 284], ["bovine", "ORGANISM", 308, 314], ["colostrum", "ORGANISM_SUBSTANCE", 315, 324], ["AFC", "PROTEIN", 14, 17], ["\u03b12,3", "PROTEIN", 76, 80], ["bovine", "SPECIES", 112, 118], ["bovine", "SPECIES", 166, 172], ["milk", "SPECIES", 173, 177], ["bovine", "SPECIES", 308, 314], ["bovine", "SPECIES", 166, 172], ["bovine", "SPECIES", 308, 314], ["AFC", "TEST", 14, 17], ["sialic acids", "TEST", 88, 100], ["total bovine colostrums", "TREATMENT", 106, 129], ["acid protein fraction", "TEST", 134, 155], ["mature bovine milk", "PROBLEM", 159, 177], ["the anionexchange chromatography", "TEST", 230, 262], ["sialic acid rich fraction", "PROBLEM", 273, 298], ["the bovine colostrum", "TREATMENT", 304, 324], ["AFC", "OBSERVATION", 14, 17], ["significantly", "OBSERVATION_MODIFIER", 27, 40], ["higher", "OBSERVATION_MODIFIER", 41, 47], ["bovine milk", "OBSERVATION", 166, 177], ["bovine colostrum", "OBSERVATION", 308, 324]]], ["The sialic acid is known to inhibit influenza virus-mediated haemagglutination and infection (Matrosovich and Klenk, 2003) .", [["sialic acid", "CHEMICAL", 4, 15], ["infection", "DISEASE", 83, 92], ["sialic acid", "CHEMICAL", 4, 15], ["sialic acid", "SIMPLE_CHEMICAL", 4, 15], ["influenza virus", "ORGANISM", 36, 51], ["influenza virus", "SPECIES", 36, 51], ["The sialic acid", "PROBLEM", 0, 15], ["influenza virus", "PROBLEM", 36, 51], ["mediated haemagglutination", "PROBLEM", 52, 78], ["infection", "PROBLEM", 83, 92], ["sialic acid", "OBSERVATION", 4, 15], ["haemagglutination", "OBSERVATION_MODIFIER", 61, 78], ["infection", "OBSERVATION", 83, 92]]], ["In addition, \u03b12,3linked sialic acid is a cell receptor for influenza A virus infection (Glaser et al., 2005) .", [["cell", "ANATOMY", 41, 45], ["sialic acid", "CHEMICAL", 24, 35], ["influenza A virus infection", "DISEASE", 59, 86], ["sialic acid", "CHEMICAL", 24, 35], ["\u03b12,3linked sialic acid", "SIMPLE_CHEMICAL", 13, 35], ["cell", "CELL", 41, 45], ["influenza A virus", "ORGANISM", 59, 76], ["influenza A virus", "SPECIES", 59, 76], ["influenza A virus", "SPECIES", 59, 76], ["influenza A virus infection", "PROBLEM", 59, 86]]], ["Therefore, it is assumed that other components of AFC such as free sialyl oligosaccharides may be beneficial on ameliorating the symptom caused by influenza virus infection.", [["influenza virus infection", "DISEASE", 147, 172], ["AFC", "SIMPLE_CHEMICAL", 50, 53], ["free sialyl oligosaccharides", "SIMPLE_CHEMICAL", 62, 90], ["influenza virus", "ORGANISM", 147, 162], ["influenza virus", "SPECIES", 147, 162], ["AFC", "PROBLEM", 50, 53], ["free sialyl oligosaccharides", "PROBLEM", 62, 90], ["the symptom", "PROBLEM", 125, 136], ["influenza virus infection", "PROBLEM", 147, 172], ["AFC", "OBSERVATION", 50, 53]]], ["The composition and quality of pooled colostrum is known to depend on a number of factors, such as the health of the cows, the timing of colostrum collection, and the manufacturing process (Kelly, 2003) .", [["colostrum", "ANATOMY", 38, 47], ["colostrum", "ANATOMY", 137, 146], ["colostrum", "ORGANISM_SUBSTANCE", 38, 47], ["cows", "ORGANISM", 117, 121], ["colostrum", "ORGANISM_SUBDIVISION", 137, 146], ["cows", "SPECIES", 117, 121], ["pooled colostrum", "PROBLEM", 31, 47], ["colostrum collection", "PROBLEM", 137, 157]]], ["However, it is uncertain what amount of each component is required for its biological activity, and what specific components are biologically active in specific diseases, and this has hindered the standardization of bovine colostrums (Struff and Sprotte, 2007) .", [["bovine", "ORGANISM", 216, 222], ["colostrums", "CELL", 223, 233], ["bovine", "SPECIES", 216, 222], ["bovine", "SPECIES", 216, 222], ["specific diseases", "PROBLEM", 152, 169], ["amount", "OBSERVATION_MODIFIER", 30, 36], ["component", "OBSERVATION_MODIFIER", 45, 54], ["biologically", "OBSERVATION_MODIFIER", 129, 141], ["active", "OBSERVATION_MODIFIER", 142, 148], ["bovine colostrums", "OBSERVATION", 216, 233]]], ["Therefore, we believe that separating novel factors from colostrum, and collecting more data on the composition of colostrum and the activity of its components are critical for obtaining high-quality colostrum products.DiscussionIn this study, we provide the first evidence that orally supplemented AFC is effective in reducing the symptoms associated with influenza A virus infection.", [["colostrum", "ANATOMY", 57, 66], ["colostrum", "ANATOMY", 115, 124], ["AFC", "CHEMICAL", 299, 302], ["influenza A virus infection", "DISEASE", 357, 384], ["colostrum", "ORGANISM", 57, 66], ["colostrum", "ORGANISM_SUBSTANCE", 115, 124], ["colostrum", "ORGANISM", 200, 209], ["AFC", "SIMPLE_CHEMICAL", 299, 302], ["influenza A virus", "ORGANISM", 357, 374], ["influenza A virus", "SPECIES", 357, 374], ["influenza A virus", "SPECIES", 357, 374], ["separating novel factors from colostrum", "PROBLEM", 27, 66], ["the composition of colostrum", "TREATMENT", 96, 124], ["high-quality colostrum products", "TREATMENT", 187, 218], ["this study", "TEST", 232, 242], ["orally supplemented AFC", "TREATMENT", 279, 302], ["the symptoms", "PROBLEM", 328, 340], ["influenza A virus infection", "PROBLEM", 357, 384]]], ["Further study of the mechanisms through which AFC modulates these symptoms will provide new insight into why colostrum components are necessary for newborns.", [["colostrum", "ANATOMY", 109, 118], ["AFC", "GENE_OR_GENE_PRODUCT", 46, 49], ["colostrum", "ORGANISM", 109, 118], ["newborns", "ORGANISM", 148, 156], ["Further study", "TEST", 0, 13], ["these symptoms", "PROBLEM", 60, 74], ["colostrum components", "TREATMENT", 109, 129]]]], "314d309c4d814a36f860bcaebe99428c33209b50": [["IntroductionTHE determination of the susceptibility of an organism to a particular antimicrobial agent is usually the result of a calculation which considers the in vitro minimum inhibitory concentration (MIC) value for the organism and the serum concentration of antimicrobial agent which can be achieved and maintained in the patient.", [["serum", "ANATOMY", 241, 246], ["serum", "ORGANISM_SUBSTANCE", 241, 246], ["patient", "ORGANISM", 328, 335], ["patient", "SPECIES", 328, 335], ["an organism", "PROBLEM", 55, 66], ["a particular antimicrobial agent", "TREATMENT", 70, 102], ["a calculation", "TEST", 128, 141], ["the organism", "PROBLEM", 220, 232], ["antimicrobial agent", "TREATMENT", 264, 283]]], ["These calculations have seldom been made for organisms and antimicrobial agents in horses or other domestic animals.IntroductionThe work reported here was undertaken to determine the serum concentrations of some aminoglycosides that can be achieved in the horse and the MICs of a number of therapeutic serum concentrations of the aminoglycosides in the horse.IntroductionThe aminoglycosides are generally considered to have their primary antibacterial activity against aerobic Gram-negative bacilli.", [["serum", "ANATOMY", 183, 188], ["serum", "ANATOMY", 302, 307], ["aminoglycosides", "CHEMICAL", 212, 227], ["aminoglycosides", "CHEMICAL", 330, 345], ["aminoglycosides", "CHEMICAL", 375, 390], ["aminoglycosides", "CHEMICAL", 212, 227], ["aminoglycosides", "CHEMICAL", 330, 345], ["aminoglycosides", "CHEMICAL", 375, 390], ["horses", "ORGANISM", 83, 89], ["serum", "ORGANISM_SUBSTANCE", 183, 188], ["aminoglycosides", "SIMPLE_CHEMICAL", 212, 227], ["horse", "ORGANISM", 256, 261], ["serum", "ORGANISM_SUBSTANCE", 302, 307], ["aminoglycosides", "SIMPLE_CHEMICAL", 330, 345], ["horse", "ORGANISM", 353, 358], ["aminoglycosides", "SIMPLE_CHEMICAL", 375, 390], ["horse", "SPECIES", 256, 261], ["horse", "SPECIES", 353, 358], ["These calculations", "TEST", 0, 18], ["organisms", "PROBLEM", 45, 54], ["antimicrobial agents", "TREATMENT", 59, 79], ["some aminoglycosides", "TREATMENT", 207, 227], ["the aminoglycosides", "TREATMENT", 326, 345], ["The aminoglycosides", "TREATMENT", 371, 390], ["aerobic Gram", "TEST", 469, 481], ["negative bacilli", "OBSERVATION", 482, 498]]], ["These antibiotics have little activity against anaerobic microorganisms or facultative bacteria under anaerobic conditions and their action against Gram-positive bacteria is limited.", [["Gram", "GENE_OR_GENE_PRODUCT", 148, 152], ["These antibiotics", "TREATMENT", 0, 17], ["anaerobic microorganisms", "PROBLEM", 47, 71], ["facultative bacteria under anaerobic conditions", "PROBLEM", 75, 122], ["Gram", "TEST", 148, 152], ["positive bacteria", "PROBLEM", 153, 170]]], ["However, because the aminoglycosides are commonly used in equine practice alone or in combination with penicillin for broad-spectrum cover, the MICs of a number of Grampositive organisms have been included in the present study.MIC determinationsMICs required to inhibit growth of the test organism for 18 h at 37\" C were measured in duplicate.", [["aminoglycosides", "CHEMICAL", 21, 36], ["penicillin", "CHEMICAL", 103, 113], ["MICs", "CHEMICAL", 245, 249], ["aminoglycosides", "CHEMICAL", 21, 36], ["penicillin", "CHEMICAL", 103, 113], ["aminoglycosides", "SIMPLE_CHEMICAL", 21, 36], ["equine", "ORGANISM", 58, 64], ["penicillin", "SIMPLE_CHEMICAL", 103, 113], ["equine", "SPECIES", 58, 64], ["the aminoglycosides", "TREATMENT", 17, 36], ["penicillin", "TREATMENT", 103, 113], ["broad-spectrum cover", "TREATMENT", 118, 138], ["the MICs", "TREATMENT", 140, 148], ["Grampositive organisms", "PROBLEM", 164, 186], ["the present study", "TEST", 209, 226], ["MIC determinations", "TEST", 227, 245], ["MICs", "TREATMENT", 245, 249], ["the test organism", "TEST", 280, 297]]], ["Serial dilutions of the aminoglycosides streptomycin, kanamycin and neomycin were made in nutrient broth (brain heart infusion; Oxoid).", [["brain", "ANATOMY", 106, 111], ["heart", "ANATOMY", 112, 117], ["aminoglycosides", "CHEMICAL", 24, 39], ["streptomycin", "CHEMICAL", 40, 52], ["kanamycin", "CHEMICAL", 54, 63], ["neomycin", "CHEMICAL", 68, 76], ["aminoglycosides", "CHEMICAL", 24, 39], ["streptomycin", "CHEMICAL", 40, 52], ["kanamycin", "CHEMICAL", 54, 63], ["neomycin", "CHEMICAL", 68, 76], ["aminoglycosides", "SIMPLE_CHEMICAL", 24, 39], ["streptomycin", "SIMPLE_CHEMICAL", 40, 52], ["kanamycin", "SIMPLE_CHEMICAL", 54, 63], ["neomycin", "SIMPLE_CHEMICAL", 68, 76], ["brain", "ORGAN", 106, 111], ["heart", "ORGAN", 112, 117], ["Serial dilutions", "TREATMENT", 0, 16], ["the aminoglycosides streptomycin", "TREATMENT", 20, 52], ["kanamycin", "TREATMENT", 54, 63], ["neomycin", "TREATMENT", 68, 76], ["nutrient broth", "TREATMENT", 90, 104], ["brain heart infusion", "TREATMENT", 106, 126], ["heart", "ANATOMY", 112, 117]]], ["The inoculum was one drop (0.025 mi) of an overnight culture of the test organism in 2 ml of nutrient broth.", [["The inoculum", "TREATMENT", 0, 12], ["an overnight culture", "TEST", 40, 60], ["the test organism", "TEST", 64, 81], ["nutrient broth", "TREATMENT", 93, 107], ["inoculum", "OBSERVATION_MODIFIER", 4, 12]]], ["The MIC was interpreted as the lowest concentration of aminoglycoside which inhibited growth of the organism.", [["aminoglycoside", "CHEMICAL", 55, 69], ["aminoglycoside", "CHEMICAL", 55, 69], ["aminoglycoside", "SIMPLE_CHEMICAL", 55, 69], ["aminoglycoside", "TREATMENT", 55, 69], ["the organism", "PROBLEM", 96, 108]]], ["MICs for each of the three aminoglycosides were performed against the following organisms : Corynebacterium equi, 17 strains ; Pseudomonas aeruginosa, 12 strains ; Klebsiella pneumoniae, four strains ; Escherichia coli, 17 strains ; Salmonella typhimurium, nine strains; Hafnia alvei, two strains; Enterobacter cloaca, two strains ; Proteus mirabilis, three strains ; Staphylococcus aureus, 11 strains; Streptococcus equi, six strains; Strep zooepidemicus, seven strains ; Strep equisimilis, six strains.Serum aminoglycoside determinations and pharmacokinetic analysesThe bioavailability and disposition kinetics of streptomycin, kanamycin and neomycin were determined in this study and have been described previously by Baggot, Love, Rose and Raus (1981) .", [["Serum", "ANATOMY", 504, 509], ["aminoglycosides", "CHEMICAL", 27, 42], ["Klebsiella pneumoniae", "DISEASE", 164, 185], ["Proteus mirabilis", "DISEASE", 333, 350], ["Staphylococcus aureus", "DISEASE", 368, 389], ["Streptococcus equi", "DISEASE", 403, 421], ["Strep equisimilis", "DISEASE", 473, 490], ["aminoglycoside", "CHEMICAL", 510, 524], ["streptomycin", "CHEMICAL", 616, 628], ["kanamycin", "CHEMICAL", 630, 639], ["neomycin", "CHEMICAL", 644, 652], ["aminoglycosides", "CHEMICAL", 27, 42], ["aminoglycoside", "CHEMICAL", 510, 524], ["streptomycin", "CHEMICAL", 616, 628], ["kanamycin", "CHEMICAL", 630, 639], ["neomycin", "CHEMICAL", 644, 652], ["aminoglycosides", "SIMPLE_CHEMICAL", 27, 42], ["Corynebacterium equi", "ORGANISM", 92, 112], ["Pseudomonas aeruginosa", "ORGANISM", 127, 149], ["Klebsiella pneumoniae", "ORGANISM", 164, 185], ["Escherichia coli", "ORGANISM", 202, 218], ["17 strains", "ORGANISM", 220, 230], ["Salmonella typhimurium", "ORGANISM", 233, 255], ["Hafnia alvei", "ORGANISM", 271, 283], ["Enterobacter cloaca", "ORGANISM", 298, 317], ["Proteus mirabilis", "ORGANISM", 333, 350], ["Staphylococcus aureus", "ORGANISM", 368, 389], ["Streptococcus equi", "ORGANISM", 403, 421], ["Strep zooepidemicus", "ORGANISM", 436, 455], ["Strep equisimilis", "ORGANISM", 473, 490], ["Serum", "ORGANISM_SUBSTANCE", 504, 509], ["aminoglycoside", "SIMPLE_CHEMICAL", 510, 524], ["streptomycin", "SIMPLE_CHEMICAL", 616, 628], ["kanamycin", "SIMPLE_CHEMICAL", 630, 639], ["neomycin", "SIMPLE_CHEMICAL", 644, 652], ["Corynebacterium equi", "SPECIES", 92, 112], ["Pseudomonas aeruginosa", "SPECIES", 127, 149], ["Klebsiella pneumoniae", "SPECIES", 164, 185], ["Escherichia coli", "SPECIES", 202, 218], ["Salmonella typhimurium", "SPECIES", 233, 255], ["Hafnia alvei", "SPECIES", 271, 283], ["Enterobacter cloaca", "SPECIES", 298, 317], ["Proteus mirabilis", "SPECIES", 333, 350], ["Staphylococcus aureus", "SPECIES", 368, 389], ["Streptococcus equi", "SPECIES", 403, 421], ["Strep zooepidemicus", "SPECIES", 436, 455], ["Strep equisimilis", "SPECIES", 473, 490], ["Corynebacterium equi", "SPECIES", 92, 112], ["Pseudomonas aeruginosa", "SPECIES", 127, 149], ["Klebsiella pneumoniae", "SPECIES", 164, 185], ["Escherichia coli", "SPECIES", 202, 218], ["Salmonella typhimurium", "SPECIES", 233, 255], ["Hafnia alvei", "SPECIES", 271, 283], ["Enterobacter cloaca", "SPECIES", 298, 317], ["Proteus mirabilis", "SPECIES", 333, 350], ["Staphylococcus aureus", "SPECIES", 368, 389], ["Streptococcus equi", "SPECIES", 403, 421], ["Strep zooepidemicus", "SPECIES", 436, 455], ["Strep equisimilis", "SPECIES", 473, 490], ["MICs", "TREATMENT", 0, 4], ["the three aminoglycosides", "TREATMENT", 17, 42], ["Corynebacterium equi", "PROBLEM", 92, 112], ["Pseudomonas aeruginosa", "PROBLEM", 127, 149], ["12 strains", "PROBLEM", 151, 161], ["Klebsiella pneumoniae", "PROBLEM", 164, 185], ["four strains", "PROBLEM", 187, 199], ["Escherichia coli", "PROBLEM", 202, 218], ["17 strains", "PROBLEM", 220, 230], ["Salmonella typhimurium", "PROBLEM", 233, 255], ["nine strains", "PROBLEM", 257, 269], ["Hafnia alvei", "PROBLEM", 271, 283], ["two strains", "PROBLEM", 285, 296], ["Enterobacter cloaca", "PROBLEM", 298, 317], ["two strains", "PROBLEM", 319, 330], ["Proteus mirabilis", "PROBLEM", 333, 350], ["three strains", "PROBLEM", 352, 365], ["Staphylococcus aureus", "PROBLEM", 368, 389], ["11 strains", "PROBLEM", 391, 401], ["Streptococcus equi", "PROBLEM", 403, 421], ["six strains", "PROBLEM", 423, 434], ["Strep zooepidemicus", "PROBLEM", 436, 455], ["seven strains", "PROBLEM", 457, 470], ["Strep equisimilis", "PROBLEM", 473, 490], ["six strains", "PROBLEM", 492, 503], ["Serum aminoglycoside determinations", "TEST", 504, 539], ["pharmacokinetic analyses", "TEST", 544, 568], ["streptomycin", "TREATMENT", 616, 628], ["kanamycin", "TREATMENT", 630, 639], ["neomycin", "TREATMENT", 644, 652], ["this study", "TEST", 672, 682], ["Klebsiella pneumoniae", "OBSERVATION", 164, 185], ["Escherichia coli", "OBSERVATION", 202, 218], ["Hafnia alvei", "OBSERVATION", 271, 283], ["Enterobacter cloaca", "ANATOMY", 298, 317], ["Staphylococcus aureus", "OBSERVATION", 368, 389]]], ["Single doses (10 mg/kg) of each aminoglycoside preparation were administered intravenously (iv) and intramuscularly (m) to six Standardbred horses.", [["intravenously", "ANATOMY", 77, 90], ["aminoglycoside", "CHEMICAL", 32, 46], ["aminoglycoside", "SIMPLE_CHEMICAL", 32, 46], ["horses", "ORGANISM", 140, 146], ["each aminoglycoside preparation", "TREATMENT", 27, 58]]], ["Blood samples were collected at fixed times after drug administration and concentrations of the antibiotics were measured in serum by the agar plate diffusion method of Bennett, Brodie, Benner and Kirby (1%6).Serum aminoglycoside determinations and pharmacokinetic analysesThe serum concentration-time data were analysed by least squares non-linear regression, using the Autoan computer program (Sedman and Wagner 1976) .", [["Blood samples", "ANATOMY", 0, 13], ["serum", "ANATOMY", 125, 130], ["Serum", "ANATOMY", 209, 214], ["serum", "ANATOMY", 277, 282], ["aminoglycoside", "CHEMICAL", 215, 229], ["aminoglycoside", "CHEMICAL", 215, 229], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["serum", "ORGANISM_SUBSTANCE", 125, 130], ["Serum", "ORGANISM_SUBSTANCE", 209, 214], ["aminoglycoside", "SIMPLE_CHEMICAL", 215, 229], ["serum", "ORGANISM_SUBSTANCE", 277, 282], ["Blood samples", "TEST", 0, 13], ["drug administration", "TREATMENT", 50, 69], ["the antibiotics", "TREATMENT", 92, 107], ["Serum aminoglycoside determinations", "TEST", 209, 244], ["pharmacokinetic analyses", "TEST", 249, 273], ["The serum concentration", "TEST", 273, 296]]], ["The experimental constants (A, B, a and p), together with the dose (10 mg/kg), were used to calculate the pharmacokinetic terms which describe disposition kinetics of each antibiotic.", [["each antibiotic", "TREATMENT", 167, 182]]], ["They were also used to calculate the individual rate constants (k,,, k,, and k that are associated with the two-compartment open model (Baggot 1977) .", [["k", "TEST", 64, 65], ["k", "TEST", 69, 70]]], ["The individual rate constants, in turn, served as the input data to a computer program which provided curves showing the level of drug (as fraction of iv dose) in each compartment of the pharmacokinetic model and the amount eliminated up to 8 h after drug administration.", [["iv dose", "TREATMENT", 151, 158], ["rate constants", "OBSERVATION", 15, 29], ["pharmacokinetic model", "OBSERVATION", 187, 208], ["amount", "OBSERVATION_MODIFIER", 217, 223]]], ["The extent of drug absorption from the im injection site was obtained by the method of corresponding areas, in which area under the im and iv curves (from 5 mins to 12 h) was calculated by the trapezoidal rule.Serum aminoglycoside determinations and pharmacokinetic analysesThe MICs for the equine pathogens tested are shown in Tables 1 and 2, and the bioavailability and disposition kinetics of streptomycin, kanamycin and neomycin in the horse are listed in Table 3 .", [["Serum", "ANATOMY", 210, 215], ["aminoglycoside", "CHEMICAL", 216, 230], ["streptomycin", "CHEMICAL", 396, 408], ["kanamycin", "CHEMICAL", 410, 419], ["neomycin", "CHEMICAL", 424, 432], ["aminoglycoside", "CHEMICAL", 216, 230], ["streptomycin", "CHEMICAL", 396, 408], ["kanamycin", "CHEMICAL", 410, 419], ["neomycin", "CHEMICAL", 424, 432], ["Serum", "ORGANISM_SUBSTANCE", 210, 215], ["aminoglycoside", "SIMPLE_CHEMICAL", 216, 230], ["equine", "ORGANISM", 291, 297], ["streptomycin", "SIMPLE_CHEMICAL", 396, 408], ["kanamycin", "SIMPLE_CHEMICAL", 410, 419], ["neomycin", "SIMPLE_CHEMICAL", 424, 432], ["horse", "ORGANISM", 440, 445], ["horse", "SPECIES", 440, 445], ["equine", "SPECIES", 291, 297], ["drug absorption", "PROBLEM", 14, 29], ["the im injection site", "TREATMENT", 35, 56], ["iv curves", "TEST", 139, 148], ["Serum aminoglycoside determinations", "TEST", 210, 245], ["pharmacokinetic analyses", "TEST", 250, 274], ["The MICs", "TREATMENT", 274, 282], ["the equine pathogens", "TEST", 287, 307], ["streptomycin", "TREATMENT", 396, 408], ["kanamycin", "TREATMENT", 410, 419], ["neomycin", "TREATMENT", 424, 432], ["extent", "OBSERVATION_MODIFIER", 4, 10], ["drug absorption", "OBSERVATION", 14, 29]]], ["The serum concentration-time data for im administration of the three aminoglycosides are shown in Fig 1.", [["serum", "ANATOMY", 4, 9], ["aminoglycosides", "CHEMICAL", 69, 84], ["aminoglycosides", "CHEMICAL", 69, 84], ["serum", "ORGANISM_SUBSTANCE", 4, 9], ["aminoglycosides", "SIMPLE_CHEMICAL", 69, 84], ["The serum concentration", "TEST", 0, 23], ["im administration", "TREATMENT", 38, 55], ["the three aminoglycosides", "TREATMENT", 59, 84]]], ["Using neomycin as the example, the following is illustrative of the use of the above data for the selection and dosage of an aminoglycoside antibiotic in the horse.", [["neomycin", "CHEMICAL", 6, 14], ["aminoglycoside", "CHEMICAL", 125, 139], ["neomycin", "CHEMICAL", 6, 14], ["aminoglycoside", "CHEMICAL", 125, 139], ["neomycin", "SIMPLE_CHEMICAL", 6, 14], ["aminoglycoside", "SIMPLE_CHEMICAL", 125, 139], ["horse", "ORGANISM", 158, 163], ["horse", "SPECIES", 158, 163], ["neomycin", "TREATMENT", 6, 14], ["the selection", "TREATMENT", 94, 107], ["an aminoglycoside antibiotic", "TREATMENT", 122, 150]]], ["Computer generated curves showing the levels of neomycin in the central and peripheral compartments of the twocompartment pharmacokinetic model (which w a s used to describe the disposition kinetics of the drug) and the fraction of dose eliminated (presumably amount in the urine) are shown in Fig 3.", [["peripheral compartments", "ANATOMY", 76, 99], ["urine", "ANATOMY", 274, 279], ["neomycin", "CHEMICAL", 48, 56], ["neomycin", "CHEMICAL", 48, 56], ["neomycin", "SIMPLE_CHEMICAL", 48, 56], ["peripheral compartments", "MULTI-TISSUE_STRUCTURE", 76, 99], ["urine", "ORGANISM_SUBSTANCE", 274, 279], ["Computer generated curves", "TEST", 0, 25], ["neomycin", "TREATMENT", 48, 56], ["neomycin", "OBSERVATION", 48, 56], ["central", "ANATOMY_MODIFIER", 64, 71], ["peripheral", "ANATOMY_MODIFIER", 76, 86], ["compartments", "ANATOMY_MODIFIER", 87, 99]]], ["A peak tissue level, which represented 40 per cent of the amount of drug in the body, was obtained at 32 mins after iv injection of the drug.", [["tissue", "ANATOMY", 7, 13], ["body", "ANATOMY", 80, 84], ["tissue", "TISSUE", 7, 13], ["body", "ORGANISM_SUBDIVISION", 80, 84], ["A peak tissue level", "TEST", 0, 19], ["the drug", "TREATMENT", 132, 140], ["peak tissue", "OBSERVATION", 2, 13], ["amount", "OBSERVATION_MODIFIER", 58, 64], ["body", "ANATOMY", 80, 84]]], ["At 8 h, the fractions of the dose in the central and peripheral compartments of the model were 1.5 per cent and 2.5 per cent, respectively; 96 per cent was the cumulative amount eliminated up to that time.Serum aminoglycoside determinations and pharmacokinetic analysesAs has been pointed out previously (Weinstein 1975a ), therapeutically effective blood concentrations require the drug to be maintained at 2 to 4 times the MIC of the organism.", [["peripheral compartments", "ANATOMY", 53, 76], ["Serum", "ANATOMY", 205, 210], ["blood", "ANATOMY", 350, 355], ["aminoglycoside", "CHEMICAL", 211, 225], ["aminoglycoside", "CHEMICAL", 211, 225], ["peripheral compartments", "MULTI-TISSUE_STRUCTURE", 53, 76], ["Serum", "ORGANISM_SUBSTANCE", 205, 210], ["aminoglycoside", "SIMPLE_CHEMICAL", 211, 225], ["blood", "ORGANISM_SUBSTANCE", 350, 355], ["Serum aminoglycoside determinations", "TEST", 205, 240], ["pharmacokinetic analysesAs", "TEST", 245, 271], ["therapeutically effective blood concentrations", "PROBLEM", 324, 370], ["the drug", "TREATMENT", 379, 387], ["central", "ANATOMY_MODIFIER", 41, 48], ["peripheral", "ANATOMY_MODIFIER", 53, 63], ["compartments", "ANATOMY_MODIFIER", 64, 76]]], ["Based on the MIC values of the majority of isolates of Cequi, and a few only isolates of K pneumoniae, E coli, S typhimurium and S equi (Tables 1 and 2) . one would expect a serum concentration of more than 2 pg neomycin/ml up to 8 h following im dosage (10 mg/kg) to be therapeutically effective.", [["serum", "ANATOMY", 174, 179], ["K", "CHEMICAL", 89, 90], ["neomycin", "CHEMICAL", 212, 220], ["neomycin", "CHEMICAL", 212, 220], ["K pneumoniae", "ORGANISM", 89, 101], ["E coli", "ORGANISM", 103, 109], ["S typhimurium", "ORGANISM", 111, 124], ["S equi", "ORGANISM", 129, 135], ["serum", "ORGANISM_SUBSTANCE", 174, 179], ["neomycin", "SIMPLE_CHEMICAL", 212, 220], ["K pneumoniae", "SPECIES", 89, 101], ["E coli", "SPECIES", 103, 109], ["S typhimurium", "SPECIES", 111, 124], ["S equi", "SPECIES", 129, 135], ["K pneumoniae", "SPECIES", 89, 101], ["E coli", "SPECIES", 103, 109], ["S typhimurium", "SPECIES", 111, 124], ["S equi", "SPECIES", 129, 135], ["the MIC values", "TEST", 9, 23], ["Cequi", "TREATMENT", 55, 60], ["K pneumoniae", "PROBLEM", 89, 101], ["E coli", "TEST", 103, 109], ["S typhimurium", "TEST", 111, 124], ["S equi (Tables", "TEST", 129, 143], ["a serum concentration", "TEST", 172, 193], ["neomycin", "TREATMENT", 212, 220]]], ["The upper limit of the therapeutic serum concentration range must be a concentration that does not produce toxic effects.DiscussionSince their isolation (streptomycin 1944, neomycin 1949 and kanamycin 1957) the aminoglycosides have been used, almost Streptomycin has been used for many years in veterinary medicine.", [["serum", "ANATOMY", 35, 40], ["streptomycin 1944", "CHEMICAL", 154, 171], ["neomycin 1949", "CHEMICAL", 173, 186], ["kanamycin 1957", "CHEMICAL", 191, 205], ["aminoglycosides", "CHEMICAL", 211, 226], ["Streptomycin", "CHEMICAL", 250, 262], ["streptomycin 1944", "CHEMICAL", 154, 171], ["neomycin 1949", "CHEMICAL", 173, 186], ["kanamycin 1957", "CHEMICAL", 191, 205], ["aminoglycosides", "CHEMICAL", 211, 226], ["Streptomycin", "CHEMICAL", 250, 262], ["serum", "ORGANISM_SUBSTANCE", 35, 40], ["streptomycin 1944", "SIMPLE_CHEMICAL", 154, 171], ["neomycin 1949", "SIMPLE_CHEMICAL", 173, 186], ["kanamycin", "SIMPLE_CHEMICAL", 191, 200], ["aminoglycosides", "SIMPLE_CHEMICAL", 211, 226], ["Streptomycin", "SIMPLE_CHEMICAL", 250, 262], ["toxic effects", "PROBLEM", 107, 120], ["streptomycin", "TREATMENT", 154, 166], ["neomycin", "TREATMENT", 173, 181], ["kanamycin", "TREATMENT", 191, 200], ["the aminoglycosides", "TREATMENT", 207, 226], ["Streptomycin", "TREATMENT", 250, 262], ["upper limit", "OBSERVATION_MODIFIER", 4, 15]]], ["On most occasions it is used in combination with penicillin to give a broad spectrum of action when empirical therapy is instituted.", [["penicillin", "CHEMICAL", 49, 59], ["penicillin", "CHEMICAL", 49, 59], ["penicillin", "SIMPLE_CHEMICAL", 49, 59], ["penicillin", "TREATMENT", 49, 59], ["a broad spectrum of action", "TREATMENT", 68, 94], ["empirical therapy", "TREATMENT", 100, 117]]], ["As can be seen from Table 1 , however, few of the common equine pathogens remain susceptible to this antibiotic.", [["equine", "ORGANISM", 57, 63], ["equine", "SPECIES", 57, 63], ["the common equine pathogens", "PROBLEM", 46, 73], ["this antibiotic", "TREATMENT", 96, 111]]], ["No species is predictably sensitive to streptomycin and sensitivity testing of isolates is mandatory before this antibiotic should be considered for therapy.", [["streptomycin", "CHEMICAL", 39, 51], ["streptomycin", "CHEMICAL", 39, 51], ["streptomycin", "SIMPLE_CHEMICAL", 39, 51], ["species", "PROBLEM", 3, 10], ["streptomycin", "TREATMENT", 39, 51], ["sensitivity testing", "TEST", 56, 75], ["isolates", "PROBLEM", 79, 87], ["this antibiotic", "TREATMENT", 108, 123], ["therapy", "TREATMENT", 149, 156], ["species", "OBSERVATION", 3, 10]]], ["Kanamycin has been used infrequently in veterinary medicine and veterinary preparations of kanamycin are not readily available.", [["Kanamycin", "CHEMICAL", 0, 9], ["kanamycin", "CHEMICAL", 91, 100], ["Kanamycin", "CHEMICAL", 0, 9], ["kanamycin", "CHEMICAL", 91, 100], ["Kanamycin", "SIMPLE_CHEMICAL", 0, 9], ["kanamycin", "SIMPLE_CHEMICAL", 91, 100], ["Kanamycin", "TREATMENT", 0, 9], ["veterinary medicine", "TREATMENT", 40, 59], ["kanamycin", "TREATMENT", 91, 100]]], ["This has added significantly to the cost of this preparation and often prohibited its use.DiscussionSerious toxicity (ototoxicity and nephrotoxicity) is a major limitation to the usefulness of the aminoglycosides and the same spectrum of toxicity is shared by all members of the group (Sande and Mandell 1980) .", [["toxicity", "DISEASE", 108, 116], ["ototoxicity", "DISEASE", 118, 129], ["nephrotoxicity", "DISEASE", 134, 148], ["aminoglycosides", "CHEMICAL", 197, 212], ["toxicity", "DISEASE", 238, 246], ["aminoglycosides", "CHEMICAL", 197, 212], ["aminoglycosides", "SIMPLE_CHEMICAL", 197, 212], ["this preparation", "TREATMENT", 44, 60], ["DiscussionSerious toxicity", "PROBLEM", 90, 116], ["ototoxicity", "PROBLEM", 118, 129], ["nephrotoxicity", "PROBLEM", 134, 148], ["the aminoglycosides", "TREATMENT", 193, 212], ["toxicity", "PROBLEM", 238, 246], ["toxicity", "OBSERVATION", 238, 246]]], ["Neomycin has gained the reputation of causing such severe renal toxicity and ototoxicity when administered parenterally in man that most authors suggest limitation of its use to topical therapy (Sande and Mendell 1980) .", [["renal", "ANATOMY", 58, 63], ["Neomycin", "CHEMICAL", 0, 8], ["renal toxicity", "DISEASE", 58, 72], ["ototoxicity", "DISEASE", 77, 88], ["Neomycin", "CHEMICAL", 0, 8], ["Neomycin", "SIMPLE_CHEMICAL", 0, 8], ["renal", "ORGAN", 58, 63], ["man", "SPECIES", 123, 126], ["Neomycin", "TREATMENT", 0, 8], ["such severe renal toxicity", "PROBLEM", 46, 72], ["ototoxicity", "PROBLEM", 77, 88], ["topical therapy", "TREATMENT", 178, 193], ["severe", "OBSERVATION_MODIFIER", 51, 57], ["renal", "ANATOMY", 58, 63], ["toxicity", "OBSERVATION", 64, 72], ["ototoxicity", "OBSERVATION", 77, 88]]], ["Care is also required in oral administration of neomycin to individuals with renal insufficiency.", [["oral", "ANATOMY", 25, 29], ["renal", "ANATOMY", 77, 82], ["neomycin", "CHEMICAL", 48, 56], ["renal insufficiency", "DISEASE", 77, 96], ["neomycin", "CHEMICAL", 48, 56], ["oral", "ORGANISM_SUBDIVISION", 25, 29], ["neomycin", "SIMPLE_CHEMICAL", 48, 56], ["renal", "ORGAN", 77, 82], ["neomycin", "TREATMENT", 48, 56], ["renal insufficiency", "PROBLEM", 77, 96], ["renal", "ANATOMY", 77, 82], ["insufficiency", "OBSERVATION", 83, 96]]], ["In these cases, enough neomycin is absorbed to enable toxic concentrations to accumulate in the circulation (Weinstein 1975b) .", [["neomycin", "CHEMICAL", 23, 31], ["neomycin", "CHEMICAL", 23, 31], ["neomycin", "SIMPLE_CHEMICAL", 23, 31], ["neomycin", "TREATMENT", 23, 31], ["enable toxic concentrations", "PROBLEM", 47, 74], ["circulation", "ANATOMY", 96, 107]]], ["Until the work of Baggot et ul(1981) . pharmacokinetic data for the aminoglycosides streptomycin, kanamycin and neomycin had not been available.", [["aminoglycosides", "CHEMICAL", 68, 83], ["streptomycin", "CHEMICAL", 84, 96], ["kanamycin", "CHEMICAL", 98, 107], ["neomycin", "CHEMICAL", 112, 120], ["aminoglycosides", "CHEMICAL", 68, 83], ["streptomycin", "CHEMICAL", 84, 96], ["kanamycin", "CHEMICAL", 98, 107], ["neomycin", "CHEMICAL", 112, 120], ["aminoglycosides", "SIMPLE_CHEMICAL", 68, 83], ["streptomycin", "SIMPLE_CHEMICAL", 84, 96], ["kanamycin", "SIMPLE_CHEMICAL", 98, 107], ["neomycin", "SIMPLE_CHEMICAL", 112, 120], ["pharmacokinetic data", "TEST", 39, 59], ["the aminoglycosides streptomycin", "TREATMENT", 64, 96], ["kanamycin", "TREATMENT", 98, 107], ["neomycin", "TREATMENT", 112, 120]]], ["This, plus the paucity of data on MICs for horse pathogens, has prevented determination of effective dosage regimens for these antibiotics in the horse.", [["horse", "ORGANISM", 43, 48], ["horse", "ORGANISM_SUBDIVISION", 146, 151], ["horse", "SPECIES", 43, 48], ["horse", "SPECIES", 146, 151], ["horse", "SPECIES", 43, 48], ["MICs", "TREATMENT", 34, 38], ["horse pathogens", "PROBLEM", 43, 58], ["effective dosage regimens", "TREATMENT", 91, 116], ["these antibiotics", "TREATMENT", 121, 138]]], ["The term dosage regimen includes size of dose (mg/kg), interval between successive doses (h) and route of administration of the drug preparation.DiscussionSystemic administration of aminoglycosides is necessary to achieve therapeutically effective blood levels as there is little absorption when given orally (Sande and Mandell 1980) .", [["blood", "ANATOMY", 248, 253], ["aminoglycosides", "CHEMICAL", 182, 197], ["aminoglycosides", "CHEMICAL", 182, 197], ["aminoglycosides", "SIMPLE_CHEMICAL", 182, 197], ["blood", "ORGANISM_SUBSTANCE", 248, 253], ["The term dosage regimen", "TREATMENT", 0, 23], ["the drug preparation", "TREATMENT", 124, 144], ["DiscussionSystemic administration of aminoglycosides", "TREATMENT", 145, 197], ["blood levels", "TEST", 248, 260]]], ["However, to avoid the initial excessively high serum concentrations which iv administration produces, it is desirable to administer aminoglycoside antibiotics im.DiscussionBased on the data presented, the im administration of the parenteral preparation of neomycin sulphate at a dose rate of 10 mg/ kg and given at 8 h intervals would be expected to filtration than adult animals.", [["serum", "ANATOMY", 47, 52], ["aminoglycoside", "CHEMICAL", 132, 146], ["neomycin sulphate", "CHEMICAL", 256, 273], ["aminoglycoside", "CHEMICAL", 132, 146], ["neomycin sulphate", "CHEMICAL", 256, 273], ["serum", "ORGANISM_SUBSTANCE", 47, 52], ["aminoglycoside", "SIMPLE_CHEMICAL", 132, 146], ["neomycin sulphate", "SIMPLE_CHEMICAL", 256, 273], ["the initial excessively high serum concentrations", "PROBLEM", 18, 67], ["iv administration", "TREATMENT", 74, 91], ["aminoglycoside antibiotics", "TREATMENT", 132, 158], ["the parenteral preparation of neomycin sulphate", "TREATMENT", 226, 273], ["a dose rate", "TREATMENT", 277, 288]]], ["Should it be necessary to administer neomycin to a foal less than six to eight weeks old, a 12 h dosage interval would be indicated.", [["neomycin", "CHEMICAL", 37, 45], ["neomycin", "CHEMICAL", 37, 45], ["neomycin", "SIMPLE_CHEMICAL", 37, 45], ["neomycin", "TREATMENT", 37, 45], ["a 12 h dosage interval", "TREATMENT", 90, 112]]], ["The clinical effectiveness of neomycin in treating a systemic infection caused by susceptible microorganisms could depend on how early in the course of the infection treatment is initiated and on the overall duration of therapy.", [["neomycin", "CHEMICAL", 30, 38], ["infection", "DISEASE", 62, 71], ["infection", "DISEASE", 156, 165], ["neomycin", "CHEMICAL", 30, 38], ["neomycin", "SIMPLE_CHEMICAL", 30, 38], ["neomycin", "TREATMENT", 30, 38], ["a systemic infection", "PROBLEM", 51, 71], ["susceptible microorganisms", "PROBLEM", 82, 108], ["the infection treatment", "TREATMENT", 152, 175], ["therapy", "TREATMENT", 220, 227], ["systemic", "OBSERVATION_MODIFIER", 53, 61], ["infection", "OBSERVATION", 62, 71], ["infection", "OBSERVATION", 156, 165]]], ["As shown in this paper and also illustrated by Barton and Hughes (1980) most strains of C equi are sensitive to neomycin.", [["neomycin", "CHEMICAL", 112, 120], ["neomycin", "CHEMICAL", 112, 120], ["C equi", "ORGANISM", 88, 94], ["neomycin", "SIMPLE_CHEMICAL", 112, 120], ["C equi", "SPECIES", 88, 94], ["C equi", "SPECIES", 88, 94], ["C equi", "PROBLEM", 88, 94], ["neomycin", "TREATMENT", 112, 120]]], ["The usefulness of neomycin for treatment of Cequi infections should be considered by clinicians treating this condition.", [["neomycin", "CHEMICAL", 18, 26], ["Cequi infections", "DISEASE", 44, 60], ["neomycin", "CHEMICAL", 18, 26], ["neomycin", "SIMPLE_CHEMICAL", 18, 26], ["neomycin", "TREATMENT", 18, 26], ["treatment", "TREATMENT", 31, 40], ["Cequi infections", "PROBLEM", 44, 60]]], ["It is a much less expensive drug than gentamicin which is used widely in North America for treatment of this condition; it is not a drug extensively used in man.", [["gentamicin", "CHEMICAL", 38, 48], ["gentamicin", "CHEMICAL", 38, 48], ["gentamicin", "SIMPLE_CHEMICAL", 38, 48], ["man", "ORGANISM", 157, 160], ["man", "SPECIES", 157, 160], ["gentamicin", "TREATMENT", 38, 48], ["this condition", "PROBLEM", 104, 118]]], ["It is considered, along with some antimicrobial policies adopted in man, that gentamicin should be reserved for use against organisms where no other antimicrobial agent is effective.DiscussionOther than the aminoglycosides, all antimicrobial drugs to which C equi is sensitive are bacteriostatic.", [["gentamicin", "CHEMICAL", 78, 88], ["aminoglycosides", "CHEMICAL", 207, 222], ["gentamicin", "CHEMICAL", 78, 88], ["aminoglycosides", "CHEMICAL", 207, 222], ["man", "ORGANISM", 68, 71], ["gentamicin", "SIMPLE_CHEMICAL", 78, 88], ["aminoglycosides", "SIMPLE_CHEMICAL", 207, 222], ["C equi", "ORGANISM", 257, 263], ["man", "SPECIES", 68, 71], ["C equi", "SPECIES", 257, 263], ["C equi", "SPECIES", 257, 263], ["some antimicrobial policies", "TREATMENT", 29, 56], ["gentamicin", "TREATMENT", 78, 88], ["organisms", "PROBLEM", 124, 133], ["other antimicrobial agent", "TREATMENT", 143, 168], ["the aminoglycosides", "TREATMENT", 203, 222], ["all antimicrobial drugs", "TREATMENT", 224, 247], ["C equi", "TEST", 257, 263], ["bacteriostatic", "PROBLEM", 281, 295], ["bacteriostatic", "OBSERVATION_MODIFIER", 281, 295]]], ["Other agents are therefore less suitable for severe systemic disease, especially in animals with already compromised immune systems, such as foals with C equi infection.", [["systemic disease", "DISEASE", 52, 68], ["C equi infection", "DISEASE", 152, 168], ["foals", "ORGANISM", 141, 146], ["C equi", "ORGANISM", 152, 158], ["C equi", "SPECIES", 152, 158], ["C equi", "SPECIES", 152, 158], ["Other agents", "TREATMENT", 0, 12], ["severe systemic disease", "PROBLEM", 45, 68], ["already compromised immune systems", "PROBLEM", 97, 131], ["C equi infection", "PROBLEM", 152, 168], ["severe", "OBSERVATION_MODIFIER", 45, 51], ["systemic", "OBSERVATION_MODIFIER", 52, 60], ["disease", "OBSERVATION", 61, 68], ["infection", "OBSERVATION", 159, 168]]], ["However, the question of renal toxicity of neomycin (and gentamicin), especially to the developing nephron of the neonatal foal, has not been addressed, despite their successful use in practice.", [["renal", "ANATOMY", 25, 30], ["nephron", "ANATOMY", 99, 106], ["renal toxicity", "DISEASE", 25, 39], ["neomycin", "CHEMICAL", 43, 51], ["gentamicin", "CHEMICAL", 57, 67], ["neomycin", "CHEMICAL", 43, 51], ["gentamicin", "CHEMICAL", 57, 67], ["renal", "ORGAN", 25, 30], ["neomycin", "SIMPLE_CHEMICAL", 43, 51], ["gentamicin", "SIMPLE_CHEMICAL", 57, 67], ["nephron", "MULTI-TISSUE_STRUCTURE", 99, 106], ["foal", "ORGANISM_SUBDIVISION", 123, 127], ["renal toxicity", "PROBLEM", 25, 39], ["neomycin", "TREATMENT", 43, 51], ["gentamicin", "TREATMENT", 57, 67], ["renal", "ANATOMY", 25, 30], ["toxicity", "OBSERVATION", 31, 39], ["nephron", "OBSERVATION", 99, 106]]], ["Before unqualified systemic use of these agents can be recommended, this situation must be investigated.", [["these agents", "TREATMENT", 35, 47]]], ["Because renal excretion, specifically glomerular filtration, is the sole mechanism of elimination of neomycin, a reduction in renal function would decrease the elimination rate of the drug.", [["renal", "ANATOMY", 8, 13], ["glomerular", "ANATOMY", 38, 48], ["renal", "ANATOMY", 126, 131], ["neomycin", "CHEMICAL", 101, 109], ["neomycin", "CHEMICAL", 101, 109], ["renal", "ORGAN", 8, 13], ["glomerular", "TISSUE", 38, 48], ["neomycin", "SIMPLE_CHEMICAL", 101, 109], ["renal", "ORGAN", 126, 131], ["renal excretion", "PROBLEM", 8, 23], ["glomerular filtration", "TREATMENT", 38, 59], ["neomycin", "TREATMENT", 101, 109], ["a reduction in renal function", "PROBLEM", 111, 140], ["renal", "ANATOMY", 8, 13], ["excretion", "OBSERVATION", 14, 23], ["glomerular filtration", "OBSERVATION", 38, 59], ["reduction", "OBSERVATION_MODIFIER", 113, 122], ["renal", "ANATOMY", 126, 131]]], ["Neonatal animals of the majority of species, including foals three to six weeks old, have a lower rate .of glomerular", [["glomerular", "ANATOMY", 107, 117], ["glomerular", "TISSUE", 107, 117], ["a lower rate .of glomerular", "PROBLEM", 90, 117], ["species", "OBSERVATION", 36, 43], ["glomerular", "OBSERVATION", 107, 117]]]], "a006aa2af8607d48f873e8f4ce6abd0dff8b41c9": [["Strengths and limitations of this study\u2022 Though the rapid spread of SARS-CoV-2 through China, Europe and the United States has been well-studied, leading to a detailed understanding of its biology and epidemiology, the population and resources for combatting the spread of the disease in Africa greatly differ to those areas and require models specific to this context. \u2022 Few models that provide estimates for policymakers, donors, and aid organizations focused on Africa to plan an effective response to the pandemic threat that optimizes the use of limited resources. \u2022 This is a compartmental model and as such has inherent weaknesses; including the possible overestimation of the number of infections as it is assumed people are well mixed, despite many social, physical and geographical barriers to mixing within countries. \u2022 Peaks in transmission are likely to occur at different times in different regions, with multiple epicenters. \u2022 This model is not stochastic and case data are modeled from the first twenty or more cases, each behaving as an average case; in reality, there are no average cases; some individuals are likely to have many contacts, causing multiple infections, and others to have very few.This work was supported by Centers for Disease Control and Prevention Modeling in InfectiousDisease (MInD) in Healthcare Network (Grant Number 1U01CK000536).COMPETING INTERESTSThe authors have no competing interests to declare.COMPETING INTERESTS.", [["SARS", "DISEASE", 68, 72], ["infections", "DISEASE", 694, 704], ["infections", "DISEASE", 1176, 1186], ["InfectiousDisease", "DISEASE", 1298, 1315], ["SARS-CoV-2", "ORGANISM", 68, 78], ["people", "ORGANISM", 722, 728], ["people", "SPECIES", 722, 728], ["SARS-CoV", "SPECIES", 68, 76], ["this study", "TEST", 29, 39], ["SARS", "PROBLEM", 68, 72], ["the disease", "PROBLEM", 273, 284], ["inherent weaknesses", "PROBLEM", 618, 637], ["infections", "PROBLEM", 694, 704], ["Peaks", "PROBLEM", 831, 836], ["multiple infections", "PROBLEM", 1167, 1186], ["Disease Control", "TREATMENT", 1255, 1270], ["rapid", "OBSERVATION_MODIFIER", 52, 57], ["spread", "OBSERVATION_MODIFIER", 58, 64], ["disease", "OBSERVATION", 277, 284], ["compartmental model", "OBSERVATION", 582, 601], ["infections", "OBSERVATION", 694, 704], ["likely to", "UNCERTAINTY", 857, 866], ["multiple", "OBSERVATION_MODIFIER", 919, 927], ["epicenters", "OBSERVATION", 928, 938], ["not", "UNCERTAINTY", 956, 959], ["stochastic", "OBSERVATION", 960, 970], ["no", "UNCERTAINTY", 1090, 1092], ["multiple", "OBSERVATION_MODIFIER", 1167, 1175], ["infections", "OBSERVATION", 1176, 1186], ["Infectious", "OBSERVATION", 1298, 1308]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprintINTRODUCTIONOn March 11, 2020 , the World Health Organization declared the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) outbreak a pandemic.", [["CC", "CHEMICAL", 0, 2], ["acute respiratory syndrome coronavirus", "DISEASE", 428, 466], ["SARS-CoV-2", "ORGANISM", 470, 480], ["severe acute respiratory syndrome coronavirus", "SPECIES", 421, 466], ["SARS-CoV-2", "SPECIES", 470, 480], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["the novel severe acute respiratory syndrome coronavirus", "PROBLEM", 411, 466], ["SARS", "TEST", 470, 474], ["a pandemic", "PROBLEM", 491, 501], ["med", "ANATOMY", 99, 102], ["severe", "OBSERVATION_MODIFIER", 421, 427], ["acute", "OBSERVATION_MODIFIER", 428, 433], ["respiratory syndrome", "OBSERVATION", 434, 454]]], ["As of 24 th August 2020, there have been over 23,472,067 cumulative confirmed cases of coronavirus disease and over 809,747 deaths reported globally.", [["coronavirus disease", "DISEASE", 87, 106], ["deaths", "DISEASE", 124, 130], ["coronavirus", "ORGANISM", 87, 98], ["coronavirus disease", "PROBLEM", 87, 106], ["coronavirus disease", "OBSERVATION", 87, 106]]], ["[1] The first confirmed COVID-19 case in Africa occurred in Egypt on February 14, 2020.", [["COVID", "TEST", 24, 29]]], ["To-date, African countries have reported lower disease incidence than most other countries, with 1,084,904 confirmed cases and 24,683 deaths as of 24 th August 2020 across the continent.", [["deaths", "DISEASE", 134, 140], ["lower disease incidence", "PROBLEM", 41, 64], ["lower", "OBSERVATION_MODIFIER", 41, 46], ["disease", "OBSERVATION", 47, 54]]], ["However, infectious disease surveillance and reporting infrastructure remain highly underdeveloped, and COVID-19 testing is limited given the shortage of human resources and appropriate laboratory and surveillance facilities across the continent.", [["infectious disease", "DISEASE", 9, 27], ["human", "ORGANISM", 154, 159], ["human", "SPECIES", 154, 159], ["human", "SPECIES", 154, 159], ["infectious disease surveillance", "TEST", 9, 40], ["COVID-19 testing", "TEST", 104, 120], ["infectious", "OBSERVATION_MODIFIER", 9, 19]]], ["[2] Although uncertainties underlying SARS-CoV-2 disease transmission and severity persist, ongoing analysis of available data suggests that old age and underlying health conditions play a critical role in the severity of disease prognosis.", [["uncertainties underlying SARS", "PROBLEM", 13, 42], ["CoV-2 disease transmission", "PROBLEM", 43, 69], ["severity", "PROBLEM", 74, 82], ["underlying health conditions", "PROBLEM", 153, 181], ["disease prognosis", "PROBLEM", 222, 239], ["SARS", "OBSERVATION", 38, 42]]], ["[5] However, these populations may also be at particular risk for high morbidity and mortality from COVID-19 given the high prevalence of immunocompromised individuals.", [["high morbidity", "PROBLEM", 66, 80], ["COVID", "TEST", 100, 105], ["immunocompromised individuals", "PROBLEM", 138, 167], ["may also be", "UNCERTAINTY", 31, 42], ["immunocompromised", "OBSERVATION", 138, 155]]], ["In 2016, 417,000 people died from tuberculosis in the African region, where 25% of the world's TB deaths occur.", [["tuberculosis", "DISEASE", 34, 46], ["TB", "DISEASE", 95, 97], ["deaths", "DISEASE", 98, 104], ["people", "ORGANISM", 17, 23], ["people", "SPECIES", 17, 23], ["tuberculosis", "PROBLEM", 34, 46], ["tuberculosis", "OBSERVATION", 34, 46]]], ["[6] Other prevalent co-morbidities include HIV, for which many patients are receiving anti-retroviral therapy, and malnutrition, in addition to other communicable and noncommunicable diseases.", [["malnutrition", "DISEASE", 115, 127], ["noncommunicable diseases", "DISEASE", 167, 191], ["HIV", "ORGANISM", 43, 46], ["patients", "ORGANISM", 63, 71], ["HIV", "SPECIES", 43, 46], ["patients", "SPECIES", 63, 71], ["HIV", "SPECIES", 43, 46], ["Other prevalent co-morbidities", "PROBLEM", 4, 34], ["HIV", "PROBLEM", 43, 46], ["anti-retroviral therapy", "TREATMENT", 86, 109], ["malnutrition", "PROBLEM", 115, 127], ["other communicable and noncommunicable diseases", "PROBLEM", 144, 191], ["HIV", "OBSERVATION", 43, 46], ["malnutrition", "OBSERVATION", 115, 127], ["noncommunicable diseases", "OBSERVATION", 167, 191]]], ["[7] [8] [9] To mitigate the spread of COVID-19, the majority of African countries reduced or banned international travel and instituted curfews, lockdowns, and other social distancing interventions beginning in March and April 2020.INTRODUCTION[10] Several studies have demonstrated the effectiveness of social distancing and other quarantine measures in tandem with a rapid scale up of SARS-CoV-2 testing.", [["SARS", "DISEASE", 387, 391], ["COVID-19", "CHEMICAL", 38, 46], ["SARS-CoV", "SPECIES", 387, 395], ["COVID", "TEST", 38, 43], ["Several studies", "TEST", 249, 264], ["social distancing", "TREATMENT", 304, 321], ["other quarantine measures", "TREATMENT", 326, 351], ["CoV-2 testing", "TEST", 392, 405]]], ["[11] By one estimate, the number of people likely to be infected with the virus after encountering an infected individual declined by 55 percent after one week of shutdown in Wuhan, China.INTRODUCTION[12] However, as the majority of these restrictions were lifted in June 2020, the transmission rate is expected to increase, especially in highly populated areas where social distancing is not feasible.INTRODUCTIONIn this analysis, we combine best available estimates of the parameters that govern SARS-CoV-2 transmission dynamics with country-specific population data to estimate potential COVID-19 case burdens under four scenarios: baseline (assuming disease transmission is not mitigated by appropriate interventions), moderate lockdown, hard lockdown, and hard lockdown with continued social distancing.", [["people", "ORGANISM", 36, 42], ["people", "SPECIES", 36, 42], ["SARS-CoV", "SPECIES", 498, 506], ["the virus", "PROBLEM", 70, 79], ["the transmission rate", "TEST", 278, 299], ["this analysis", "TEST", 417, 430], ["COVID", "TEST", 591, 596], ["infected", "OBSERVATION", 56, 64], ["infected", "OBSERVATION", 102, 110], ["increase", "OBSERVATION_MODIFIER", 315, 323], ["highly", "OBSERVATION_MODIFIER", 339, 345], ["populated", "OBSERVATION", 346, 355], ["moderate", "OBSERVATION_MODIFIER", 723, 731]]], ["Given the current lack of data and understanding of how COVID-19 will impact the continent, these estimates are generated to inform national and continental COVID-19 preparation and response efforts on the basis of how this disease has spread elsewhere.Data.", [["continental COVID-19 preparation", "TREATMENT", 145, 177], ["this disease", "PROBLEM", 219, 231]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)DataThe copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprintDataThe number of confirmed COVID-19 cases and the date of the first twenty or more cases were obtained for each country using data aggregated by the Johns Hopkins Centers for Systems Science and Engineering as of 25 th June 2020.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["medRxiv", "TREATMENT", 329, 336], ["COVID", "TEST", 373, 378], ["med", "ANATOMY", 99, 102]]], ["Model start and end dates for each country are provided in Table 2 . is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)DataThe copyright holder for this preprint this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. .", [["The copyright holder", "TREATMENT", 420, 440], ["med", "ANATOMY", 107, 110], ["med", "ANATOMY", 324, 327]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprint(which was not certified by peer review)To incorporate the varying age structures of different countries into the model, parameters were weighted by the proportion of the population in the 0-64, 65-79, and 80 and above age brackets in each country to form a unique set of parameters for each country (Appendix 2).", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["the population", "TEST", 507, 521], ["above age brackets", "TREATMENT", 553, 571], ["med", "ANATOMY", 99, 102]]], ["Demographic data were obtained from the World Bank for 2018, [13] with the exception of Eritrea, for which population data came from IndexMundi.[14] Many African countries have high rates of TB and HIV/AIDS which are likely to make their populations more vulnerable to severe infection.", [["TB", "DISEASE", 191, 193], ["HIV/AIDS", "DISEASE", 198, 206], ["infection", "DISEASE", 276, 285], ["HIV", "SPECIES", 198, 201], ["HIV", "SPECIES", 198, 201], ["Demographic data", "TEST", 0, 16], ["Eritrea", "PROBLEM", 88, 95], ["population data", "TEST", 107, 122], ["TB", "PROBLEM", 191, 193], ["HIV/AIDS", "PROBLEM", 198, 206], ["severe infection", "PROBLEM", 269, 285], ["Eritrea", "OBSERVATION", 88, 95], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["infection", "OBSERVATION", 276, 285]]], ["To further consider the impact of this on our analysis we reweighted the parameters according to the proportion of the younger population with HIV and/or TB.", [["HIV and/or TB", "DISEASE", 143, 156], ["HIV", "SPECIES", 143, 146], ["HIV", "SPECIES", 143, 146], ["our analysis", "TEST", 42, 54], ["HIV", "PROBLEM", 143, 146], ["TB", "PROBLEM", 154, 156]]], ["Those over age 80, and 65-79 were modeled as before, however the under 64 cohort was split into healthy individuals and those affected by TB and/or HIV/AIDS.", [["TB", "DISEASE", 138, 140], ["HIV/AIDS", "DISEASE", 148, 156], ["HIV", "SPECIES", 148, 151], ["HIV", "SPECIES", 148, 151], ["TB", "PROBLEM", 138, 140], ["HIV/AIDS", "PROBLEM", 148, 156]]], ["For this group we employed the parameter set previously used for the 0-64-year-old cohort, with the exception of progression to severe disease, which was doubled to 0\u00b7404 (upper bound tripled to 0\u00b7606 and lower bound of 0\u00b7202), for populations with HIV/AIDS and/or TB, based on estimates for mortality from South Africa.", [["HIV/AIDS and/or TB", "DISEASE", 249, 267], ["HIV", "SPECIES", 249, 252], ["severe disease", "PROBLEM", 128, 142], ["HIV/AIDS", "PROBLEM", 249, 257], ["TB", "PROBLEM", 265, 267], ["severe", "OBSERVATION_MODIFIER", 128, 134], ["disease", "OBSERVATION", 135, 142]]], ["[15, 16] Algeria, Mauritius, Eritrea, and Seychelles were excluded from this second analysis due to lack of data.Epidemiological equations and parametersThe model follows a modified SEIR structure ( Figure 1 ) with seven unique compartments to describe the epidemiology of SARS-CoV-2.", [["SARS", "DISEASE", 273, 277], ["SARS-CoV-2", "ORGANISM", 273, 283], ["SEIR structure", "PROTEIN", 182, 196], ["SARS-CoV", "SPECIES", 273, 281], ["Eritrea", "PROBLEM", 29, 36], ["this second analysis", "TEST", 72, 92], ["Epidemiological equations", "TEST", 113, 138], ["CoV", "TEST", 278, 281]]], ["[17] Susceptible individuals, S, are those in the population that can become infected with the virus.", [["the virus", "PROBLEM", 91, 100], ["infected", "OBSERVATION", 77, 85]]], ["They become exposed, E, to SARS-CoV-2 by encountering infected individuals in the population at rate \u07da \u0b35 for asymptomatic individuals or \u07da \u0b36 for symptomatic individuals.", [["SARS", "DISEASE", 27, 31], ["CoV-2", "ORGANISM", 32, 37], ["SARS-CoV", "SPECIES", 27, 35], ["asymptomatic individuals", "PROBLEM", 109, 133], ["symptomatic individuals", "PROBLEM", 145, 168]]], ["We assume that individuals that are asymptomatic or mildly symptomatic have a lower transmission rate, \u03b2 1, than more symptomatic individuals, \u03b2 2 .Epidemiological equations and parameters[17] Exposed individuals incubate the virus at rate \u07e4 (calculated as the inverse of the incubation period).", [["\u03b2 1", "GENE_OR_GENE_PRODUCT", 103, 106], ["\u03b2 2", "GENE_OR_GENE_PRODUCT", 143, 146], ["individuals", "ORGANISM", 201, 212], ["asymptomatic", "PROBLEM", 36, 48], ["mildly symptomatic", "PROBLEM", 52, 70], ["Epidemiological equations", "TEST", 148, 173], ["the virus", "PROBLEM", 222, 231], ["mildly", "OBSERVATION_MODIFIER", 52, 58], ["symptomatic", "OBSERVATION_MODIFIER", 59, 70]]], ["A proportion of these individuals, \u07e0 , become symptomatically infected while the rest become contagious with mild or no symptoms, C. Of the symptomatically infected individuals, a proportion, h, have severe symptoms, to the extent that they will require hospitalization if available, I S , and the rest have moderate or non-severe symptoms, I N .", [["individuals", "ORGANISM", 22, 33], ["symptomatically infected", "PROBLEM", 46, 70], ["symptoms", "PROBLEM", 120, 128], ["the symptomatically infected individuals", "PROBLEM", 136, 176], ["severe symptoms", "PROBLEM", 200, 215], ["moderate or non-severe symptoms", "PROBLEM", 308, 339], ["symptomatically", "OBSERVATION_MODIFIER", 46, 61], ["infected", "OBSERVATION", 62, 70], ["mild", "OBSERVATION_MODIFIER", 109, 113], ["severe", "OBSERVATION_MODIFIER", 200, 206], ["moderate", "OBSERVATION_MODIFIER", 308, 316]]], ["Asymptomatic or mildly symptomatic, moderately symptomatic, and severely symptomatic individuals recover (or otherwise become non-contagious) at rates \u07db \u0b35 , \u07db \u0b36 , and \u07db \u0b37 , respectively.", [["mildly symptomatic", "PROBLEM", 16, 34], ["moderately symptomatic", "PROBLEM", 36, 58], ["severely symptomatic individuals", "PROBLEM", 64, 96], ["mildly", "OBSERVATION_MODIFIER", 16, 22], ["symptomatic", "OBSERVATION_MODIFIER", 23, 34], ["moderately", "OBSERVATION_MODIFIER", 36, 46], ["symptomatic", "OBSERVATION_MODIFIER", 47, 58], ["severely", "OBSERVATION_MODIFIER", 64, 72], ["symptomatic", "OBSERVATION_MODIFIER", 73, 84]]], ["It is assumed that recovered individuals are immune from becoming re-infected during the time period of the study.", [["the study", "TEST", 104, 113]]], ["Severely infected individuals may also die, D, at rate \u07dc .", [["individuals", "ORGANISM", 18, 29], ["Severely infected individuals", "PROBLEM", 0, 29], ["infected", "OBSERVATION", 9, 17]]], ["The model is described by the following set of differential equations:Epidemiological equations and parameters.", [["Epidemiological equations", "TEST", 70, 95]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprintEstimation of Epidemiological ParametersParameters are estimated from the literature and the sources for this are outlined in Table 1 and the supplementary materials.Estimation of Epidemiological ParametersTo assess the uncertainty of the parameter ranges on model estimations, we used Latin Hypercube Sampling (LHS), a stratified sampling technique that efficiently analyzes large numbers of input parameters by treating each parameter as a separate random variable.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv", "TREATMENT", 324, 331], ["Epidemiological ParametersParameters", "TEST", 354, 390], ["Epidemiological Parameters", "TEST", 520, 546], ["model estimations", "TEST", 599, 616], ["Latin Hypercube Sampling (LHS)", "TREATMENT", 626, 656], ["a stratified sampling technique", "TREATMENT", 658, 689], ["med", "ANATOMY", 99, 102], ["large", "OBSERVATION_MODIFIER", 716, 721], ["numbers", "OBSERVATION_MODIFIER", 722, 729]]], ["Stochastic sampling of the parameters with LHS was based on an estimation of parameter ranges obtained from the literature (Table 1) .", [["an estimation of parameter ranges", "TEST", 60, 93]]], ["From the parameter sampling, we were able to calculate the 95% confidence interval (CI) for all compartment values over the temporal domain.Scenarios and AssumptionsWe provide case projections for the following four scenarios:Scenarios and Assumptions1.", [["temporal domain", "PROTEIN", 124, 139], ["the parameter sampling", "TEST", 5, 27], ["CI", "TEST", 84, 86], ["all compartment values", "TEST", 92, 114]]], ["Baseline: Disease continues to spread with no curfew, lockdown, social distancing, or other intervention(s) and with no change in transmission rate.Scenarios and Assumptions2.", [["Disease", "PROBLEM", 10, 17], ["change in transmission rate", "PROBLEM", 120, 147], ["Assumptions2", "TREATMENT", 162, 174], ["Disease", "OBSERVATION", 10, 17]]], ["Moderate Lockdown: Disease transmission is reduced by 25% during the lockdown period, then transmission resumes at 90% of the pre-lockdown value due to sustained changes in behavior.Hard Lockdown:Disease transmission falls 44% during the lockdown period, then transmission resumes at 90% of pre-lockdown levels.Hard Lockdown and Continued Social Distancing/Isolating Cases:Disease transmission is reduced by 44% during the lockdown period then, through social distancing regulations and isolation of symptomatic individuals, resumes at 75% of pre-lockdown levels.Hard Lockdown and Continued Social Distancing/Isolating Cases:For each scenario, we estimate the total number of infections that are asymptomatic or mildly symptomatic, moderately symptomatic, and severely symptomatic cases.", [["infections", "DISEASE", 676, 686], ["Disease transmission", "PROBLEM", 19, 39], ["the pre-lockdown value", "TEST", 122, 144], ["sustained changes in behavior", "PROBLEM", 152, 181], ["Disease transmission falls", "PROBLEM", 196, 222], ["Disease transmission", "PROBLEM", 373, 393], ["symptomatic individuals", "PROBLEM", 500, 523], ["infections", "PROBLEM", 676, 686], ["asymptomatic", "PROBLEM", 696, 708], ["mildly symptomatic", "PROBLEM", 712, 730], ["moderately symptomatic", "PROBLEM", 732, 754], ["severely symptomatic cases", "PROBLEM", 760, 786], ["Disease", "OBSERVATION", 19, 26], ["reduced", "OBSERVATION_MODIFIER", 43, 50], ["Disease", "OBSERVATION", 196, 203], ["reduced", "OBSERVATION_MODIFIER", 397, 404], ["symptomatic", "OBSERVATION_MODIFIER", 500, 511], ["infections", "OBSERVATION", 676, 686], ["mildly", "OBSERVATION_MODIFIER", 712, 718], ["symptomatic", "OBSERVATION_MODIFIER", 719, 730], ["moderately", "OBSERVATION_MODIFIER", 732, 742], ["symptomatic", "OBSERVATION_MODIFIER", 743, 754], ["severely", "OBSERVATION_MODIFIER", 760, 768], ["symptomatic", "OBSERVATION_MODIFIER", 769, 780]]], ["The rate of severely symptomatic cases is based on the rate of hospitalization in other parts of the world, although access to hospital care is likely to differ greatly between different parts of Africa.", [["severely symptomatic cases", "PROBLEM", 12, 38], ["severely", "OBSERVATION_MODIFIER", 12, 20], ["symptomatic", "OBSERVATION", 21, 32]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020.Patient and Public Involvement StatementIt was not appropriate or possible to involve patients or the public in the design, or conduct, or reporting, or dissemination plans of our research.RESULTSUnder baseline conditions, the most populous countries stand to bear the greatest disease burden with Nigeria having an estimated peak case load of 645,081 severe infections (0\u00b731 percent of total country population) and 9,359,221 total infections (4\u00b754% of total country population), followed by Ethiopia, with an estimated peak case load of 335,024 (0\u00b729%) severe infections and 4,978,734 (4\u00b733%) total infections (Figure 2 ; Table 3 ).", [["CC", "CHEMICAL", 0, 2], ["infections", "DISEASE", 843, 853], ["infections", "DISEASE", 917, 927], ["infections", "DISEASE", 1046, 1056], ["infections", "DISEASE", 1085, 1095], ["patients", "ORGANISM", 570, 578], ["Patient", "SPECIES", 484, 491], ["patients", "SPECIES", 570, 578], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["The copyright holder", "TREATMENT", 407, 427], ["baseline conditions", "PROBLEM", 686, 705], ["the greatest disease burden", "PROBLEM", 749, 776], ["severe infections", "PROBLEM", 836, 853], ["total infections", "PROBLEM", 911, 927], ["severe infections", "PROBLEM", 1039, 1056], ["total infections", "PROBLEM", 1079, 1095], ["med", "ANATOMY", 99, 102], ["med", "ANATOMY", 311, 314], ["greatest", "OBSERVATION_MODIFIER", 753, 761], ["disease", "OBSERVATION", 762, 769], ["severe", "OBSERVATION_MODIFIER", 836, 842], ["infections", "OBSERVATION", 843, 853], ["severe", "OBSERVATION_MODIFIER", 1039, 1045], ["infections", "OBSERVATION", 1046, 1056]]], ["Smaller countries have a lower case load; Cabo Verde is projected to have a peak case load of 2,244 severe infections (0\u00b740% of total country population) and 32,811 (5\u00b790%) total infections, Sao Tome and Principe are estimated to experience peaks of 14,012 (6\u00b740%) total infections and 1,048 (0\u00b748%) severe infections ( Figure S1 ).", [["infections", "DISEASE", 107, 117], ["infections", "DISEASE", 179, 189], ["infections", "DISEASE", 271, 281], ["infections", "DISEASE", 307, 317], ["a lower case load", "PROBLEM", 23, 40], ["severe infections", "PROBLEM", 100, 117], ["total infections", "PROBLEM", 173, 189], ["Sao Tome", "TEST", 191, 199], ["total infections", "PROBLEM", 265, 281], ["severe infections ( Figure S1 )", "PROBLEM", 300, 331], ["severe", "OBSERVATION_MODIFIER", 100, 106], ["infections", "OBSERVATION", 107, 117], ["infections", "OBSERVATION", 179, 189], ["severe", "OBSERVATION_MODIFIER", 300, 306], ["infections", "OBSERVATION", 307, 317]]], ["However, the baseline scenario does not reflect the current situation in any country as all countries have instituted some form of social distancing policies.RESULTSModerate lockdowns (assumed to lower transmission by 25% during lockdown), reduced estimated peak severe infections by 10% in Senegal, to 37%, in Ethiopia and Egypt.", [["infections", "DISEASE", 270, 280], ["reduced estimated peak severe infections", "PROBLEM", 240, 280], ["peak", "OBSERVATION_MODIFIER", 258, 262], ["severe", "OBSERVATION_MODIFIER", 263, 269], ["infections", "OBSERVATION", 270, 280]]], ["However, South Africa the peak of the severe case load showed a 1% increase of 1,929, given a moderate lockdown of 35 days (Figures S1 and S6) .", [["S6", "PROTEIN", 139, 141], ["severe", "OBSERVATION_MODIFIER", 38, 44], ["moderate", "OBSERVATION_MODIFIER", 94, 102]]], ["In Egypt and Ethiopia, who have the longest planned lockdowns of any of the African countries (137 and 170 days, respectively), the estimated impact was a reduction in total peak cases of 37%, or 130,998 and 123,890 severe cases, respectively ( Figure 5 ).", [["total peak cases", "TEST", 168, 184], ["severe cases", "PROBLEM", 216, 228], ["reduction", "OBSERVATION_MODIFIER", 155, 164]]], ["In addition, the estimated peak of infections was shifted by 35 and 27 days, respectively ( Table 2 ).", [["infections", "DISEASE", 35, 45], ["the estimated peak of infections", "PROBLEM", 13, 45], ["peak", "OBSERVATION_MODIFIER", 27, 31], ["infections", "OBSERVATION", 35, 45]]], ["In Cabo Verde, which had the shortest planned lockdown of 17 days, the estimated reduction in severe peak cases was 19% under a moderate lockdown, and the peak date of infections was shifted by 10 days (Figure 5 ).RESULTSThe effect of hard temporary lockdowns without extended post-lockdown social distancing compared to moderate lockdowns varied by country.", [["infections", "DISEASE", 168, 178], ["the estimated reduction in severe peak cases", "PROBLEM", 67, 111], ["infections", "PROBLEM", 168, 178], ["hard temporary lockdowns", "TREATMENT", 235, 259], ["reduction", "OBSERVATION_MODIFIER", 81, 90], ["severe", "OBSERVATION_MODIFIER", 94, 100], ["peak", "OBSERVATION_MODIFIER", 101, 105], ["moderate", "OBSERVATION_MODIFIER", 128, 136], ["infections", "OBSERVATION", 168, 178], ["hard temporary", "OBSERVATION_MODIFIER", 235, 249]]], ["The reduction in severe peak infections ranged from 7%, in Rwanda, to 35% in Egypt, compared to baseline values.", [["infections", "DISEASE", 29, 39], ["The reduction", "PROBLEM", 0, 13], ["severe peak infections", "PROBLEM", 17, 39], ["reduction", "OBSERVATION_MODIFIER", 4, 13], ["severe", "OBSERVATION_MODIFIER", 17, 23], ["peak", "OBSERVATION_MODIFIER", 24, 28], ["infections", "OBSERVATION", 29, 39]]], ["In some countries a hard lockdown had a lower impact on reducing peak cases than a moderate one.", [["moderate", "OBSERVATION_MODIFIER", 83, 91]]], ["For example, in Ethiopia the expected impact of a moderate lockdown reduced severe cases by 123,890 cases compared to baseline, while a hard lockdown reduced cases by 100,743.", [["a moderate lockdown reduced severe cases", "PROBLEM", 48, 88], ["moderate", "OBSERVATION_MODIFIER", 50, 58], ["lockdown", "OBSERVATION_MODIFIER", 59, 67], ["reduced", "OBSERVATION_MODIFIER", 68, 75], ["severe", "OBSERVATION_MODIFIER", 76, 82]]], ["However, hard lockdowns delayed the onset of the peak in infections compared to moderate lockdowns by several weeks.", [["infections", "DISEASE", 57, 67], ["the peak in infections", "PROBLEM", 45, 67], ["peak", "OBSERVATION_MODIFIER", 49, 53], ["infections", "OBSERVATION", 57, 67]]], ["For example, in Tanzania, a moderate lockdown of 60 days delayed the peak in severe infections by 16 days compared to a 47-day delay in the case of a hard lockdown.RESULTSFor all countries, hard lockdowns with continued post-lockdown interventions were the most effective in delaying and reducing peak infections.", [["infections", "DISEASE", 84, 94], ["infections", "DISEASE", 302, 312], ["severe infections", "PROBLEM", 77, 94], ["a hard lockdown", "PROBLEM", 148, 163], ["continued post-lockdown interventions", "TREATMENT", 210, 247], ["peak infections", "PROBLEM", 297, 312], ["moderate", "OBSERVATION_MODIFIER", 28, 36], ["severe", "OBSERVATION_MODIFIER", 77, 83], ["infections", "OBSERVATION", 84, 94], ["peak infections", "OBSERVATION", 297, 312]]], ["Delays to the peak in infections ranged from 22 days in Libya to 123 days in Ethiopia (Table 2) .", [["infections", "DISEASE", 22, 32], ["the peak in infections", "PROBLEM", 10, 32]]], ["This reflects the different lengths of lockdowns in these countries which lasted 20, and 170 days respectively.", [["different", "OBSERVATION_MODIFIER", 18, 27], ["lengths", "OBSERVATION_MODIFIER", 28, 35]]], ["Hard lockdowns with continued interventions also led to the greatest reductions in the peak in estimated total infections to the greatest extent in these model projections, from 36% in Ghana and South Africa to 58% in .", [["infections", "DISEASE", 111, 121], ["continued interventions", "TREATMENT", 20, 43], ["estimated total infections", "PROBLEM", 95, 121], ["greatest", "OBSERVATION_MODIFIER", 60, 68], ["reductions", "OBSERVATION_MODIFIER", 69, 79], ["peak", "OBSERVATION_MODIFIER", 87, 91], ["total", "OBSERVATION_MODIFIER", 105, 110], ["infections", "OBSERVATION", 111, 121], ["greatest extent", "OBSERVATION_MODIFIER", 129, 144]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprint Namibia.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["med", "ANATOMY", 99, 102]]], ["In Kenya this would reduce the peak case load in severe infections by 100,552 cases with a lockdown of 43 days.(which was not certified by peer review)Many African countries have young populations, who have been less likely to show severe symptoms in other countries, however, the high prevalence of HIV/AIDS and TB in these populations potentially renders them more vulnerable to COVID-19.", [["infections", "DISEASE", 56, 66], ["HIV/AIDS", "DISEASE", 300, 308], ["TB", "DISEASE", 313, 315], ["COVID-19", "CHEMICAL", 381, 389], ["HIV", "ORGANISM", 300, 303], ["HIV", "SPECIES", 300, 303], ["HIV", "SPECIES", 300, 303], ["severe infections", "PROBLEM", 49, 66], ["severe symptoms", "PROBLEM", 232, 247], ["HIV/AIDS", "PROBLEM", 300, 308], ["TB", "PROBLEM", 313, 315], ["COVID", "TEST", 381, 386], ["severe", "OBSERVATION_MODIFIER", 49, 55], ["infections", "OBSERVATION", 56, 66], ["severe", "OBSERVATION_MODIFIER", 232, 238], ["symptoms", "OBSERVATION", 239, 247]]], ["[15] The highest proportional burden HIV countries in Africa are Eswatini, Botswana and South Africa and the highest proportional burden tuberculosis countries are Burundi and Central African Republic.", [["tuberculosis", "DISEASE", 137, 149], ["HIV", "SPECIES", 37, 40], ["burden", "OBSERVATION_MODIFIER", 130, 136], ["tuberculosis", "OBSERVATION", 137, 149], ["Central", "OBSERVATION_MODIFIER", 176, 183], ["African", "OBSERVATION_MODIFIER", 184, 191]]], ["Assuming individuals with TB and HIV/AIDS, once infected, are more likely to progress to severe disease increased the peak number of infections significantly (Figure 2 ).", [["TB", "DISEASE", 26, 28], ["HIV/AIDS", "DISEASE", 33, 41], ["infections", "DISEASE", 133, 143], ["HIV", "SPECIES", 33, 36], ["HIV", "SPECIES", 33, 36], ["TB", "PROBLEM", 26, 28], ["HIV/AIDS", "PROBLEM", 33, 41], ["infected", "PROBLEM", 48, 56], ["severe disease", "PROBLEM", 89, 103], ["infections", "PROBLEM", 133, 143], ["more likely", "UNCERTAINTY", 62, 73], ["severe", "OBSERVATION_MODIFIER", 89, 95], ["disease", "OBSERVATION", 96, 103], ["peak", "OBSERVATION_MODIFIER", 118, 122], ["number", "OBSERVATION_MODIFIER", 123, 129], ["infections", "OBSERVATION", 133, 143]]], ["In Eswatini, Botswana, and South Africa the baseline peak number of severe infections increased from 4,529 to 5,279, 9,334 to 10,023, and from 162,977 to 203,261, respectively ( Figure S2 , S11-S18).", [["infections", "DISEASE", 75, 85], ["severe infections", "PROBLEM", 68, 85], ["peak", "OBSERVATION_MODIFIER", 53, 57], ["number", "OBSERVATION_MODIFIER", 58, 64], ["severe", "OBSERVATION_MODIFIER", 68, 74], ["infections", "OBSERVATION", 75, 85], ["increased", "OBSERVATION_MODIFIER", 86, 95]]], ["In Burundi, the peak number of severe cases increased from 40,417 to 44,058.", [["severe cases", "PROBLEM", 31, 43], ["peak", "OBSERVATION_MODIFIER", 16, 20], ["number", "OBSERVATION_MODIFIER", 21, 27], ["severe", "OBSERVATION_MODIFIER", 31, 37], ["cases", "OBSERVATION", 38, 43], ["increased", "OBSERVATION_MODIFIER", 44, 53]]], ["However, progression to severe disease may, under certain circumstances, lead to less infections, as those with severe disease may be more likely to die, quarantine, or be sick enough that they are not widely transmitting the disease.", [["infections", "DISEASE", 86, 96], ["severe disease", "PROBLEM", 24, 38], ["less infections", "PROBLEM", 81, 96], ["severe disease", "PROBLEM", 112, 126], ["the disease", "PROBLEM", 222, 233], ["severe", "OBSERVATION_MODIFIER", 24, 30], ["disease", "OBSERVATION", 31, 38], ["less", "OBSERVATION_MODIFIER", 81, 85], ["infections", "OBSERVATION", 86, 96], ["severe", "OBSERVATION_MODIFIER", 112, 118], ["disease", "OBSERVATION", 119, 126], ["may be more likely", "UNCERTAINTY", 127, 145]]], ["For example, in Nigeria, severe infections decrease from 645,081 to 591,888 under this scenario.ConclusionMost African countries are likely early in the outbreak of SARS-CoV-2, and the initial peak in infections may be several months away in many cases.", [["infections", "DISEASE", 32, 42], ["SARS", "DISEASE", 165, 169], ["infections", "DISEASE", 201, 211], ["SARS-CoV-2", "ORGANISM", 165, 175], ["SARS-CoV", "SPECIES", 165, 173], ["severe infections", "PROBLEM", 25, 42], ["SARS", "PROBLEM", 165, 169], ["CoV", "TEST", 170, 173], ["the initial peak in infections", "PROBLEM", 181, 211], ["severe", "OBSERVATION_MODIFIER", 25, 31], ["infections", "OBSERVATION", 32, 42], ["decrease", "OBSERVATION_MODIFIER", 43, 51], ["peak", "OBSERVATION_MODIFIER", 193, 197], ["infections", "OBSERVATION", 201, 211]]], ["Policymakers need mathematical models that are attuned to the context in Africa to aid in planning for continued transmission of the virus and to develop interventions that reduce disease transmission.", [["mathematical models", "PROBLEM", 18, 37], ["the virus", "PROBLEM", 129, 138], ["interventions", "TREATMENT", 154, 167], ["disease transmission", "PROBLEM", 180, 200]]], ["Here we analyzed a model of transmission of SARS-CoV-2 parameterized for low-resource settings.", [["SARS", "DISEASE", 44, 48], ["SARS-CoV", "SPECIES", 44, 52], ["SARS", "TEST", 44, 48], ["CoV", "TEST", 49, 52]]], ["Based on current observed cases of COVID-19 in African countries, we assessed the impact of strict social distancing measures.", [["COVID", "TEST", 35, 40], ["strict social distancing measures", "TREATMENT", 92, 125]]], ["However, the extent and efficacy of lockdown policies is certain to vary between and within countries.", [["lockdown policies", "TREATMENT", 36, 53], ["extent", "OBSERVATION_MODIFIER", 13, 19], ["efficacy", "OBSERVATION_MODIFIER", 24, 32]]], ["Furthermore, after a lockdown, and in response to a high death toll, citizens are likely to continue to adjust their social behavior.", [["death", "DISEASE", 57, 62]]], ["[33] The results from our simulations suggest that national lockdowns will likely slow viral transmission, reducing the peak number of active cases and delaying the time until the peak occurs.", [["our simulations", "TEST", 22, 37], ["slow viral transmission", "PROBLEM", 82, 105]]], ["This delay can allow governments time to prepare by setting up designated COVID-19 treatment sections in hospitals and additional testing centers in densely populated areas, as well as practical measures within communities such as handwashing stations and soap distribution and information campaigns educating the public in infection prevention behaviors including mask wearing, social distancing and handwashing.", [["infection", "DISEASE", 324, 333], ["additional testing centers", "TREATMENT", 119, 145], ["practical measures", "TREATMENT", 185, 203], ["mask wearing", "TREATMENT", 365, 377], ["infection", "OBSERVATION", 324, 333]]], ["Our models suggest that by using this time to prepare, transmission is likely to decrease enough to substantially to reduce the peak in infections, even after lockdowns cease.", [["infections", "DISEASE", 136, 146], ["the peak in infections", "PROBLEM", 124, 146], ["peak", "OBSERVATION_MODIFIER", 128, 132], ["infections", "OBSERVATION", 136, 146]]], ["This may make the consequences of the pandemic more manageable for health and social systems, though many are still likely to become overwhelmed.ConclusionThe predicted dates of peak cases varied greatly by country, from 1 st August in South Africa to 22 nd December in Ethiopia in the case of a hard lockdown with continued social distancing (Scenario 3) ( Table 6 ).", [["peak cases", "PROBLEM", 178, 188]]], ["This is due to many factors including differences in population size, when the virus first arrived in the country, and length and severity of lockdown interventions.", [["many factors", "PROBLEM", 15, 27], ["the virus", "PROBLEM", 75, 84], ["lockdown interventions", "TREATMENT", 142, 164], ["population", "OBSERVATION_MODIFIER", 53, 63], ["size", "OBSERVATION_MODIFIER", 64, 68]]], ["Most infections are mild; however, some countries are likely to bear a much higher per capita burden than others, largely due to differences in the duration and efficacy of lockdowns.Conclusion.", [["infections", "DISEASE", 5, 15], ["Most infections", "PROBLEM", 0, 15], ["lockdowns", "TREATMENT", 173, 182], ["infections", "OBSERVATION", 5, 15], ["mild", "OBSERVATION_MODIFIER", 20, 24]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprint This model considers the impact of lockdown on transmission of SARS-CoV-2; however, effective implementation of large-scale mitigation measures thus far implemented in developed countries may not be feasible or sustainable in many low-and middle-income countries (LMICs) in Africa and around the world given various sociocultural, economic, and political challenges.", [["CC", "CHEMICAL", 0, 2], ["SARS", "DISEASE", 404, 408], ["SARS-CoV-2", "ORGANISM", 404, 414], ["SARS-CoV", "SPECIES", 404, 412], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["medRxiv", "TREATMENT", 324, 331], ["large-scale mitigation measures", "TREATMENT", 453, 484], ["med", "ANATOMY", 99, 102], ["large", "OBSERVATION_MODIFIER", 453, 458]]], ["[34, 35] Across the African continent, an estimated 40% of people live below the international poverty line making less than $1\u00b790 (in 2011 purchasing parity power) per day, and approximately 85\u00b78% of employment is informal.", [["people", "ORGANISM", 59, 65], ["people", "SPECIES", 59, 65]]], ["Furthermore, access to hygiene and sanitation facilities is limited; in 2017, only 15% of people across sub-Saharan Africa had access to basic handwashing facilities with soap and water.", [["people", "ORGANISM", 90, 96], ["people", "SPECIES", 90, 96]]], ["[38] Social distancing within communities and within households is often not possible given over 55% of Africa's urban populations live in densely populated slums, higher than the global average of 30%.", [["densely", "OBSERVATION_MODIFIER", 139, 146], ["populated", "OBSERVATION", 147, 156], ["higher", "OBSERVATION_MODIFIER", 164, 170]]], ["[39] In addition, there are 6\u00b73 million refugees and 17\u00b77 million internally displaced persons in the African continent, and ongoing humanitarian crises have displaced over 20 million people.", [["persons", "ORGANISM", 87, 94], ["people", "ORGANISM", 184, 190], ["persons", "SPECIES", 87, 94], ["people", "SPECIES", 184, 190]]], ["[40] COVID-19 presents most severely in the elderly population and those with chronic noncommunicable diseases such as diabetes and hypertension, which affects an estimated 55% of Africans.", [["chronic noncommunicable diseases", "DISEASE", 78, 110], ["diabetes", "DISEASE", 119, 127], ["hypertension", "DISEASE", 132, 144], ["chronic noncommunicable diseases", "PROBLEM", 78, 110], ["diabetes", "PROBLEM", 119, 127], ["hypertension", "PROBLEM", 132, 144], ["most severely", "OBSERVATION_MODIFIER", 23, 36], ["chronic", "OBSERVATION_MODIFIER", 78, 85], ["noncommunicable", "OBSERVATION_MODIFIER", 86, 101], ["diseases", "OBSERVATION", 102, 110], ["diabetes", "OBSERVATION", 119, 127], ["hypertension", "OBSERVATION", 132, 144]]], ["[41] African populations may benefit from having a younger population and low prevalence of diabetes (3\u00b79%) compared to the global average (9\u00b73%).", [["diabetes", "DISEASE", 92, 100], ["diabetes", "PROBLEM", 92, 100], ["low prevalence", "OBSERVATION_MODIFIER", 74, 88]]], ["[42, 43] In the model, we modify the transmission and mortality rates according to the age structure of countries, based on evidence that morbidity and mortality is concentrated in older individuals.", [["mortality rates", "TEST", 54, 69], ["morbidity", "PROBLEM", 138, 147], ["morbidity", "OBSERVATION", 138, 147]]], ["However emerging reports of COVID-19 cases in the developing world, particularly Brazil, suggest the death toll in the young may be higher than expected.", [["death", "DISEASE", 101, 106], ["COVID", "TEST", 28, 33], ["higher", "OBSERVATION_MODIFIER", 132, 138]]], ["[44] Young populations who go out to work, buy food and look after the family are hard to shield and likely to be highly exposed to the virus.", [["the virus", "PROBLEM", 132, 141]]], ["The average size of households with older members is 12\u00b71 in Senegal and 12\u00b76 in the Gambia, the highest in the world, [45] and this may increase the potential for exposure to the virus and hinder isolation of symptomatic cases.", [["the virus", "TREATMENT", 176, 185], ["symptomatic cases", "PROBLEM", 210, 227], ["average", "OBSERVATION_MODIFIER", 4, 11], ["size", "OBSERVATION_MODIFIER", 12, 16]]], ["High rates of tuberculosis, HIV, malaria, and other infectious diseases may also make young African populations more vulnerable to severe infection with COVID-19.", [["tuberculosis", "DISEASE", 14, 26], ["HIV, malaria", "DISEASE", 28, 40], ["infectious diseases", "DISEASE", 52, 71], ["infection", "DISEASE", 138, 147], ["COVID-19", "CHEMICAL", 153, 161], ["HIV", "SPECIES", 28, 31], ["HIV", "SPECIES", 28, 31], ["High rates of tuberculosis", "PROBLEM", 0, 26], ["HIV", "PROBLEM", 28, 31], ["malaria", "PROBLEM", 33, 40], ["other infectious diseases", "PROBLEM", 46, 71], ["severe infection", "PROBLEM", 131, 147], ["COVID", "TEST", 153, 158], ["tuberculosis", "OBSERVATION", 14, 26], ["malaria", "OBSERVATION", 33, 40], ["infectious", "OBSERVATION", 52, 62], ["severe", "OBSERVATION_MODIFIER", 131, 137], ["infection", "OBSERVATION", 138, 147]]], ["In West and Central Africa 60% of people living with HIV do not receive treatment.", [["people", "ORGANISM", 34, 40], ["people", "SPECIES", 34, 40], ["HIV", "SPECIES", 53, 56], ["HIV", "SPECIES", 53, 56], ["treatment", "TREATMENT", 72, 81]]], ["[46] The high prevalence of malnutrition, anemia, and exposure to indoor air pollution, often from cooking fires, may also increase vulnerability.", [["malnutrition", "DISEASE", 28, 40], ["anemia", "DISEASE", 42, 48], ["malnutrition", "PROBLEM", 28, 40], ["anemia", "PROBLEM", 42, 48], ["indoor air pollution", "PROBLEM", 66, 86], ["high prevalence", "OBSERVATION_MODIFIER", 9, 24], ["malnutrition", "OBSERVATION", 28, 40], ["anemia", "OBSERVATION", 42, 48], ["air pollution", "OBSERVATION", 73, 86], ["increase", "OBSERVATION_MODIFIER", 123, 131], ["vulnerability", "OBSERVATION", 132, 145]]], ["Additionally, the poor air quality in many Africa cities, which has been shown to be associated with increased morbidity and mortality from COVID-19,[47,48] may exacerbate issues for the region.", [["the poor air quality", "PROBLEM", 14, 34], ["increased morbidity", "PROBLEM", 101, 120], ["COVID", "TEST", 140, 145], ["poor", "OBSERVATION_MODIFIER", 18, 22], ["air quality", "OBSERVATION", 23, 34], ["many", "OBSERVATION_MODIFIER", 38, 42], ["Africa", "OBSERVATION_MODIFIER", 43, 49], ["increased", "OBSERVATION_MODIFIER", 101, 110], ["morbidity", "OBSERVATION", 111, 120]]], ["[49] Testing capacity is limited in much of Africa, [50] and confirmed cases may increase faster than predicted in the near future as testing capacity increases and contact tracing continues.", [["Testing capacity", "TEST", 5, 21], ["testing capacity", "TEST", 134, 150], ["contact tracing", "TEST", 165, 180]]], ["In addition, evidence suggests that many cases are asymptomatic and may be missed by testing protocols that only include those with symptoms who have recently travelled to an infected area or their contacts.", [["area", "ANATOMY", 184, 188], ["asymptomatic", "PROBLEM", 51, 63], ["testing protocols", "TEST", 85, 102], ["symptoms", "PROBLEM", 132, 140], ["an infected area", "PROBLEM", 172, 188], ["evidence suggests", "UNCERTAINTY", 13, 30], ["infected", "OBSERVATION", 175, 183]]], ["Furthermore, social stigma and inability to access healthcare may prevent symptomatic individuals from seeking treatment.", [["symptomatic individuals", "PROBLEM", 74, 97], ["seeking treatment", "TREATMENT", 103, 120]]], ["This may affect the results of the model as it uses the initial numbers of confirmed COVID-19 cases recorded.", [["COVID", "TEST", 85, 90]]], ["In addition, results from the model suggest cases may rapidly rise after a hard lockdown if there are no further mitigation measures.", [["further mitigation measures", "TREATMENT", 105, 132]]], ["Contact tracing and testing are needed to maintain the reduction in cases gained from early lockdowns.", [["Contact tracing and testing", "TEST", 0, 27], ["the reduction in cases", "PROBLEM", 51, 73]]], ["Pooled testing can make mass testing more affordable and achievable with limited resources.", [["Pooled testing", "TEST", 0, 14], ["mass testing", "PROBLEM", 24, 36]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprint(which was not certified by peer review)There are inherent difficulties in inferring real world results from mass action models such as the one in this study.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 195, 215], ["inherent difficulties", "PROBLEM", 390, 411], ["mass action models", "PROBLEM", 449, 467], ["this study", "TEST", 487, 497], ["med", "ANATOMY", 99, 102], ["inherent", "OBSERVATION_MODIFIER", 390, 398], ["difficulties", "OBSERVATION", 399, 411], ["mass", "OBSERVATION", 449, 453]]], ["Our models tend to overestimate the number of infections as they assume people are well mixed, despite many social, physical and geographical barriers to mixing within countries.", [["infections", "DISEASE", 46, 56], ["people", "ORGANISM", 72, 78], ["people", "SPECIES", 72, 78], ["infections", "PROBLEM", 46, 56], ["infections", "OBSERVATION", 46, 56]]], ["Peaks in transmission are likely to occur at different times in different regions, as has occurred in the United States and Europe where there have been multiple epicenters.", [["likely to", "UNCERTAINTY", 26, 35], ["multiple", "OBSERVATION_MODIFIER", 153, 161], ["epicenters", "OBSERVATION", 162, 172]]], ["This model is not stochastic and case data are modeled from the first twenty or more cases, each behaving as an average case.", [["not", "UNCERTAINTY", 14, 17], ["stochastic", "OBSERVATION", 18, 28]]], ["In reality, there are no average cases; some individuals are likely to have many contacts, causing multiple infections, [52] and others to have very few.", [["infections", "DISEASE", 108, 118], ["individuals", "ORGANISM", 45, 56], ["multiple infections", "PROBLEM", 99, 118], ["no", "UNCERTAINTY", 22, 24], ["multiple", "OBSERVATION_MODIFIER", 99, 107], ["infections", "OBSERVATION", 108, 118]]], ["The different contact patterns of different segments of the population were also not included in this model and may have an impact on transmission between vulnerable groups.(which was not certified by peer review)The estimates presented here suggest that the burden of severe disease caused by SARS-CoV-2 is likely to be high for the African continent.", [["SARS", "DISEASE", 294, 298], ["SARS-CoV-2", "ORGANISM", 294, 304], ["SARS-CoV", "SPECIES", 294, 302], ["severe disease", "PROBLEM", 269, 283], ["SARS", "PROBLEM", 294, 298], ["CoV", "TEST", 299, 302], ["different", "OBSERVATION_MODIFIER", 4, 13], ["contact", "OBSERVATION", 14, 21], ["different", "OBSERVATION_MODIFIER", 34, 43], ["segments", "OBSERVATION_MODIFIER", 44, 52], ["impact", "OBSERVATION", 124, 130], ["severe", "OBSERVATION_MODIFIER", 269, 275], ["disease", "OBSERVATION", 276, 283], ["likely to be", "UNCERTAINTY", 308, 320], ["high", "OBSERVATION", 321, 325]]], ["Projections of disease progression are needed to enable policy makers, governments, aid agencies and other actors to optimize resource allocation and planning decisions.", [["disease progression", "PROBLEM", 15, 34], ["disease", "OBSERVATION", 15, 22]]], ["The high prevalence of TB, HIV, and malnutrition and other immunocompromising conditions accompanied by limited testing capacity and access to healthcare in many African countries are likely to make populations particularly vulnerable to this pandemic.", [["TB", "DISEASE", 23, 25], ["HIV", "DISEASE", 27, 30], ["malnutrition", "DISEASE", 36, 48], ["HIV", "SPECIES", 27, 30], ["HIV", "SPECIES", 27, 30], ["TB", "PROBLEM", 23, 25], ["HIV", "PROBLEM", 27, 30], ["malnutrition", "PROBLEM", 36, 48], ["other immunocompromising conditions", "PROBLEM", 53, 88], ["limited testing capacity", "PROBLEM", 104, 128], ["high prevalence", "OBSERVATION_MODIFIER", 4, 19], ["TB", "OBSERVATION", 23, 25], ["malnutrition", "OBSERVATION", 36, 48]]], ["Immediate planning and appropriate resource allocation are essential to save lives and mitigate the impact of COVID-19 in Africa.(which was not certified by peer review).", [["COVID", "TREATMENT", 110, 115]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)(which was not certified by peer review)The copyright holder for this preprint this version posted September 7, 2020.DATA SHARINGThe data for this study is included in the manuscript and supplementary materials, however please contact the corresponding author for any further data.DATA SHARING.", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["The copyright holder", "TREATMENT", 236, 256], ["this study", "TEST", 338, 348], ["med", "ANATOMY", 99, 102]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)DATA SHARINGThe copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprint FIGURE LEGENDS Figure 1 .", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["med", "ANATOMY", 99, 102]]], ["Modified SEIR model structure.", [["SEIR model structure", "OBSERVATION", 9, 29]]], ["Susceptible individuals, S, become exposed, E, to SARS-CoV-2.", [["SARS", "DISEASE", 50, 54], ["CoV-2", "ORGANISM", 55, 60], ["SARS-CoV", "SPECIES", 50, 58], ["Susceptible individuals", "PROBLEM", 0, 23]]], ["A proportion of these individuals become symptomatically infected with severe symptoms, I S , or non-severe, symptoms, I N , while the rest become contagious with mild or no symptoms, C. Asymptomatic or mildly symptomatic, moderately symptomatic and severely symptomatic individuals recover, R, and severely infected individuals may also die, D. .", [["individuals", "ORGANISM", 22, 33], ["individuals", "ORGANISM", 317, 328], ["severe symptoms", "PROBLEM", 71, 86], ["non-severe, symptoms", "PROBLEM", 97, 117], ["symptoms", "PROBLEM", 174, 182], ["mildly symptomatic", "PROBLEM", 203, 221], ["moderately symptomatic", "PROBLEM", 223, 245], ["severely symptomatic individuals", "PROBLEM", 250, 282], ["severely infected individuals", "PROBLEM", 299, 328], ["symptomatically", "OBSERVATION_MODIFIER", 41, 56], ["infected", "OBSERVATION", 57, 65], ["severe", "OBSERVATION_MODIFIER", 71, 77], ["mildly", "OBSERVATION_MODIFIER", 203, 209], ["symptomatic", "OBSERVATION_MODIFIER", 210, 221], ["moderately", "OBSERVATION_MODIFIER", 223, 233], ["symptomatic", "OBSERVATION_MODIFIER", 234, 245], ["infected", "OBSERVATION", 308, 316]]], ["CC-BY 4.0 International license It is made available under a is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review)DATA SHARINGThe copyright holder for this preprint this version posted September 7, 2020. . https://doi.org/10.1101/2020.09.04.20188102 doi: medRxiv preprint", [["CC", "CHEMICAL", 0, 2], ["CC", "TEST", 0, 2], ["medRxiv", "TREATMENT", 337, 344], ["med", "ANATOMY", 99, 102]]]], "21bc72381784b06599a8fcfd2ccb9c018499bf61": [["BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease 2019 (COVID-19) [1] have resulted in a World Health Organization (WHO)classified pandemic [2] .", [["acute respiratory syndrome coronavirus", "DISEASE", 17, 55], ["coronavirus disease", "DISEASE", 75, 94], ["BackgroundSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 57], ["SARS-CoV-2", "ORGANISM", 59, 69], ["coronavirus", "SPECIES", 75, 86], ["BackgroundSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 55], ["SARS-CoV-2", "SPECIES", 59, 69], ["BackgroundSevere acute respiratory syndrome coronavirus", "PROBLEM", 0, 55], ["SARS", "TEST", 59, 63], ["CoV", "TEST", 64, 67], ["coronavirus disease", "PROBLEM", 75, 94], ["COVID", "TEST", 101, 106], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43], ["coronavirus", "ANATOMY", 75, 86]]], ["Most patients with SARS-CoV-2 infection are asymptomatic or exhibit mild-to-moderate symptoms, but approximately 15% progress to severe pneumonia, and 5% require intensive care unit (ICU) management due to acute respiratory distress syndrome, septic shock and/or multiple organ failure.", [["respiratory", "ANATOMY", 212, 223], ["organ", "ANATOMY", 272, 277], ["SARS-CoV-2 infection", "DISEASE", 19, 39], ["pneumonia", "DISEASE", 136, 145], ["respiratory distress syndrome", "DISEASE", 212, 241], ["septic shock", "DISEASE", 243, 255], ["organ failure", "DISEASE", 272, 285], ["patients", "ORGANISM", 5, 13], ["SARS-CoV-2", "ORGANISM", 19, 29], ["organ", "ORGAN", 272, 277], ["patients", "SPECIES", 5, 13], ["CoV-", "SPECIES", 24, 28], ["SARS", "PROBLEM", 19, 23], ["CoV-2 infection", "PROBLEM", 24, 39], ["asymptomatic", "PROBLEM", 44, 56], ["mild-to-moderate symptoms", "PROBLEM", 68, 93], ["severe pneumonia", "PROBLEM", 129, 145], ["ICU) management", "TREATMENT", 183, 198], ["acute respiratory distress syndrome", "PROBLEM", 206, 241], ["septic shock", "PROBLEM", 243, 255], ["multiple organ failure", "PROBLEM", 263, 285], ["mild", "OBSERVATION_MODIFIER", 68, 72], ["moderate", "OBSERVATION_MODIFIER", 76, 84], ["symptoms", "OBSERVATION", 85, 93], ["severe", "OBSERVATION_MODIFIER", 129, 135], ["pneumonia", "OBSERVATION", 136, 145], ["acute", "OBSERVATION_MODIFIER", 206, 211], ["respiratory", "ANATOMY", 212, 223], ["distress syndrome", "OBSERVATION", 224, 241], ["septic shock", "OBSERVATION", 243, 255], ["multiple", "OBSERVATION_MODIFIER", 263, 271], ["organ", "ANATOMY", 272, 277], ["failure", "OBSERVATION", 278, 285]]], ["As of July 29, 2020, 16,708,920 cases of COVID-19 have been reported, including 660,123 deaths [3] .", [["deaths", "DISEASE", 88, 94], ["COVID", "TEST", 41, 46]]], ["Case fatality is reported at 3.95% [3] , but this varies widely by location [3] .BackgroundPoor-risk factors for outcome in COVID-19 patients include old age, hypertension, cardiovascular disease and diabetes [4] .", [["cardiovascular", "ANATOMY", 173, 187], ["hypertension", "DISEASE", 159, 171], ["cardiovascular disease", "DISEASE", 173, 195], ["diabetes", "DISEASE", 200, 208], ["patients", "ORGANISM", 133, 141], ["patients", "SPECIES", 133, 141], ["Poor-risk factors", "PROBLEM", 91, 108], ["hypertension", "PROBLEM", 159, 171], ["cardiovascular disease", "PROBLEM", 173, 195], ["diabetes", "PROBLEM", 200, 208], ["hypertension", "OBSERVATION", 159, 171], ["cardiovascular", "ANATOMY", 173, 187], ["disease", "OBSERVATION", 188, 195]]], ["Cancer patients also appear to have a worse prognosis [5] .", [["Cancer", "ANATOMY", 0, 6], ["Cancer", "DISEASE", 0, 6], ["Cancer", "CANCER", 0, 6], ["patients", "ORGANISM", 7, 15], ["patients", "SPECIES", 7, 15]]], ["A meta-analysis found that cancer prevalence in people with COVID-19 was 2% [6] .", [["cancer", "ANATOMY", 27, 33], ["cancer", "DISEASE", 27, 33], ["cancer", "CANCER", 27, 33], ["people", "ORGANISM", 48, 54], ["people", "SPECIES", 48, 54], ["A meta-analysis", "TEST", 0, 15], ["COVID", "TEST", 60, 65], ["cancer", "OBSERVATION", 27, 33]]], ["More importantly, patients with cancer had a higher risk of severe events (admission to an ICU requiring invasive ventilation, or death) compared to those without cancer (11-39% vs 5.8-7.6%) [7, 8] .", [["cancer", "ANATOMY", 32, 38], ["cancer", "ANATOMY", 163, 169], ["cancer", "DISEASE", 32, 38], ["death", "DISEASE", 130, 135], ["cancer", "DISEASE", 163, 169], ["patients", "ORGANISM", 18, 26], ["cancer", "CANCER", 32, 38], ["cancer", "CANCER", 163, 169], ["patients", "SPECIES", 18, 26], ["cancer", "PROBLEM", 32, 38], ["severe events", "PROBLEM", 60, 73], ["invasive ventilation", "TREATMENT", 105, 125], ["death", "PROBLEM", 130, 135], ["cancer", "PROBLEM", 163, 169], ["cancer", "OBSERVATION", 32, 38], ["severe", "OBSERVATION_MODIFIER", 60, 66], ["cancer", "OBSERVATION", 163, 169]]], ["A large-scale study using UK Coronavirus Cancer Monitoring Project data gave consistent findings [9] .BackgroundPatients with hematologic malignancies usually have higher levels of immunosuppression and may develop more severe respiratory viral infections than patients with solid tumors [10] .", [["Cancer", "ANATOMY", 41, 47], ["hematologic malignancies", "ANATOMY", 126, 150], ["respiratory", "ANATOMY", 227, 238], ["solid tumors", "ANATOMY", 275, 287], ["Cancer", "DISEASE", 41, 47], ["hematologic malignancies", "DISEASE", 126, 150], ["respiratory viral infections", "DISEASE", 227, 255], ["tumors", "DISEASE", 281, 287], ["Patients", "ORGANISM", 112, 120], ["hematologic malignancies", "CANCER", 126, 150], ["patients", "ORGANISM", 261, 269], ["solid tumors", "CANCER", 275, 287], ["Patients", "SPECIES", 112, 120], ["patients", "SPECIES", 261, 269], ["A large-scale study", "TEST", 0, 19], ["UK Coronavirus Cancer", "PROBLEM", 26, 47], ["hematologic malignancies", "PROBLEM", 126, 150], ["immunosuppression", "TREATMENT", 181, 198], ["more severe respiratory viral infections", "PROBLEM", 215, 255], ["solid tumors", "PROBLEM", 275, 287], ["large", "OBSERVATION_MODIFIER", 2, 7], ["hematologic malignancies", "OBSERVATION", 126, 150], ["severe", "OBSERVATION_MODIFIER", 220, 226], ["respiratory", "ANATOMY", 227, 238], ["viral infections", "OBSERVATION", 239, 255]]], ["In Europe and the USA, hematologic malignancies comprise the fourth most common cancer site [11, 12] .", [["hematologic malignancies", "ANATOMY", 23, 47], ["cancer", "ANATOMY", 80, 86], ["hematologic malignancies", "DISEASE", 23, 47], ["cancer", "DISEASE", 80, 86], ["hematologic malignancies", "CANCER", 23, 47], ["cancer", "CANCER", 80, 86], ["hematologic malignancies", "PROBLEM", 23, 47], ["hematologic malignancies", "OBSERVATION", 23, 47], ["fourth", "OBSERVATION_MODIFIER", 61, 67], ["most", "OBSERVATION_MODIFIER", 68, 72], ["common", "OBSERVATION_MODIFIER", 73, 79], ["cancer", "OBSERVATION", 80, 86]]], ["The use of new antineoplastic agents, particularly novel targeted therapies, has improved overall survival.", [["antineoplastic", "ANATOMY", 15, 29], ["new antineoplastic agents", "TREATMENT", 11, 36], ["novel targeted therapies", "TREATMENT", 51, 75]]], ["However, these therapies have side effects on humoral and cell-mediated immunity, increasing the risk of infections caused by viral agents [13] .", [["cell", "ANATOMY", 58, 62], ["infections", "DISEASE", 105, 115], ["cell", "CELL", 58, 62], ["these therapies", "TREATMENT", 9, 24], ["side effects", "PROBLEM", 30, 42], ["humoral and cell-mediated immunity", "TREATMENT", 46, 80], ["infections", "PROBLEM", 105, 115], ["viral agents", "TREATMENT", 126, 138], ["infections", "OBSERVATION", 105, 115]]], ["To date, few data are available on COVID-19 in patients with hematologic malignancies.", [["hematologic malignancies", "ANATOMY", 61, 85], ["hematologic malignancies", "DISEASE", 61, 85], ["COVID-19", "GENE_OR_GENE_PRODUCT", 35, 43], ["patients", "ORGANISM", 47, 55], ["hematologic malignancies", "CANCER", 61, 85], ["patients", "SPECIES", 47, 55], ["COVID", "TEST", 35, 40], ["hematologic malignancies", "PROBLEM", 61, 85], ["malignancies", "OBSERVATION", 73, 85]]], ["Reported studies have focused on hospitalized patients.", [["patients", "ORGANISM", 46, 54], ["patients", "SPECIES", 46, 54]]], ["One showed very high mortality (40% at 1 month) among 25 patients in France [14] .", [["patients", "ORGANISM", 57, 65], ["patients", "SPECIES", 57, 65], ["very high mortality", "PROBLEM", 11, 30], ["very", "OBSERVATION_MODIFIER", 11, 15], ["high", "OBSERVATION_MODIFIER", 16, 20]]], ["A second suggested that hospitalized patients with hematologic malignancies have a higher mortality rate than patients without hematologic malignancies (62% vs 8%) [15] .", [["hematologic malignancies", "ANATOMY", 51, 75], ["hematologic malignancies", "ANATOMY", 127, 151], ["hematologic malignancies", "DISEASE", 51, 75], ["malignancies", "DISEASE", 139, 151], ["patients", "ORGANISM", 37, 45], ["hematologic malignancies", "CANCER", 51, 75], ["patients", "ORGANISM", 110, 118], ["hematologic malignancies", "CANCER", 127, 151], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 110, 118], ["hematologic malignancies", "PROBLEM", 51, 75], ["hematologic malignancies", "PROBLEM", 127, 151]]], ["However, these were small patient series; the clinical impact of COVID-19 in this population remains unclear.", [["COVID-19", "CHEMICAL", 65, 73], ["COVID-19", "CHEMICAL", 65, 73], ["patient", "ORGANISM", 26, 33], ["COVID-19", "GENE_OR_GENE_PRODUCT", 65, 73], ["patient", "SPECIES", 26, 33], ["COVID", "TEST", 65, 70], ["small", "OBSERVATION_MODIFIER", 20, 25]]], ["Therefore, real-time collection, analysis, and dissemination of data about COVID-19 in patients with hematologic malignancies and their outcomes are needed.", [["hematologic malignancies", "ANATOMY", 101, 125], ["hematologic malignancies", "DISEASE", 101, 125], ["patients", "ORGANISM", 87, 95], ["hematologic malignancies", "CANCER", 101, 125], ["patients", "SPECIES", 87, 95], ["analysis", "TEST", 33, 41], ["COVID", "TEST", 75, 80], ["hematologic malignancies", "PROBLEM", 101, 125]]], ["Meanwhile, impactful decisions are being suggested on the basis of expert opinion [16, 17] .BackgroundThe Madrid region was the epicenter of Spain's COVID-19 crisis.", [["Spain's COVID", "TEST", 141, 154], ["crisis", "PROBLEM", 158, 164]]], ["As of 29 July, 78,807 patients had been diagnosed with COVID-19 and 15,199 fatalities reported in the Madrid region [18] .", [["COVID", "DISEASE", 55, 60], ["fatalities", "DISEASE", 75, 85], ["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["COVID", "TEST", 55, 60]]], ["We considered it critical to collect clinical data in patients with hematologic malignancies within a defined geographical area with high excess mortality in order to understand the epidemiology of COVID-19.", [["hematologic malignancies", "ANATOMY", 68, 92], ["hematologic malignancies", "DISEASE", 68, 92], ["patients", "ORGANISM", 54, 62], ["hematologic malignancies", "CANCER", 68, 92], ["patients", "SPECIES", 54, 62], ["clinical data", "TEST", 37, 50], ["hematologic malignancies", "PROBLEM", 68, 92], ["high excess mortality", "PROBLEM", 133, 154], ["COVID", "TEST", 198, 203], ["high", "OBSERVATION_MODIFIER", 133, 137], ["excess mortality", "OBSERVATION", 138, 154]]], ["We aimed to identify independent prognostic factors for mortality that could support recommendations for managing patients with hematologic malignancies in healthcare emergency situations such as the COVID-19 pandemic.Study design and participantsThis was a multicenter, registry-based study with prospective data collection sponsored by the Madrid Society of Hematology (Asociaci\u00f3n Madrile\u00f1a de Hematolog\u00eda y Hemoterapia, AMHH).", [["hematologic malignancies", "ANATOMY", 128, 152], ["hematologic malignancies", "DISEASE", 128, 152], ["patients", "ORGANISM", 114, 122], ["hematologic malignancies", "CANCER", 128, 152], ["participants", "ORGANISM", 235, 247], ["patients", "SPECIES", 114, 122], ["participants", "SPECIES", 235, 247], ["hematologic malignancies", "PROBLEM", 128, 152], ["the COVID", "TEST", 196, 205], ["pandemic", "PROBLEM", 209, 217], ["based study", "TEST", 280, 291]]], ["AHMM established the registry on March 13 by contacting all members to register patients with hematologic malignancies who had microbiological confirmation of SARS-CoV-2 infection.", [["hematologic malignancies", "ANATOMY", 94, 118], ["hematologic malignancies", "DISEASE", 94, 118], ["SARS-CoV-2 infection", "DISEASE", 159, 179], ["patients", "ORGANISM", 80, 88], ["hematologic malignancies", "CANCER", 94, 118], ["SARS-CoV-2", "ORGANISM", 159, 169], ["patients", "SPECIES", 80, 88], ["SARS-CoV-2", "SPECIES", 159, 169], ["hematologic malignancies", "PROBLEM", 94, 118], ["microbiological confirmation", "TEST", 127, 155], ["SARS", "PROBLEM", 159, 163], ["CoV", "PROBLEM", 164, 167], ["2 infection", "PROBLEM", 168, 179], ["infection", "OBSERVATION", 170, 179]]], ["Health care for patients with hematologic malignancies in the Madrid region is provided at 26 hospitals affiliated with the Madrid regional health service (Servicio Madrile\u00f1o de Salud, SERMAS), covering a population of 6.6 million inhabitants.", [["hematologic malignancies", "ANATOMY", 30, 54], ["hematologic malignancies", "DISEASE", 30, 54], ["patients", "ORGANISM", 16, 24], ["hematologic malignancies", "CANCER", 30, 54], ["patients", "SPECIES", 16, 24], ["hematologic malignancies", "PROBLEM", 30, 54], ["malignancies", "OBSERVATION", 42, 54]]], ["Additionally, patients are seen at six private non-SERMAS-affiliated healthcare centers.", [["patients", "ORGANISM", 14, 22], ["patients", "SPECIES", 14, 22]]], ["This case series included consecutive patients with hematologic malignancies aged \u2265 18 years who received a confirmed diagnosis of COVID-19 in the emergency departments, hospital wards (patients infected while hospitalized) or outpatient clinics of these Madrid hospitals up to May 25, 2020.", [["hematologic malignancies", "ANATOMY", 52, 76], ["hematologic malignancies", "DISEASE", 52, 76], ["patients", "ORGANISM", 38, 46], ["hematologic malignancies", "CANCER", 52, 76], ["patients", "ORGANISM", 186, 194], ["patients", "SPECIES", 38, 46], ["patients", "SPECIES", 186, 194], ["hematologic malignancies", "PROBLEM", 52, 76], ["COVID", "TEST", 131, 136]]], ["Clinical specimens for diagnosis confirmation were obtained by nasopharyngeal swab collection in accordance with Spanish disease control and prevention guidelines.", [["specimens", "ANATOMY", 9, 18], ["nasopharyngeal swab", "ANATOMY", 63, 82], ["nasopharyngeal swab", "MULTI-TISSUE_STRUCTURE", 63, 82], ["Clinical specimens", "TEST", 0, 18], ["diagnosis confirmation", "TEST", 23, 45], ["nasopharyngeal swab collection", "TEST", 63, 93], ["Spanish disease control", "TREATMENT", 113, 136], ["nasopharyngeal", "ANATOMY", 63, 77]]], ["Samples were processed at local microbiology laboratories, and SARS-CoV-2 one-step real-time reverse transcriptase PCR diagnostic assay was performed [19] .Study design and participantsThe study was approved by the Institutional Review Board (IRB) of University Hospital 12 de Octubre (n 20/189) and then by the IRBs of all participating centers.", [["Samples", "ANATOMY", 0, 7], ["participants", "ORGANISM", 173, 185], ["reverse transcriptase", "PROTEIN", 93, 114], ["participants", "SPECIES", 173, 185], ["SARS-CoV", "SPECIES", 63, 71], ["Samples", "TEST", 0, 7], ["SARS", "TEST", 63, 67], ["CoV", "TEST", 68, 71], ["diagnostic assay", "TEST", 119, 135], ["The study", "TEST", 185, 194]]], ["The study was performed in accordance with the principles of the Declaration of Helsinki and the International Conference on Harmonization Good Clinical Practice guidelines.ProceduresData were prospectively extracted locally from electronic health records by hospital hematology department study coordinators and uploaded to a secure web platform (HEMATO-MADRID COVID-19), which utilized RED-Cap data capture tools and was supported by AMHH.", [["RED", "PROTEIN", 388, 391], ["AMHH", "PROTEIN", 436, 440], ["The study", "TEST", 0, 9]]], ["Clinical management decisions were made according to local protocols at each center; national guidelines for COVID-19 treatment issued by the Spanish Ministry of Health, National Health System, and National Medicine Agency were widely implemented.", [["Clinical management", "TREATMENT", 0, 19], ["COVID-19 treatment", "TREATMENT", 109, 127]]], ["Decisions about hospital/ICU admissions were made locally based on daily updated criteria during the healthcare emergency period.ProceduresPotential prognostic factors were collected including pre-infection patient characteristics (age, sex, comorbidities, type of hematologic malignancy and therapy), COVID-19 clinical severity, treatments and care setting. '", [["malignancy", "DISEASE", 277, 287], ["patient", "ORGANISM", 207, 214], ["patient", "SPECIES", 207, 214], ["Potential prognostic factors", "PROBLEM", 139, 167], ["hematologic malignancy", "PROBLEM", 265, 287], ["therapy", "TREATMENT", 292, 299], ["COVID", "TEST", 302, 307], ["treatments", "TREATMENT", 330, 340]]], ["Active antineoplastic treatment' was defined as having received anticancer therapy within 30 days prior to COVID-19 diagnosis.", [["antineoplastic", "ANATOMY", 7, 21], ["anticancer", "ANATOMY", 64, 74], ["anticancer", "CANCER", 64, 74], ["Active antineoplastic treatment", "TREATMENT", 0, 31], ["anticancer therapy", "TREATMENT", 64, 82], ["COVID", "TEST", 107, 112], ["antineoplastic treatment", "OBSERVATION", 7, 31]]], ["Therapies were classified as 'conventional chemotherapy, ' 'low-intensity chemotherapy, ' hypomethylating agents, monoclonal antibodies, immunomodulatory drugs, 'molecular targeted therapies, ' or supportive care (Table 1) .", [["hypomethylating agents", "SIMPLE_CHEMICAL", 90, 112], ["monoclonal antibodies", "PROTEIN", 114, 135], ["Therapies", "TREATMENT", 0, 9], ["conventional chemotherapy", "TREATMENT", 30, 55], ["' 'low-intensity chemotherapy", "TREATMENT", 57, 86], ["' hypomethylating agents", "TREATMENT", 88, 112], ["monoclonal antibodies", "TREATMENT", 114, 135], ["immunomodulatory drugs", "TREATMENT", 137, 159], ["'molecular targeted therapies", "TREATMENT", 161, 190], ["supportive care", "TREATMENT", 197, 212]]], ["Patients who were receiving monoclonal antibodies in combination with cytotoxic chemotherapy were classified into the category of 'conventional chemotherapy. '", [["Patients", "ORGANISM", 0, 8], ["monoclonal antibodies", "PROTEIN", 28, 49], ["Patients", "SPECIES", 0, 8], ["monoclonal antibodies", "TREATMENT", 28, 49], ["cytotoxic chemotherapy", "TREATMENT", 70, 92], ["'conventional chemotherapy", "TREATMENT", 130, 156]]], ["COVID-19 severity classification followed WHO guidelines [20] .", [["COVID", "TEST", 0, 5]]], ["No data on symptoms, laboratory findings, respiratory support, or viral kinetics were available for analyses as standardization was not achieved.OutcomesParticipant vital status (death from any cause vs alive) was the main study outcome.", [["respiratory", "ANATOMY", 42, 53], ["death", "DISEASE", 179, 184], ["symptoms", "PROBLEM", 11, 19], ["laboratory findings", "TEST", 21, 40], ["respiratory support", "TREATMENT", 42, 61], ["viral kinetics", "PROBLEM", 66, 80], ["analyses", "TEST", 100, 108]]], ["Study centers could update patient status through data cutoff (May 25, 2020).", [["patient", "ORGANISM", 27, 34], ["patient", "SPECIES", 27, 34]]], ["Observation time for individual patients was calculated from the date of SARS-CoV-2 positivity to the date of death or last information update.Statistical analysisPotential pre-infection prognostic factors for mortality were analyzed in three steps: unadjusted, partially adjusted and adjusted analyses.", [["death", "DISEASE", 110, 115], ["patients", "ORGANISM", 32, 40], ["patients", "SPECIES", 32, 40], ["CoV", "TEST", 78, 81], ["Statistical analysisPotential pre-infection prognostic factors", "PROBLEM", 143, 205]]], ["The associations between mortality and therapies received for COVID-19 were determined according to clinical severity (dichotomized as mild/moderate or severe/critical).", [["therapies", "TREATMENT", 39, 48], ["COVID", "TEST", 62, 67], ["mild/moderate or severe/critical)", "PROBLEM", 135, 168], ["mild", "OBSERVATION_MODIFIER", 135, 139], ["moderate", "OBSERVATION_MODIFIER", 140, 148]]], ["Hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with Cox regression analyses.", [["Hazard ratios", "TEST", 0, 13], ["CIs", "TEST", 50, 53], ["Cox regression analyses", "TEST", 75, 98]]], ["Variables included in the models were pre-specified and restricted in number to limit model overfitting.", [["limit model", "OBSERVATION_MODIFIER", 80, 91], ["overfitting", "OBSERVATION", 92, 103]]], ["Analyses were generated using SAS/ STAT software, Version 9.4, SAS Institute Inc.ResultsOf 833 patients reported to the HEMATO-MADRID COVID-19 registry by 27/32 healthcare providers, 697 were included in the present analyses (Fig. 1) .", [["patients", "ORGANISM", 95, 103], ["patients", "SPECIES", 95, 103], ["Analyses", "TEST", 0, 8], ["Version", "TEST", 50, 57]]], ["The earliest PCR confirmation date in registered patients was February 28, 2020; during the 12-week reporting period, 5% of cases were reported in the 2 weeks prior to the start of lockdown, 75% in the following 4 weeks and the remaining 20% in the last 6 weeks.ResultsOf the 697 patients, 479 (69%) had a lymphoid malignancy, including 187 (27%) with non-Hodgkin lymphoma and 137 (20%) with multiple myeloma, and 218 (31%) had a myeloid malignancy, including 78 (11%) with myelodysplastic syndrome (MDS), 61 (9%) with acute myeloid leukemia (AML) and 63 (9%) with Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (Table 1) .", [["lymphoid malignancy", "ANATOMY", 306, 325], ["non-Hodgkin lymphoma", "ANATOMY", 352, 372], ["myeloma", "ANATOMY", 401, 408], ["myeloid malignancy", "ANATOMY", 430, 448], ["acute myeloid leukemia", "ANATOMY", 519, 541], ["AML", "ANATOMY", 543, 546], ["myeloproliferative neoplasms", "ANATOMY", 603, 631], ["lymphoid malignancy", "DISEASE", 306, 325], ["non-Hodgkin lymphoma", "DISEASE", 352, 372], ["multiple myeloma", "DISEASE", 392, 408], ["myeloid malignancy", "DISEASE", 430, 448], ["myelodysplastic syndrome", "DISEASE", 474, 498], ["MDS", "DISEASE", 500, 503], ["acute myeloid leukemia", "DISEASE", 519, 541], ["AML", "DISEASE", 543, 546], ["myeloproliferative neoplasms", "DISEASE", 603, 631], ["patients", "ORGANISM", 49, 57], ["patients", "ORGANISM", 280, 288], ["lymphoid malignancy", "CANCER", 306, 325], ["non-Hodgkin lymphoma", "CANCER", 352, 372], ["myeloma", "CANCER", 401, 408], ["myeloid malignancy", "CANCER", 430, 448], ["acute myeloid leukemia", "CANCER", 519, 541], ["AML", "CANCER", 543, 546], ["Philadelphia chromosome (Ph)", "GENE_OR_GENE_PRODUCT", 565, 593], ["myeloproliferative neoplasms", "CANCER", 603, 631], ["patients", "SPECIES", 49, 57], ["patients", "SPECIES", 280, 288], ["The earliest PCR confirmation", "TEST", 0, 29], ["a lymphoid malignancy", "PROBLEM", 304, 325], ["non-Hodgkin lymphoma", "PROBLEM", 352, 372], ["multiple myeloma", "PROBLEM", 392, 408], ["a myeloid malignancy", "PROBLEM", 428, 448], ["myelodysplastic syndrome", "PROBLEM", 474, 498], ["MDS", "TEST", 500, 503], ["acute myeloid leukemia", "PROBLEM", 519, 541], ["AML", "TEST", 543, 546], ["Philadelphia chromosome", "TEST", 565, 588], ["Ph", "TEST", 590, 592], ["myeloproliferative neoplasms", "PROBLEM", 603, 631], ["lymphoid malignancy", "OBSERVATION", 306, 325], ["non-Hodgkin lymphoma", "OBSERVATION", 352, 372], ["multiple", "OBSERVATION_MODIFIER", 392, 400], ["myeloma", "OBSERVATION", 401, 408], ["myeloid malignancy", "OBSERVATION", 430, 448], ["myelodysplastic syndrome", "OBSERVATION", 474, 498], ["acute", "OBSERVATION_MODIFIER", 519, 524], ["myeloid leukemia", "OBSERVATION", 525, 541], ["myeloproliferative neoplasms", "OBSERVATION", 603, 631]]], ["Overall median age of patients was 72 years (IQR 60-79), and 413/690 (60%) were male.", [["patients", "ORGANISM", 22, 30], ["patients", "SPECIES", 22, 30], ["IQR", "TEST", 45, 48]]], ["Comorbidities were present in 80% of patients, the commonest being hypertension (40%), cardiac disease (20%) and diabetes (17%) ( Table 1 ).ResultsIn total, 405 (59%) patients were receiving active antineoplastic treatment, including at least 75% of patients with multiple myeloma, AML, chronic myeloid leukemia (CML), and Philadelphia chromosome (Ph)-negative myeloproliferative neoplasms (MPNs).", [["cardiac", "ANATOMY", 87, 94], ["antineoplastic", "ANATOMY", 198, 212], ["myeloma", "ANATOMY", 273, 280], ["AML", "ANATOMY", 282, 285], ["chronic myeloid leukemia", "ANATOMY", 287, 311], ["CML", "ANATOMY", 313, 316], ["myeloproliferative neoplasms", "ANATOMY", 361, 389], ["MPNs", "ANATOMY", 391, 395], ["hypertension", "DISEASE", 67, 79], ["cardiac disease", "DISEASE", 87, 102], ["diabetes", "DISEASE", 113, 121], ["multiple myeloma", "DISEASE", 264, 280], ["AML", "DISEASE", 282, 285], ["chronic myeloid leukemia", "DISEASE", 287, 311], ["CML", "DISEASE", 313, 316], ["myeloproliferative neoplasms", "DISEASE", 361, 389], ["MPNs", "DISEASE", 391, 395], ["patients", "ORGANISM", 37, 45], ["cardiac", "ORGAN", 87, 94], ["patients", "ORGANISM", 167, 175], ["patients", "ORGANISM", 250, 258], ["myeloma", "CANCER", 273, 280], ["AML", "CANCER", 282, 285], ["chronic myeloid leukemia", "CANCER", 287, 311], ["CML", "CANCER", 313, 316], ["Philadelphia chromosome", "GENE_OR_GENE_PRODUCT", 323, 346], ["myeloproliferative neoplasms", "CANCER", 361, 389], ["MPNs", "CANCER", 391, 395], ["patients", "SPECIES", 37, 45], ["patients", "SPECIES", 167, 175], ["patients", "SPECIES", 250, 258], ["Comorbidities", "PROBLEM", 0, 13], ["hypertension", "PROBLEM", 67, 79], ["cardiac disease", "PROBLEM", 87, 102], ["diabetes", "PROBLEM", 113, 121], ["active antineoplastic treatment", "TREATMENT", 191, 222], ["multiple myeloma", "PROBLEM", 264, 280], ["AML", "PROBLEM", 282, 285], ["chronic myeloid leukemia", "PROBLEM", 287, 311], ["CML)", "PROBLEM", 313, 317], ["Philadelphia chromosome (Ph)", "PROBLEM", 323, 351], ["myeloproliferative neoplasms", "PROBLEM", 361, 389], ["hypertension", "OBSERVATION", 67, 79], ["cardiac", "ANATOMY", 87, 94], ["disease", "OBSERVATION", 95, 102], ["antineoplastic treatment", "OBSERVATION", 198, 222], ["multiple", "OBSERVATION_MODIFIER", 264, 272], ["myeloma", "OBSERVATION", 273, 280], ["AML", "ANATOMY", 282, 285], ["chronic", "OBSERVATION_MODIFIER", 287, 294], ["myeloid leukemia", "OBSERVATION", 295, 311], ["Philadelphia chromosome", "OBSERVATION", 323, 346], ["negative", "UNCERTAINTY", 352, 360], ["myeloproliferative neoplasms", "OBSERVATION", 361, 389]]], ["The rate was 31% in patients with chronic lymphocytic leukemia or (27) 137 (20) 109 (15) 33 (5) 13 (2) 78 (11) 61 (9) 16 (2) 63 (9) Age, yearsResultsCardiac disease 138 (20) 33 (18) 30 (22) 20 (18) 8 (24) 1 (8) 22 (28) 7 (11) 3 (13) 14 (22) Pulmonary disease 90 (13) 21 (11) 20 (15) 16 (15) 2 (6) 1 (8) 14 (18) 6 (10) 4 (25) 6 (10)ResultsRenal disease 77 (11) 11 (6) 32 (23) 8 (7) 4 (12) 1 (8) 9 (12) 22 (36) 4 (25) 9 (14) Hypertension 277 (40) 64 (34) 63 (46) 44 (40) 13 (39) 2 (15) 35 (45) 1 (2) 2 (13) 30 (48) Diabetes 121 (17) 29 (16) 29 (21) 20 (18) 7 (21) 0 18 (23) 5 (8) 3 (19) 10 (16) Other cancer 79 (11) 19 (10) 14 (10) 13 (12) 1 (3) 2 (15) 16 (21) 2 (3) 1 (6) 11 (17) Active antineoplastic treatment \u2020 % shown as proportion of all patients with that malignancy 92 (49) 27 (20) 75 (69) 14 (44) 4 (33) 54 (69) 15 (25) 0(8)Care setting % shown as proportion of all patients with that malignancy Ambulatory 89 (13) 24 (13) 16 (12) 15 (14) 4 (12) 3 (23) 6 (8) 9 (15) 6 (37)(14)Hospital 608 (87) 163 (87) 121 (88) 97 (89) 29 (88) 10 (77) 72 (92) 52 (85) 10 (63) 54 (86) Outcome Survivors 467 (67) 128 (68) 90 (66) 70 (64) 24 (73) 11 (85) 45 (58) 34 (56) 14 (87) 51 (81) Non-survivors 230 (33) 59 (32) 47 (34) 39 (36) 9 (27) 2 (15) 33 (42) 27 (44) 2 (13) 12 (19) myelodysplastic syndrome (Table 1) COVID-19 clinical severity was classified as severe/ critical in 62% of patients, moderate in 23% and mild in 15% ( Table 2) ; 46% of transplant recipients had severe/ critical disease.", [["chronic lymphocytic leukemia", "ANATOMY", 34, 62], ["cancer", "ANATOMY", 599, 605], ["chronic lymphocytic leukemia", "DISEASE", 34, 62], ["Cardiac disease", "DISEASE", 149, 164], ["Pulmonary disease", "DISEASE", 241, 258], ["Renal disease", "DISEASE", 338, 351], ["Hypertension", "DISEASE", 423, 435], ["Diabetes", "DISEASE", 513, 521], ["cancer", "DISEASE", 599, 605], ["malignancy", "DISEASE", 761, 771], ["malignancy", "DISEASE", 892, 902], ["myelodysplastic syndrome", "DISEASE", 1267, 1291], ["patients", "ORGANISM", 20, 28], ["chronic lymphocytic leukemia", "CANCER", 34, 62], ["patients", "ORGANISM", 742, 750], ["patients", "ORGANISM", 873, 881], ["patients", "ORGANISM", 1374, 1382], ["recipients", "ORGANISM", 1447, 1457], ["patients", "SPECIES", 20, 28], ["patients", "SPECIES", 742, 750], ["patients", "SPECIES", 873, 881], ["patients", "SPECIES", 1374, 1382], ["The rate", "TEST", 0, 8], ["chronic lymphocytic leukemia", "PROBLEM", 34, 62], ["Cardiac disease", "TEST", 149, 164], ["Pulmonary disease", "TEST", 241, 258], ["Renal disease", "TEST", 338, 351], ["Hypertension", "TEST", 423, 435], ["Diabetes", "TEST", 513, 521], ["Other cancer", "TEST", 593, 605], ["Active antineoplastic treatment", "TREATMENT", 679, 710], ["malignancy", "TEST", 761, 771], ["that malignancy", "PROBLEM", 887, 902], ["Ambulatory", "TEST", 903, 913], ["Survivors", "TEST", 1083, 1092], ["Non-survivors", "TEST", 1175, 1188], ["myelodysplastic syndrome", "PROBLEM", 1267, 1291], ["COVID", "TEST", 1302, 1307], ["clinical severity", "TEST", 1311, 1328], ["moderate in 23%", "PROBLEM", 1384, 1399], ["transplant recipients", "TREATMENT", 1436, 1457], ["severe/ critical disease", "PROBLEM", 1462, 1486], ["chronic", "OBSERVATION_MODIFIER", 34, 41], ["lymphocytic leukemia", "OBSERVATION", 42, 62], ["Cardiac", "ANATOMY", 149, 156], ["disease", "OBSERVATION", 157, 164], ["Pulmonary", "ANATOMY", 241, 250], ["disease", "OBSERVATION", 251, 258], ["Renal", "ANATOMY", 338, 343], ["disease", "OBSERVATION", 344, 351], ["malignancy", "OBSERVATION", 761, 771], ["malignancy", "OBSERVATION", 892, 902], ["myelodysplastic syndrome", "OBSERVATION", 1267, 1291], ["severe", "OBSERVATION_MODIFIER", 1347, 1353], ["moderate", "OBSERVATION_MODIFIER", 1384, 1392], ["mild", "OBSERVATION_MODIFIER", 1404, 1408], ["severe", "OBSERVATION_MODIFIER", 1462, 1468], ["critical disease", "OBSERVATION", 1470, 1486]]], ["Patients with severe/critical disease were older and more likely (51%/22%) to have \u2265 3 comorbidities than those with mild COVID-19 (9%) ( Table 2) .", [["Patients", "ORGANISM", 0, 8], ["Patients", "SPECIES", 0, 8], ["severe/critical disease", "PROBLEM", 14, 37], ["\u2265 3 comorbidities", "PROBLEM", 83, 100], ["mild COVID", "PROBLEM", 117, 127], ["severe", "OBSERVATION_MODIFIER", 14, 20], ["critical", "OBSERVATION_MODIFIER", 21, 29], ["disease", "OBSERVATION", 30, 37], ["mild", "OBSERVATION_MODIFIER", 117, 121]]], ["Overall, 87% of patients required hospitalization, and 13% received ambulatory management (Table 1) ; 55 (8%) were admitted to an ICU ( Table 2 ), most of whom had organ function damage, including 40/55 (73%) with acute respiratory distress syndrome and 2 (4%) with sepsis.", [["organ", "ANATOMY", 164, 169], ["respiratory", "ANATOMY", 220, 231], ["organ function damage", "DISEASE", 164, 185], ["acute respiratory distress syndrome", "DISEASE", 214, 249], ["sepsis", "DISEASE", 266, 272], ["patients", "ORGANISM", 16, 24], ["organ", "ORGAN", 164, 169], ["patients", "SPECIES", 16, 24], ["ambulatory management", "TREATMENT", 68, 89], ["organ function damage", "PROBLEM", 164, 185], ["acute respiratory distress syndrome", "PROBLEM", 214, 249], ["sepsis", "PROBLEM", 266, 272], ["acute", "OBSERVATION_MODIFIER", 214, 219], ["respiratory distress", "OBSERVATION", 220, 240], ["sepsis", "OBSERVATION", 266, 272]]], ["(Table 3) were increasing age > 60 years, > 2 comorbidities (HR 1.4, 95% CI 1.05-1.90, vs \u2264 2 comorbidities), AML (vs non-Hodgkin lymphoma), and active antineoplastic treatment with monoclonal antibodies vs no active therapy; there was 50% increased mortality in patients receiving conventional chemotherapy vs no active therapy (HR 1.50, 0.99-2.29, p value 0.0561).", [["AML", "ANATOMY", 110, 113], ["non-Hodgkin lymphoma", "ANATOMY", 118, 138], ["AML", "DISEASE", 110, 113], ["non-Hodgkin lymphoma", "DISEASE", 118, 138], ["AML", "CANCER", 110, 113], ["non-Hodgkin lymphoma", "CANCER", 118, 138], ["patients", "ORGANISM", 263, 271], ["monoclonal antibodies", "PROTEIN", 182, 203], ["patients", "SPECIES", 263, 271], ["HR", "TEST", 61, 63], ["CI", "TEST", 73, 75], ["\u2264 2 comorbidities", "PROBLEM", 90, 107], ["AML", "PROBLEM", 110, 113], ["non-Hodgkin lymphoma", "PROBLEM", 118, 138], ["active antineoplastic treatment", "TREATMENT", 145, 176], ["monoclonal antibodies", "TREATMENT", 182, 203], ["active therapy", "TREATMENT", 210, 224], ["50% increased mortality", "PROBLEM", 236, 259], ["conventional chemotherapy", "TREATMENT", 282, 307], ["active therapy", "TREATMENT", 314, 328], ["HR", "TEST", 330, 332], ["p value", "TEST", 350, 357], ["AML", "OBSERVATION", 110, 113], ["non-Hodgkin lymphoma", "OBSERVATION", 118, 138], ["active", "OBSERVATION_MODIFIER", 145, 151], ["antineoplastic", "OBSERVATION_MODIFIER", 152, 166], ["increased", "OBSERVATION_MODIFIER", 240, 249], ["mortality", "OBSERVATION_MODIFIER", 250, 259]]], ["Prognostic variables associated with lower mortality included Ph-negative MPNs (HR 0.33 vs non-Hodgkin lymphoma) and active treatment with hypomethylating agents (HR 0.47 vs no active treatment).", [["non-Hodgkin lymphoma", "ANATOMY", 91, 111], ["MPNs", "DISEASE", 74, 78], ["non-Hodgkin lymphoma", "DISEASE", 91, 111], ["non-Hodgkin lymphoma", "CANCER", 91, 111], ["Prognostic variables", "PROBLEM", 0, 20], ["lower mortality", "PROBLEM", 37, 52], ["Ph-negative MPNs", "PROBLEM", 62, 78], ["HR", "TEST", 80, 82], ["non-Hodgkin lymphoma", "PROBLEM", 91, 111], ["active treatment", "TREATMENT", 117, 133], ["hypomethylating agents", "TREATMENT", 139, 161], ["HR", "TEST", 163, 165], ["active treatment", "TREATMENT", 177, 193], ["Ph-negative MPNs", "OBSERVATION", 62, 78], ["non-Hodgkin lymphoma", "OBSERVATION", 91, 111]]], ["Mortality rate among patients who underwent transplantation was 18%.(14)Overall, 574 (82%) patients received antiviral therapy (with \u03b2-interferon in 50 patients as an immunity booster), the most common being hydroxychloroquine in combination with antiretrovirals, azithromycin, or both (Table 4 ).", [["\u03b2-interferon", "CHEMICAL", 133, 145], ["hydroxychloroquine", "CHEMICAL", 208, 226], ["azithromycin", "CHEMICAL", 264, 276], ["hydroxychloroquine", "CHEMICAL", 208, 226], ["azithromycin", "CHEMICAL", 264, 276], ["patients", "ORGANISM", 21, 29], ["patients", "ORGANISM", 91, 99], ["\u03b2-interferon", "GENE_OR_GENE_PRODUCT", 133, 145], ["patients", "ORGANISM", 152, 160], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 208, 226], ["azithromycin", "SIMPLE_CHEMICAL", 264, 276], ["interferon", "PROTEIN", 135, 145], ["patients", "SPECIES", 21, 29], ["patients", "SPECIES", 91, 99], ["patients", "SPECIES", 152, 160], ["transplantation", "TREATMENT", 44, 59], ["antiviral therapy", "TREATMENT", 109, 126], ["interferon", "TREATMENT", 135, 145], ["an immunity booster", "TREATMENT", 164, 183], ["hydroxychloroquine", "TREATMENT", 208, 226], ["antiretrovirals", "TREATMENT", 247, 262], ["azithromycin", "TREATMENT", 264, 276]]], ["Additionally, 346 (50%), 318 (46%) and 132 (19%) patients received empirical antibiotics, systemic corticosteroids (mainly methylprednisolone and prednisone) and off-label tocilizumab, respectively.", [["methylprednisolone", "CHEMICAL", 123, 141], ["prednisone", "CHEMICAL", 146, 156], ["methylprednisolone", "CHEMICAL", 123, 141], ["prednisone", "CHEMICAL", 146, 156], ["patients", "ORGANISM", 49, 57], ["methylprednisolone", "SIMPLE_CHEMICAL", 123, 141], ["prednisone", "SIMPLE_CHEMICAL", 146, 156], ["off-label tocilizumab", "SIMPLE_CHEMICAL", 162, 183], ["patients", "SPECIES", 49, 57], ["empirical antibiotics", "TREATMENT", 67, 88], ["systemic corticosteroids", "TREATMENT", 90, 114], ["methylprednisolone", "TREATMENT", 123, 141], ["prednisone", "TREATMENT", 146, 156], ["label tocilizumab", "TREATMENT", 166, 183]]], ["Patients with severe/critical COVID-19 who did not receive antiviral therapy had a higher risk of death than patients receiving any antiviral combination therapy (HR 2.20, 95% CI 1.44-3.35) on multivariable analysis (Table 4) .", [["death", "DISEASE", 98, 103], ["Patients", "ORGANISM", 0, 8], ["patients", "ORGANISM", 109, 117], ["Patients", "SPECIES", 0, 8], ["patients", "SPECIES", 109, 117], ["severe/critical COVID", "PROBLEM", 14, 35], ["antiviral therapy", "TREATMENT", 59, 76], ["death", "PROBLEM", 98, 103], ["any antiviral combination therapy", "TREATMENT", 128, 161], ["HR", "TEST", 163, 165], ["CI", "TEST", 176, 178], ["multivariable analysis", "TEST", 193, 215], ["severe", "OBSERVATION_MODIFIER", 14, 20]]], ["Mortality in patients treated with tocilizumab differed according to clinical severity of COVID-19 (test for strata homogeneity, p < 0.0001), with a higher risk in patients with mild/moderate COVID-19 treated vs not treated with tocilizumab (HR 5.94).DiscussionTo our knowledge, this is the first large-scale case series describing the epidemiology and outcome of COVID-19 in patients with hematologic malignancies.", [["hematologic malignancies", "ANATOMY", 390, 414], ["tocilizumab", "CHEMICAL", 35, 46], ["tocilizumab", "CHEMICAL", 229, 240], ["COVID-19", "CHEMICAL", 364, 372], ["hematologic malignancies", "DISEASE", 390, 414], ["patients", "ORGANISM", 13, 21], ["tocilizumab", "SIMPLE_CHEMICAL", 35, 46], ["patients", "ORGANISM", 164, 172], ["tocilizumab", "SIMPLE_CHEMICAL", 229, 240], ["patients", "ORGANISM", 376, 384], ["hematologic malignancies", "CANCER", 390, 414], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 164, 172], ["patients", "SPECIES", 376, 384], ["tocilizumab", "TREATMENT", 35, 46], ["COVID", "TEST", 90, 95], ["strata homogeneity", "PROBLEM", 109, 127], ["mild/moderate COVID", "PROBLEM", 178, 197], ["tocilizumab", "TREATMENT", 229, 240], ["HR", "TEST", 242, 244], ["COVID", "TEST", 364, 369], ["hematologic malignancies", "PROBLEM", 390, 414], ["mild", "OBSERVATION_MODIFIER", 178, 182], ["moderate", "OBSERVATION_MODIFIER", 183, 191], ["malignancies", "OBSERVATION", 402, 414]]], ["To date, only small case series in this setting have been reported [14, 15, 21, 22] in mainly hospitalized patients, whereas our study included both inpatients and outpatients.", [["patients", "ORGANISM", 107, 115], ["outpatients", "ORGANISM", 164, 175], ["patients", "SPECIES", 107, 115], ["our study", "TEST", 125, 134], ["small", "OBSERVATION_MODIFIER", 14, 19]]], ["Our findings show that patients with hematologic malignancies and COVID-19 have threefold-fourfold higher rates of severe/critical disease (62% vs 15%) and mortality (33% vs 10%) compared to COVID-19 cases in the general population [23] [24] [25] .", [["hematologic malignancies", "ANATOMY", 37, 61], ["hematologic malignancies", "DISEASE", 37, 61], ["patients", "ORGANISM", 23, 31], ["hematologic malignancies", "CANCER", 37, 61], ["patients", "SPECIES", 23, 31], ["hematologic malignancies", "PROBLEM", 37, 61], ["COVID", "TEST", 66, 71], ["severe/critical disease", "PROBLEM", 115, 138], ["mortality", "TEST", 156, 165], ["COVID", "TEST", 191, 196], ["severe", "OBSERVATION_MODIFIER", 115, 121], ["critical disease", "OBSERVATION", 122, 138]]], ["Clinical severity of COVID-19 was worse, and mortality rates were higher among older patients and those with a greater number of comorbidities and varied by type of hematologic malignancy and active antineoplastic treatment.", [["hematologic malignancy", "ANATOMY", 165, 187], ["antineoplastic", "ANATOMY", 199, 213], ["malignancy", "DISEASE", 177, 187], ["patients", "ORGANISM", 85, 93], ["patients", "SPECIES", 85, 93], ["COVID", "TEST", 21, 26], ["mortality rates", "PROBLEM", 45, 60], ["hematologic malignancy", "PROBLEM", 165, 187], ["active antineoplastic treatment", "TREATMENT", 192, 223], ["hematologic malignancy", "OBSERVATION", 165, 187], ["active", "OBSERVATION_MODIFIER", 192, 198], ["antineoplastic treatment", "OBSERVATION", 199, 223]]], ["Rates of severe/critical COVID-19 and mortality in our study were higher than reported in patients with solid tumors (26-43% and 13-28%; respectively) [9] .DiscussionDespite the high societal impact of COVID-19 in Spain, the ENE-COVID nation-wide, population-based study reported a SARS-CoV-2 seroprevalence of 11.5% for the Madrid region [26] , which is clearly insufficient to provide herd immunity.", [["solid tumors", "ANATOMY", 104, 116], ["tumors", "DISEASE", 110, 116], ["patients", "ORGANISM", 90, 98], ["solid tumors", "CANCER", 104, 116], ["patients", "SPECIES", 90, 98], ["severe/critical COVID", "PROBLEM", 9, 30], ["our study", "TEST", 51, 60], ["solid tumors", "PROBLEM", 104, 116], ["COVID", "TEST", 202, 207], ["based study", "TEST", 259, 270], ["a SARS", "TEST", 280, 286], ["CoV", "TEST", 287, 290], ["severe", "OBSERVATION_MODIFIER", 9, 15], ["tumors", "OBSERVATION", 110, 116]]], ["Together with our study, these findings have important policy implications, including the need for increased surveillance for SARS-CoV-2 in patients with hematologic malignancies.DiscussionAmong the strengths of this study are the prospective and comprehensive collection of clinical and outcome data, and the use of multivariable analysis to identify independent risk factors for death.", [["hematologic malignancies", "ANATOMY", 154, 178], ["SARS", "DISEASE", 126, 130], ["hematologic malignancies", "DISEASE", 154, 178], ["death", "DISEASE", 381, 386], ["SARS-CoV-2", "ORGANISM", 126, 136], ["patients", "ORGANISM", 140, 148], ["hematologic malignancies", "CANCER", 154, 178], ["patients", "SPECIES", 140, 148], ["SARS-CoV", "SPECIES", 126, 134], ["our study", "TEST", 14, 23], ["increased surveillance", "TEST", 99, 121], ["SARS", "PROBLEM", 126, 130], ["CoV", "TEST", 131, 134], ["hematologic malignancies", "PROBLEM", 154, 178], ["this study", "TEST", 212, 222], ["multivariable analysis", "TEST", 317, 339], ["death", "PROBLEM", 381, 386], ["hematologic malignancies", "OBSERVATION", 154, 178]]], ["Our patient series is highly representative of this population as, in Spain, COVID-19 severity classification followed WHO guidelines (20) .", [["patient", "ORGANISM", 4, 11], ["patient", "SPECIES", 4, 11]]], ["Severe disease was defined as: bilateral lung infiltrates on chest imaging that were not fully explained by congestive heart failure or other forms of volume overload; tachypnea (\u2265 30 breaths/min); oxygen saturation \u2264 90% at rest; and/or PaO 2 /FIO 2 ratio < 300 mmHg.", [["lung", "ANATOMY", 41, 45], ["chest", "ANATOMY", 61, 66], ["heart", "ANATOMY", 119, 124], ["congestive heart failure", "DISEASE", 108, 132], ["volume overload", "DISEASE", 151, 166], ["tachypnea", "DISEASE", 168, 177], ["oxygen", "CHEMICAL", 198, 204], ["oxygen", "CHEMICAL", 198, 204], ["lung", "ORGAN", 41, 45], ["chest", "ORGAN", 61, 66], ["heart", "ORGAN", 119, 124], ["oxygen", "SIMPLE_CHEMICAL", 198, 204], ["Severe disease", "PROBLEM", 0, 14], ["bilateral lung infiltrates", "PROBLEM", 31, 57], ["chest imaging", "TEST", 61, 74], ["congestive heart failure", "PROBLEM", 108, 132], ["volume overload", "PROBLEM", 151, 166], ["tachypnea", "PROBLEM", 168, 177], ["oxygen saturation", "TEST", 198, 215], ["PaO", "TEST", 238, 241], ["FIO", "TEST", 245, 248], ["disease", "OBSERVATION", 7, 14], ["bilateral", "ANATOMY_MODIFIER", 31, 40], ["lung", "ANATOMY", 41, 45], ["infiltrates", "OBSERVATION", 46, 57], ["chest", "ANATOMY", 61, 66], ["congestive", "OBSERVATION", 108, 118], ["heart", "ANATOMY", 119, 124], ["failure", "OBSERVATION", 125, 132], ["volume overload", "OBSERVATION", 151, 166], ["tachypnea", "OBSERVATION", 168, 177]]], ["'Critical' severity was defined as patients presenting with sepsis/septic shock, acute respiratory distress syndrome or multiple organ dysfunction/failure health care for all patients with hematologic malignancies is centralized in hospitals.", [["respiratory", "ANATOMY", 87, 98], ["organ", "ANATOMY", 129, 134], ["hematologic malignancies", "ANATOMY", 189, 213], ["sepsis", "DISEASE", 60, 66], ["septic shock", "DISEASE", 67, 79], ["acute respiratory distress syndrome", "DISEASE", 81, 116], ["organ dysfunction", "DISEASE", 129, 146], ["malignancies", "DISEASE", 201, 213], ["patients", "ORGANISM", 35, 43], ["organ", "ORGAN", 129, 134], ["patients", "ORGANISM", 175, 183], ["hematologic malignancies", "CANCER", 189, 213], ["patients", "SPECIES", 35, 43], ["patients", "SPECIES", 175, 183], ["Critical' severity", "PROBLEM", 1, 19], ["sepsis", "PROBLEM", 60, 66], ["septic shock", "PROBLEM", 67, 79], ["acute respiratory distress syndrome", "PROBLEM", 81, 116], ["multiple organ dysfunction", "PROBLEM", 120, 146], ["failure health care", "TREATMENT", 147, 166], ["hematologic malignancies", "PROBLEM", 189, 213], ["sepsis", "OBSERVATION", 60, 66], ["septic shock", "OBSERVATION", 67, 79], ["acute", "OBSERVATION_MODIFIER", 81, 86], ["respiratory distress", "OBSERVATION", 87, 107], ["syndrome", "OBSERVATION", 108, 116], ["multiple", "OBSERVATION_MODIFIER", 120, 128], ["organ", "ANATOMY", 129, 134], ["dysfunction", "OBSERVATION", 135, 146], ["failure", "OBSERVATION", 147, 154], ["malignancies", "OBSERVATION", 201, 213]]], ["We therefore believe that the mortality rate in our study reflects the true mortality rate in patients with hematologic malignancies and COVID-19 that contacted the healthcare system during the growth phase of the pandemic.", [["hematologic malignancies", "ANATOMY", 108, 132], ["hematologic malignancies", "DISEASE", 108, 132], ["patients", "ORGANISM", 94, 102], ["hematologic malignancies", "CANCER", 108, 132], ["patients", "SPECIES", 94, 102], ["the mortality rate", "TEST", 26, 44], ["our study", "TEST", 48, 57], ["hematologic malignancies", "PROBLEM", 108, 132], ["COVID", "TEST", 137, 142], ["the pandemic", "PROBLEM", 210, 222]]], ["Another strength was the selection of a restricted number of prognostic factors based on clinical features for determining associations with mortality rate.", [["prognostic factors", "PROBLEM", 61, 79], ["mortality rate", "TEST", 141, 155]]], ["These factors could be utilized in a prognostic model to stratify patients with hematologic malignancies and to implement preventive strategies for future healthcare crises.", [["hematologic malignancies", "ANATOMY", 80, 104], ["hematologic malignancies", "DISEASE", 80, 104], ["patients", "ORGANISM", 66, 74], ["hematologic malignancies", "CANCER", 80, 104], ["patients", "SPECIES", 66, 74], ["hematologic malignancies", "PROBLEM", 80, 104], ["preventive strategies", "TREATMENT", 122, 143], ["future healthcare crises", "PROBLEM", 148, 172]]], ["Key risk factors for clinical severity and mortality previously reported in the general population (e.g., older age, higher number of comorbidities) were validated in our study.", [["Key risk factors", "PROBLEM", 0, 16], ["clinical severity", "PROBLEM", 21, 38], ["mortality", "PROBLEM", 43, 52], ["our study", "TEST", 167, 176]]], ["Notably, the median age of patients in our series was higher than in the general population with COVID-19 (72 vs 60 years), with 32% of cases occurring in patients aged 70-79 years; in the general population, COVID-19 cases were more uniformly distributed across age groups [23] .", [["patients", "ORGANISM", 27, 35], ["patients", "ORGANISM", 155, 163], ["patients", "SPECIES", 27, 35], ["patients", "SPECIES", 155, 163], ["COVID", "TEST", 209, 214]]], ["Additionally, our findings highlight that the type of hematologic malignancy was associated with COVID-19 mortality.", [["hematologic malignancy", "ANATOMY", 54, 76], ["malignancy", "DISEASE", 66, 76], ["hematologic malignancy", "PROBLEM", 54, 76], ["COVID", "TEST", 97, 102], ["hematologic", "OBSERVATION_MODIFIER", 54, 65], ["malignancy", "OBSERVATION", 66, 76]]], ["Our study showed relatively higher mortality rates in patients with AML (44%) and myelodysplastic syndrome (42%) and relatively lower rates in patients with Ph-negative MPNs (19%) and CML (13%), consistent with a Chinese study of 5 patients with CML receiving tyrosine kinase inhibitor (TKI) therapy [27] .DiscussionThe differential outcomes from COVID-19 between patients with different hematologic malignancies could be associated with multiple factors.", [["AML", "ANATOMY", 68, 71], ["CML", "ANATOMY", 184, 187], ["CML", "ANATOMY", 246, 249], ["hematologic malignancies", "ANATOMY", 388, 412], ["AML", "DISEASE", 68, 71], ["myelodysplastic syndrome", "DISEASE", 82, 106], ["MPNs", "DISEASE", 169, 173], ["CML", "DISEASE", 184, 187], ["CML", "DISEASE", 246, 249], ["tyrosine", "CHEMICAL", 260, 268], ["TKI", "CHEMICAL", 287, 290], ["hematologic malignancies", "DISEASE", 388, 412], ["tyrosine", "CHEMICAL", 260, 268], ["patients", "ORGANISM", 54, 62], ["AML", "CANCER", 68, 71], ["patients", "ORGANISM", 143, 151], ["CML", "CANCER", 184, 187], ["patients", "ORGANISM", 232, 240], ["CML", "CANCER", 246, 249], ["tyrosine kinase inhibitor", "SIMPLE_CHEMICAL", 260, 285], ["TKI", "SIMPLE_CHEMICAL", 287, 290], ["patients", "ORGANISM", 364, 372], ["malignancies", "CANCER", 400, 412], ["COVID-19", "DNA", 347, 355], ["patients", "SPECIES", 54, 62], ["patients", "SPECIES", 143, 151], ["patients", "SPECIES", 232, 240], ["patients", "SPECIES", 364, 372], ["Our study", "TEST", 0, 9], ["AML", "PROBLEM", 68, 71], ["myelodysplastic syndrome", "PROBLEM", 82, 106], ["Ph-negative MPNs", "PROBLEM", 157, 173], ["CML", "TEST", 184, 187], ["a Chinese study", "TEST", 211, 226], ["CML", "PROBLEM", 246, 249], ["tyrosine kinase inhibitor", "TREATMENT", 260, 285], ["TKI) therapy", "TREATMENT", 287, 299], ["COVID", "TEST", 347, 352], ["different hematologic malignancies", "PROBLEM", 378, 412], ["relatively", "OBSERVATION_MODIFIER", 17, 27], ["higher", "OBSERVATION_MODIFIER", 28, 34], ["AML", "OBSERVATION", 68, 71], ["myelodysplastic syndrome", "OBSERVATION", 82, 106], ["lower", "OBSERVATION_MODIFIER", 128, 133], ["MPNs", "OBSERVATION", 169, 173], ["consistent with", "UNCERTAINTY", 195, 210], ["hematologic malignancies", "OBSERVATION", 388, 412]]], ["On multivariate analysis, we found that type of active antineoplastic treatment appeared associated with mortality from COVID-19.", [["antineoplastic", "ANATOMY", 55, 69], ["COVID-19", "CHEMICAL", 120, 128], ["antineoplastic", "CANCER", 55, 69], ["multivariate analysis", "TEST", 3, 24], ["active antineoplastic treatment", "TREATMENT", 48, 79], ["COVID", "TEST", 120, 125], ["active", "OBSERVATION_MODIFIER", 48, 54], ["antineoplastic treatment", "OBSERVATION", 55, 79]]], ["Patients receiving monoclonal antibody-based therapy had a significantly greater (HR 2.02) risk of death vs those not receiving active antineoplastic treatment, while those receiving active conventional chemotherapy were 50% more likely to die from COVID-19.", [["antineoplastic", "ANATOMY", 135, 149], ["death", "DISEASE", 99, 104], ["COVID-19", "CHEMICAL", 249, 257], ["Patients", "ORGANISM", 0, 8], ["monoclonal antibody", "PROTEIN", 19, 38], ["Patients", "SPECIES", 0, 8], ["monoclonal antibody", "TREATMENT", 19, 38], ["based therapy", "TREATMENT", 39, 52], ["death", "PROBLEM", 99, 104], ["active antineoplastic treatment", "TREATMENT", 128, 159], ["active conventional chemotherapy", "TREATMENT", 183, 215], ["COVID", "TEST", 249, 254]]], ["By contrast, there was a significant 53% lower mortality among patients receiving hypomethylating agents (HMA).", [["HMA", "CHEMICAL", 106, 109], ["patients", "ORGANISM", 63, 71], ["hypomethylating agents", "SIMPLE_CHEMICAL", 82, 104], ["HMA", "SIMPLE_CHEMICAL", 106, 109], ["patients", "SPECIES", 63, 71], ["a significant 53% lower mortality", "PROBLEM", 23, 56], ["hypomethylating agents", "TREATMENT", 82, 104], ["significant", "OBSERVATION_MODIFIER", 25, 36]]], ["Among the 33 patients treated with HMA, 45% were MDS and 52% were AML; 23% of patients with MDS or AML were treated with HMAs.Table 4 COVID-19 pharmacological therapies and association with mortality in patients with hematologic malignancies and COVID-19, according to clinical severity of COVID-19: time-to-event analysisCI confidence interval, COVID-19 coronavirus disease 2019, HR hazard ratio * Multivariable analyses for the mild/moderate severity group are adjusted for age only, due to the limited number of events. \u2020 Multivariable analyses for the severe/ critical severity group are adjusted for age (years), sex and comorbidity count, except for the analysis of \u03b2-interferon, which was adjusted for age only. \u2021 HRs and 95% CI were estimated with Cox regression analyses The association between low-intensity chemotherapy and lower COVID-19 mortality in our partially adjusted analysis could be in part because nearly half of patients with Ph-negative MPNs were receiving this chemotherapy.", [["AML", "ANATOMY", 66, 69], ["AML", "ANATOMY", 99, 102], ["hematologic malignancies", "ANATOMY", 217, 241], ["HMA", "CHEMICAL", 35, 38], ["MDS", "DISEASE", 49, 52], ["AML", "DISEASE", 66, 69], ["MDS", "DISEASE", 92, 95], ["AML", "DISEASE", 99, 102], ["hematologic malignancies", "DISEASE", 217, 241], ["coronavirus disease", "DISEASE", 355, 374], ["MPNs", "DISEASE", 961, 965], ["HMA", "CHEMICAL", 35, 38], ["patients", "ORGANISM", 13, 21], ["AML", "CANCER", 66, 69], ["patients", "ORGANISM", 78, 86], ["AML", "CANCER", 99, 102], ["patients", "ORGANISM", 203, 211], ["hematologic malignancies", "CANCER", 217, 241], ["\u03b2-interferon", "GENE_OR_GENE_PRODUCT", 672, 684], ["patients", "ORGANISM", 935, 943], ["MPNs", "CANCER", 961, 965], ["\u03b2-interferon", "PROTEIN", 672, 684], ["patients", "SPECIES", 13, 21], ["patients", "SPECIES", 78, 86], ["patients", "SPECIES", 203, 211], ["patients", "SPECIES", 935, 943], ["HMA", "TREATMENT", 35, 38], ["MDS", "TEST", 49, 52], ["AML", "PROBLEM", 66, 69], ["MDS", "PROBLEM", 92, 95], ["AML", "PROBLEM", 99, 102], ["HMAs", "TREATMENT", 121, 125], ["pharmacological therapies", "TREATMENT", 143, 168], ["hematologic malignancies", "PROBLEM", 217, 241], ["COVID", "TEST", 246, 251], ["COVID", "TEST", 290, 295], ["interval", "TEST", 336, 344], ["COVID", "TEST", 346, 351], ["coronavirus disease", "PROBLEM", 355, 374], ["HR hazard ratio", "TEST", 381, 396], ["Multivariable analyses", "TEST", 399, 421], ["the mild/moderate severity group", "PROBLEM", 426, 458], ["Multivariable analyses", "TEST", 525, 547], ["the severe/ critical severity group", "PROBLEM", 552, 587], ["comorbidity count", "TEST", 626, 643], ["the analysis", "TEST", 656, 668], ["\u03b2-interferon", "TREATMENT", 672, 684], ["HRs", "TEST", 721, 724], ["CI", "TEST", 733, 735], ["Cox regression analyses", "TEST", 756, 779], ["low-intensity chemotherapy", "TREATMENT", 804, 830], ["lower COVID", "TREATMENT", 835, 846], ["Ph-negative MPNs", "PROBLEM", 949, 965], ["this chemotherapy", "TREATMENT", 981, 998], ["AML", "OBSERVATION", 99, 102], ["mild", "OBSERVATION_MODIFIER", 430, 434], ["moderate", "OBSERVATION_MODIFIER", 435, 443], ["Ph-negative MPNs", "OBSERVATION", 949, 965]]], ["Interestingly, acknowledging that the number of patients with CML was low, 88% were receiving molecular targeted therapies (TKI therapy), and mortality rate was only 13%.", [["CML", "ANATOMY", 62, 65], ["CML", "DISEASE", 62, 65], ["patients", "ORGANISM", 48, 56], ["CML", "CANCER", 62, 65], ["patients", "SPECIES", 48, 56], ["CML", "PROBLEM", 62, 65], ["molecular targeted therapies", "TREATMENT", 94, 122], ["TKI therapy", "TREATMENT", 124, 135], ["mortality rate", "TEST", 142, 156], ["CML", "OBSERVATION", 62, 65]]], ["Kinase inhibitor-targeted therapy was demonstrated to block dissemination of SARS-CoV and Middle East respiratory syndrome coronavirus and is being investigated as a potential therapeutic approach against SARS-CoV-2 [28] .", [["SARS-CoV", "DISEASE", 77, 85], ["Middle East respiratory syndrome coronavirus", "DISEASE", 90, 134], ["SARS", "DISEASE", 205, 209], ["Kinase", "GENE_OR_GENE_PRODUCT", 0, 6], ["SARS-CoV", "ORGANISM", 77, 85], ["Middle East respiratory syndrome coronavirus", "ORGANISM", 90, 134], ["SARS-CoV-2", "ORGANISM", 205, 215], ["SARS-CoV", "SPECIES", 77, 85], ["Middle East respiratory syndrome coronavirus", "SPECIES", 90, 134], ["SARS-CoV", "SPECIES", 205, 213], ["Kinase inhibitor", "TREATMENT", 0, 16], ["targeted therapy", "TREATMENT", 17, 33], ["SARS", "PROBLEM", 77, 81], ["CoV", "PROBLEM", 82, 85], ["Middle East respiratory syndrome coronavirus", "PROBLEM", 90, 134], ["SARS", "PROBLEM", 205, 209], ["CoV", "TEST", 210, 213], ["Middle", "ANATOMY_MODIFIER", 90, 96], ["respiratory syndrome", "OBSERVATION", 102, 122]]], ["Our findings suggest that patients with CML may even garner some protection against poor outcomes with COVID-19 due to their TKI therapy; discontinuing such therapy out of fear of COVID-19 might not be warranted.N (%), patients n, events Clinical severity of COVID-The clinical characteristics, management and outcome of COVID-19 in patients undergoing HSCT remain unknown; guidelines are being generated by various organizations [29, 30] .", [["CML", "ANATOMY", 40, 43], ["CML", "DISEASE", 40, 43], ["COVID-19", "CHEMICAL", 321, 329], ["COVID-19", "CHEMICAL", 180, 188], ["COVID-19", "CHEMICAL", 321, 329], ["patients", "ORGANISM", 26, 34], ["CML", "CANCER", 40, 43], ["TKI", "SIMPLE_CHEMICAL", 125, 128], ["patients", "ORGANISM", 219, 227], ["patients", "ORGANISM", 333, 341], ["patients", "SPECIES", 26, 34], ["patients", "SPECIES", 219, 227], ["patients", "SPECIES", 333, 341], ["CML", "PROBLEM", 40, 43], ["COVID", "TEST", 103, 108], ["their TKI therapy", "TREATMENT", 119, 136], ["such therapy", "TREATMENT", 152, 164], ["COVID", "TEST", 180, 185], ["COVID", "PROBLEM", 259, 264], ["COVID", "TEST", 321, 326], ["HSCT", "TREATMENT", 353, 357]]], ["Our real-world data showed a mortality rate of 18%.", [["a mortality rate", "TEST", 27, 43]]], ["However, this figure should be interpreted with caution as both type of transplant and time from transplant (IQR 8-56 months) were heterogeneous.", [["transplant", "TREATMENT", 72, 82], ["transplant", "TREATMENT", 97, 107], ["transplant", "OBSERVATION", 72, 82], ["heterogeneous", "OBSERVATION_MODIFIER", 131, 144]]], ["Our data suggest that life-saving transplantation should not be delayed in patients with hematologic malignancies, although close monitoring is of paramount importance.N (%), patients n, events Clinical severity of COVID-Although the majority of the 230 deaths in our case series occurred during hospitalization, only 55 (8%) patients were admitted to an ICU.", [["hematologic malignancies", "ANATOMY", 89, 113], ["hematologic malignancies", "DISEASE", 89, 113], ["deaths", "DISEASE", 254, 260], ["patients", "ORGANISM", 75, 83], ["hematologic malignancies", "CANCER", 89, 113], ["patients", "ORGANISM", 175, 183], ["patients", "ORGANISM", 326, 334], ["patients", "SPECIES", 75, 83], ["patients", "SPECIES", 175, 183], ["patients", "SPECIES", 326, 334], ["Our data", "TEST", 0, 8], ["life-saving transplantation", "TREATMENT", 22, 49], ["hematologic malignancies", "PROBLEM", 89, 113], ["close monitoring", "TEST", 124, 140], ["COVID", "TEST", 215, 220]]], ["This rate is consistent with reports from the UK [9] and USA [31] , in which the incidence of ICU admission among patients with all types of cancer and COVID-19 was 6-14%.", [["cancer", "ANATOMY", 141, 147], ["cancer", "DISEASE", 141, 147], ["patients", "ORGANISM", 114, 122], ["cancer", "CANCER", 141, 147], ["patients", "SPECIES", 114, 122], ["This rate", "TEST", 0, 9], ["cancer", "PROBLEM", 141, 147], ["COVID", "TEST", 152, 157], ["cancer", "OBSERVATION", 141, 147]]], ["We were not able to determine from our dataset whether a diagnosis of a hematologic malignancy decreases a patient's chances of accessing such intensive support, for example due to equipment and/or personnel shortages.", [["hematologic malignancy", "ANATOMY", 72, 94], ["malignancy", "DISEASE", 84, 94], ["hematologic malignancy", "CANCER", 72, 94], ["patient", "ORGANISM", 107, 114], ["patient", "SPECIES", 107, 114], ["a hematologic malignancy", "PROBLEM", 70, 94], ["accessing such intensive support", "TREATMENT", 128, 160], ["hematologic", "OBSERVATION_MODIFIER", 72, 83], ["malignancy", "OBSERVATION", 84, 94]]], ["In our cohort, overall mortality rate in patients admitted to an ICU was 51%, suggesting that many patients with hematologic malignancy can survive COVID-19 and require equivalent access to ICU care.N (%), patients n, events Clinical severity of COVID-There are currently no approved treatment options for patients with COVID-19 in Europe, and no clear recommendations can be made regarding specific therapies due to limited data and unknown risk: benefit profiles.", [["hematologic malignancy", "ANATOMY", 113, 135], ["malignancy", "DISEASE", 125, 135], ["patients", "ORGANISM", 41, 49], ["patients", "ORGANISM", 99, 107], ["hematologic malignancy", "CANCER", 113, 135], ["patients", "ORGANISM", 206, 214], ["patients", "ORGANISM", 306, 314], ["patients", "SPECIES", 41, 49], ["patients", "SPECIES", 99, 107], ["patients", "SPECIES", 206, 214], ["patients", "SPECIES", 306, 314], ["hematologic malignancy", "PROBLEM", 113, 135], ["ICU care", "TREATMENT", 190, 198], ["treatment options", "TREATMENT", 284, 301], ["COVID", "TEST", 320, 325], ["specific therapies", "TREATMENT", 391, 409]]], ["Even fewer such data are available for patients with hematologic malignancies.", [["hematologic malignancies", "ANATOMY", 53, 77], ["hematologic malignancies", "DISEASE", 53, 77], ["patients", "ORGANISM", 39, 47], ["hematologic malignancies", "CANCER", 53, 77], ["patients", "SPECIES", 39, 47], ["hematologic malignancies", "PROBLEM", 53, 77]]], ["Our study is the first in which the effect of COVID-19 treatments has been studied in such patients with different degrees of clinical severity of COVID-19.", [["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "CHEMICAL", 46, 54], ["COVID-19", "CHEMICAL", 147, 155], ["patients", "ORGANISM", 91, 99], ["patients", "SPECIES", 91, 99], ["Our study", "TEST", 0, 9], ["COVID-19 treatments", "TREATMENT", 46, 65], ["COVID", "TEST", 147, 152]]], ["Interestingly, our findings showed that in patients with severe/critical COVID-19, not receiving any antiviral therapy was associated with higher mortality than being treated with any antiviral combination therapy.", [["patients", "ORGANISM", 43, 51], ["patients", "SPECIES", 43, 51], ["severe/critical COVID", "PROBLEM", 57, 78], ["any antiviral therapy", "TREATMENT", 97, 118], ["any antiviral combination therapy", "TREATMENT", 180, 213]]], ["However, this was a non-randomized study and residual confounding by indication may explain this finding.", [["a non-randomized study", "TEST", 18, 40]]], ["These data provide a rationale for including patients with hematologic malignancies in investigational strategies of antiviral therapy.", [["hematologic malignancies", "ANATOMY", 59, 83], ["hematologic malignancies", "DISEASE", 59, 83], ["patients", "ORGANISM", 45, 53], ["hematologic malignancies", "CANCER", 59, 83], ["patients", "SPECIES", 45, 53], ["hematologic malignancies", "PROBLEM", 59, 83], ["investigational strategies", "TREATMENT", 87, 113], ["antiviral therapy", "TREATMENT", 117, 134], ["antiviral therapy", "OBSERVATION", 117, 134]]], ["Regarding the effect of corticoids, although some clinical trials have showed that corticoids have a survival benefit, in patients with hematological malignancies, we have not seen this effect.", [["hematological malignancies", "ANATOMY", 136, 162], ["hematological malignancies", "DISEASE", 136, 162], ["corticoids", "SIMPLE_CHEMICAL", 24, 34], ["corticoids", "SIMPLE_CHEMICAL", 83, 93], ["patients", "ORGANISM", 122, 130], ["hematological malignancies", "CANCER", 136, 162], ["patients", "SPECIES", 122, 130], ["corticoids", "TREATMENT", 24, 34], ["corticoids", "TREATMENT", 83, 93], ["hematological malignancies", "PROBLEM", 136, 162], ["corticoids", "OBSERVATION", 24, 34]]], ["Notably, we also observed that the mortality rate in patients with mild/moderate COVID-19 was nearly sixfold higher among those treated with, vs not receiving, tocilizumab.", [["patients", "ORGANISM", 53, 61], ["tocilizumab", "SIMPLE_CHEMICAL", 160, 171], ["patients", "SPECIES", 53, 61], ["the mortality rate", "TEST", 31, 49], ["mild/moderate COVID", "PROBLEM", 67, 86], ["tocilizumab", "TREATMENT", 160, 171], ["mild", "OBSERVATION_MODIFIER", 67, 71], ["moderate", "OBSERVATION_MODIFIER", 72, 80]]], ["Further, tocilizumab was not associated with any benefit in patients with severe/ critical COVID-19.", [["tocilizumab", "CHEMICAL", 9, 20], ["tocilizumab", "SIMPLE_CHEMICAL", 9, 20], ["patients", "ORGANISM", 60, 68], ["patients", "SPECIES", 60, 68], ["tocilizumab", "TREATMENT", 9, 20], ["severe/ critical COVID", "PROBLEM", 74, 96]]], ["As no reference guidelines were available, these results may be related to the expected high variability in the criteria used for prescribing tocilizumab, doses administered and clinical severity of the disease at the time of drug administration.", [["tocilizumab", "CHEMICAL", 142, 153], ["tocilizumab", "SIMPLE_CHEMICAL", 142, 153], ["prescribing tocilizumab", "TREATMENT", 130, 153], ["the disease", "PROBLEM", 199, 210], ["drug administration", "TREATMENT", 226, 245], ["high variability", "OBSERVATION", 88, 104], ["disease", "OBSERVATION", 203, 210]]], ["These findings call for optimizing precision medicine strategies when designing controlled studies on the use of tocilizumab.LimitationsOur study has some limitations.", [["tocilizumab", "CHEMICAL", 113, 124], ["tocilizumab", "SIMPLE_CHEMICAL", 113, 124], ["optimizing precision medicine strategies", "TREATMENT", 24, 64], ["tocilizumab", "TREATMENT", 113, 124], ["Our study", "TEST", 136, 145]]], ["First, this was primarily an observational cohort study designed for rapid patient accrual during the nonlinear growth phase of the COVID-19 outbreak.", [["patient", "ORGANISM", 75, 82], ["patient", "SPECIES", 75, 82], ["an observational cohort study", "TEST", 26, 55], ["the COVID", "TEST", 128, 137]]], ["For this reason, our study introduces uncertainty into the exact timing of therapeutic intervals, as required to meet IRB regulatory requirements.", [["our study", "TEST", 17, 26]]], ["Second, although to the best of our knowledge we included all patients with hematologic malignancies and COVID-19, the true number of such patients might have been higher because of the low rate of testing or misdiagnoses at the beginning of the pandemic and including only patients who contacted the healthcare system.", [["hematologic malignancies", "ANATOMY", 76, 100], ["hematologic malignancies", "DISEASE", 76, 100], ["patients", "ORGANISM", 62, 70], ["hematologic malignancies", "CANCER", 76, 100], ["patients", "ORGANISM", 139, 147], ["patients", "ORGANISM", 274, 282], ["patients", "SPECIES", 62, 70], ["patients", "SPECIES", 139, 147], ["patients", "SPECIES", 274, 282], ["hematologic malignancies", "PROBLEM", 76, 100], ["COVID", "TEST", 105, 110], ["the low rate of testing", "PROBLEM", 182, 205], ["misdiagnoses", "PROBLEM", 209, 221]]], ["More data on the prevalence and outcomes of COVID-19 in asymptomatic patients with hematologic malignancies could emerge as hospital systems implement more comprehensive testing of all patients seeking care.", [["hematologic malignancies", "ANATOMY", 83, 107], ["hematologic malignancies", "DISEASE", 83, 107], ["patients", "ORGANISM", 69, 77], ["hematologic malignancies", "CANCER", 83, 107], ["patients", "ORGANISM", 185, 193], ["patients", "SPECIES", 69, 77], ["patients", "SPECIES", 185, 193], ["COVID", "TEST", 44, 49], ["hematologic malignancies", "PROBLEM", 83, 107], ["comprehensive testing", "TEST", 156, 177]]], ["Third, data on clinical symptoms, laboratory findings, disease status and details on therapy were missing.", [["clinical symptoms", "PROBLEM", 15, 32], ["laboratory findings", "TEST", 34, 53], ["disease status", "PROBLEM", 55, 69], ["therapy", "TREATMENT", 85, 92]]], ["We did not collect data on contacts although during the first wave of the COVID-19 pandemic in Madrid, we expected most patients to be infected by community transmission.", [["patients", "ORGANISM", 120, 128], ["patients", "SPECIES", 120, 128], ["the COVID", "TEST", 70, 79], ["infected", "OBSERVATION", 135, 143]]], ["Finally, our case series incorporates a heterogeneous patient population with multiple different hematologic malignancies; further studies in patients with specific malignancies [32] are needed, as it is possible that type of malignancy and disease status may affect the clinical course of COVID-19.", [["hematologic malignancies", "ANATOMY", 97, 121], ["malignancies", "ANATOMY", 165, 177], ["hematologic malignancies", "DISEASE", 97, 121], ["malignancies", "DISEASE", 165, 177], ["malignancy", "DISEASE", 226, 236], ["COVID-19", "CHEMICAL", 290, 298], ["patient", "ORGANISM", 54, 61], ["hematologic malignancies", "CANCER", 97, 121], ["patients", "ORGANISM", 142, 150], ["malignancies", "CANCER", 165, 177], ["malignancy", "CANCER", 226, 236], ["patient", "SPECIES", 54, 61], ["patients", "SPECIES", 142, 150], ["a heterogeneous patient population", "PROBLEM", 38, 72], ["multiple different hematologic malignancies", "PROBLEM", 78, 121], ["further studies", "TEST", 123, 138], ["specific malignancies", "PROBLEM", 156, 177], ["malignancy", "PROBLEM", 226, 236], ["disease status", "PROBLEM", 241, 255], ["COVID", "TEST", 290, 295], ["heterogeneous", "OBSERVATION_MODIFIER", 40, 53], ["multiple", "OBSERVATION_MODIFIER", 78, 86], ["different", "OBSERVATION_MODIFIER", 87, 96], ["hematologic malignancies", "OBSERVATION", 97, 121], ["malignancy", "OBSERVATION", 226, 236]]], ["Nevertheless, our study included a large number of patients with some malignancies, which could overcome in part this perceived limitation.Learn more biomedcentral.com/submissionsReady to submit your research Ready to submit your research ?", [["malignancies", "ANATOMY", 70, 82], ["malignancies", "DISEASE", 70, 82], ["patients", "ORGANISM", 51, 59], ["malignancies", "CANCER", 70, 82], ["patients", "SPECIES", 51, 59], ["our study", "TEST", 14, 23], ["some malignancies", "PROBLEM", 65, 82], ["large", "OBSERVATION_MODIFIER", 35, 40], ["malignancies", "OBSERVATION", 70, 82]]], ["Choose BMC and benefit from:Learn more biomedcentral.com/submissions?", [["BMC", "ANATOMY", 7, 10], ["BMC", "CANCER", 7, 10]]], ["Choose BMC and benefit from:", [["BMC", "ANATOMY", 7, 10], ["BMC", "CANCER", 7, 10]]]]}